| # | Thr. | #G | #C | Species | Tissues | GO BP | GO CC | GO MF | KEGG | miRNA | CHR |
| 1 | 3/3 | 18 | 5 | hsa, ptr, ppa, ggo | ts | intermediate filament cytoskeleton (4.1e-02/8.1e-02/ 2/ 22) | |||||
| 2 | 3/3 | 21 | 5 | hsa, ppa, ggo | cb | response to tumor cell (9.1e-03/1.8e-02/ 2/ 5) | sequence-specific DNA binding transcription factor activity (1.3e-02/9.8e-01/ 6/ 290) | ||||
| 3 | 3/3 | 26 | 4 | mdo | br, cb | attachment of GPI anchor to protein (5.1e-03/1.4e-02/ 2/ 3) | GPI-anchor transamidase complex (1.6e-03/1.3e-02/ 2/ 3) | GPI-anchor transamidase activity (4.6e-03/1.4e-02/ 2/ 3) | Parkinson's disease (1.1e-03/ 0.1628/ 4/27) | MT (2.3e-03/ 0.027/ 3/ 6) | |
| 4 | 3/3 | 32 | 3 | ptr, ppa | kd | determination of adult lifespan (2.4e-02/3.4e-02/ 2/ 5) | sequence-specific DNA binding transcription factor activity (3.0e-03/1.8e+00/ 9/ 290) | ||||
| 5 | 3/3 | 26 | 4 | gga | kd, lv | regulation of response to biotic stimulus (1.0e-03/4.3e-02/ 3/ 10) | extracellular region (8.6e-03/2.5e+00/ 9/ 533) | cytokine binding (2.6e-02/1.7e-01/ 3/ 43) | Allograft rejection (3.6e-04/ 0.0362/ 3/5) | ||
| 6 | 3/3 | 26 | 3 | oan | ts | acid secretion (2.2e-02/3.1e-02/ 2/ 6) | brush border (4.6e-02/8.8e-02/ 2/ 18) | peptide receptor activity (2.9e-02/1.8e-01/ 3/ 37) | |||
| 7 | 3/2.8 | 20 | 4 | oan | br, cb | ||||||
| 8 | 3/2.8 | 20 | 7 | hsa, ptr, ppa | kd | multicellular organismal process (4.6e-02/6.1e+00/ 13/1507) | sequence-specific DNA binding transcription factor activity (5.6e-03/1.2e+00/ 7/ 290) | ||||
| 9 | 3/2.8 | 31 | 3 | gga | ht, kd | carbohydrate biosynthetic process (1.2e-02/2.9e-01/ 4/ 51) | transcription factor TFIID complex (4.4e-03/2.2e-02/ 2/ 4) | ||||
| 10 | 3/2.8 | 15 | 3 | mml, mmu | ts | microtubule-based flagellum (5.0e-02/3.7e-03/ 1/ 2) | |||||
| 11 | 3/2.8 | 21 | 4 | mdo, oan | ht | myofibril (9.5e-03/1.6e-01/ 3/ 45) | deaminase activity (3.2e-02/4.4e-02/ 2/ 11) | ||||
| 12 | 3/2.8 | 43 | 10 | mdo | br, cb, ht, kd, lv | GPI anchor biosynthetic process (8.0e-03/9.7e-02/ 3/ 13) | GPI-anchor transamidase complex (4.8e-03/2.4e-02/ 2/ 3) | GPI-anchor transamidase activity (7.5e-03/1.9e-02/ 2/ 3) | Parkinson's disease (2.2e-03/ 0.1954/ 4/27) | MT (5.8e-03/ 0.046/ 3/ 6) | |
| 13 | 3/2.8 | 17 | 5 | ppa, ggo, ppy, mml | lv | immune response (1.5e-03/5.9e-01/ 6/ 174) | nuclear nucleosome (4.3e-02/3.1e-03/ 1/ 1) | cytokine receptor activity (6.1e-03/9.2e-02/ 3/ 29) | Hematopoietic cell lineage (1.2e-02/ 0.1261/ 3/19) | ||
| 14 | 3/2.6 | 31 | 8 | hsa, ptr, ppa, ggo, ppy | kd | multicellular organismal process (5.2e-03/9.6e+00/ 20/1507) | sequence-specific DNA binding (9.5e-03/1.2e+00/ 7/ 201) | ||||
| 15 | 3/2.6 | 13 | 4 | mmu, mdo | ts | ||||||
| 16 | 3/2.6 | 12 | 7 | ppa, ggo, ppy, mml | lv | response to wounding (7.0e-03/5.3e-01/ 5/ 211) | extracellular space (2.0e-02/5.1e-01/ 4/ 226) | growth factor binding (1.1e-02/1.2e-01/ 3/ 57) | |||
| 17 | 3/2.6 | 26 | 3 | mmu | kd | extracellular space (3.3e-03/1.2e+00/ 7/ 226) | metalloendopeptidase activity (1.8e-02/1.5e-01/ 3/ 33) | ||||
| 18 | 3/2.6 | 15 | 7 | mmu, mdo, oan | ts | meiosis (9.5e-03/1.1e-01/ 3/ 47) | double-stranded DNA binding (4.4e-02/5.5e-02/ 2/ 26) | ||||
| 19 | 3/2.6 | 24 | 3 | mmu | lv | ||||||
| 20 | 3/2.6 | 14 | 6 | ppa, ggo, ppy, mml | lv | cell surface receptor linked signaling pathway (1.3e-02/1.5e+00/ 7/ 550) | external side of plasma membrane (4.8e-03/1.2e-01/ 3/ 49) | growth factor binding (1.3e-03/1.6e-01/ 4/ 57) | Cytokine-cytokine receptor interaction (3.5e-03/ 0.4765/ 5/79) | ||
| 21 | 3/2.6 | 20 | 5 | mdo, oan | ts | meiotic chromosome segregation (3.9e-03/1.2e-02/ 2/ 3) | brush border (2.7e-02/6.2e-02/ 2/ 18) | ||||
| 22 | 3/2.4 | 50 | 12 | mdo | br, cb, ht, kd, lv, ts | Parkinson's disease (9.0e-03/ 0.2931/ 4/27) | MT (8.9e-03/ 0.056/ 3/ 6) | ||||
| 23 | 3/2.4 | 21 | 5 | mmu, oan | ts | meiosis (1.3e-04/1.8e-01/ 5/ 47) | BRCA2-MAGE-D1 complex (4.8e-02/3.5e-03/ 1/ 1) | DNA binding (4.9e-02/1.9e+00/ 7/ 529) | Homologous recombination (3.2e-03/ 0.0133/ 2/11) | ||
| 24 | 3/2.4 | 30 | 13 | oan | br, cb, ht, kd, lv, ts | nucleic acid binding (1.1e-02/4.1e+00/ 12/ 802) | |||||
| 25 | 3/2.4 | 11 | 7 | hsa, ptr, ppa, ggo, mml | ts | ||||||
| 26 | 3/2.4 | 22 | 4 | mdo, gga | ts | chromosomal part (1.7e-02/4.5e-01/ 4/ 124) | cis-trans isomerase activity (3.0e-02/4.2e-02/ 2/ 11) | ||||
| 27 | 3/2.4 | 21 | 6 | mdo, oan, gga | ht | muscle contraction (1.3e-02/3.0e-01/ 4/ 74) | myofibril (4.2e-04/1.5e-01/ 4/ 45) | Gastric acid secretion (6.8e-03/ 0.1086/ 3/30) | |||
| 28 | 3/2.4 | 31 | 9 | hsa, ptr, ppa, ggo, ppy, mml | ht | striated muscle contraction (8.7e-03/1.0e-01/ 3/ 20) | sarcomere (1.5e-06/1.8e-01/ 6/ 37) | Hypertrophic cardiomyopathy (HCM) (2.0e-02/ 0.1641/ 3/34) | |||
| 29 | 3/2.4 | 11 | 11 | hsa, ptr, ppa, ggo, ppy, mml | lv | activin receptor signaling pathway (1.4e-02/2.3e-02/ 2/ 10) | |||||
| 30 | 3/2.4 | 11 | 10 | hsa, ptr, ppa, ggo, ppy, mml | lv | wound healing (4.1e-03/2.2e-01/ 4/ 88) | extracellular space (2.2e-03/5.1e-01/ 5/ 226) | growth factor binding (1.1e-02/1.2e-01/ 3/ 57) | Complement and coagulation cascades (6.4e-03/ 0.1013/ 3/21) | ||
| 31 | 3/2.4 | 18 | 7 | mmu, oan, gga | ts | M phase (1.5e-02/3.4e-01/ 4/ 152) | |||||
| 32 | 3/2.4 | 16 | 8 | mmu | ht, kd, lv | ||||||
| 33 | 3/2.4 | 26 | 6 | gga | ht, kd, lv | regulation of response to biotic stimulus (8.9e-04/4.1e-02/ 3/ 10) | extracellular region (2.4e-02/2.4e+00/ 8/ 533) | cytokine binding (2.6e-02/1.7e-01/ 3/ 43) | Allograft rejection (3.6e-04/ 0.0362/ 3/5) | ||
| 34 | 3/2.4 | 12 | 7 | hsa, ptr, ppa, ggo, mml | ts | integral to membrane (4.2e-02/3.9e+00/ 9/1584) | |||||
| 35 | 3/2.4 | 37 | 5 | mmu, mdo | kd | metal ion transport (5.8e-04/1.4e+00/ 9/ 199) | intrinsic to membrane (1.1e-03/1.2e+01/ 24/1617) | structural molecule activity (1.8e-02/1.0e+00/ 6/ 147) | |||
| 36 | 3/2.4 | 41 | 5 | hsa, mml, mmu | ht | muscle structure development (2.7e-04/8.9e-01/ 8/ 141) | myofibril (3.9e-11/3.0e-01/ 10/ 45) | structural constituent of muscle (8.0e-03/1.0e-01/ 3/ 14) | Hypertrophic cardiomyopathy (HCM) (1.6e-03/ 0.1846/ 4/34) | ||
| 37 | 3/2.2 | 35 | 15 | hsa, ptr, ppa, ppy, mml, mmu, mdo, oan | lv | wound healing (4.3e-07/7.0e-01/ 10/ 88) | extracellular region (2.8e-09/3.7e+00/ 20/ 533) | endopeptidase inhibitor activity (1.3e-06/2.4e-01/ 7/ 34) | Complement and coagulation cascades (2.3e-08/ 0.2786/ 8/21) | ||
| 38 | 3/2.2 | 15 | 9 | mml, mmu, mdo, oan | lv | cellular amino acid metabolic process (7.5e-04/2.9e-01/ 5/ 90) | ornithine carbamoyltransferase complex (4.1e-02/2.8e-03/ 1/ 1) | amino acid binding (3.0e-03/6.9e-02/ 3/ 25) | Cysteine and methionine metabolism (4.8e-02/ 0.0597/ 2/11) | ||
| 39 | 3/2.2 | 14 | 12 | hsa, ptr, ppa, ggo, ppy, mml | lv | activin receptor signaling pathway (2.1e-02/2.9e-02/ 2/ 10) | external side of plasma membrane (7.2e-03/1.4e-01/ 3/ 49) | Complement and coagulation cascades (8.7e-03/ 0.1140/ 3/21) | |||
| 40 | 3/2.2 | 22 | 4 | mmu, gga | ts | organ development (5.7e-04/2.6e+00/ 11/ 718) | rough microsome (4.8e-02/3.5e-03/ 1/ 1) | ||||
| 41 | 3/2.2 | 29 | 3 | mmu | ht | synaptic transmission, cholinergic (4.9e-02/5.2e-02/ 2/ 11) | sarcoplasm (1.7e-02/4.8e-02/ 2/ 9) | ||||
| 42 | 3/2.2 | 26 | 6 | mdo, oan, gga | kd | brush border membrane (2.3e-02/5.6e-02/ 2/ 13) | |||||
| 43 | 3/2.2 | 16 | 9 | mmu, mdo, oan, gga | ts | M phase (7.1e-04/3.1e-01/ 5/ 152) | non-membrane-bounded organelle (2.4e-02/1.6e+00/ 6/ 855) | ||||
| 44 | 3/2.2 | 38 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | excretion (1.7e-04/1.9e-01/ 5/ 24) | apical plasma membrane (9.7e-06/4.2e-01/ 7/ 59) | sequence-specific DNA binding transcription factor activity (3.2e-03/2.2e+00/ 10/ 290) | Aldosterone-regulated sodium reabsorption (1.6e-02/ 0.1448/ 3/16) | ||
| 45 | 3/2.2 | 20 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | nervous system development (1.1e-03/1.7e+00/ 9/ 467) | sequence-specific DNA binding transcription factor activity (4.9e-02/9.2e-01/ 5/ 290) | ||||
| 46 | 3/2.2 | 38 | 10 | ggo | br, cb, ht, kd, lv | SCF ubiquitin ligase complex (3.5e-02/7.4e-02/ 2/ 13) | |||||
| 47 | 3/2.2 | 57 | 13 | hsa, ptr, ggo, ppy, mml, mmu, mdo | kd | excretion (9.8e-08/2.8e-01/ 8/ 24) | apical plasma membrane (8.5e-08/6.6e-01/ 10/ 59) | transmembrane transporter activity (6.1e-05/4.1e+00/ 17/ 368) | Aldosterone-regulated sodium reabsorption (4.6e-05/ 0.1641/ 5/16) | ||
| 48 | 3/2.2 | 11 | 6 | mmu, mdo, gga | ts | chromosome (2.4e-02/2.4e-01/ 3/ 150) | nucleotide phosphatase activity (4.4e-02/1.3e-03/ 1/ 1) | ||||
| 49 | 3/2.2 | 53 | 11 | hsa, ptr, ppa, ggo, ppy, mml, mdo | kd | excretion (5.5e-08/2.6e-01/ 8/ 24) | apical plasma membrane (1.8e-09/6.0e-01/ 11/ 59) | transmembrane transporter activity (2.8e-05/3.9e+00/ 17/ 368) | Aldosterone-regulated sodium reabsorption (6.0e-05/ 0.1737/ 5/16) | ||
| 50 | 3/2.2 | 38 | 10 | gga | br, cb, ht, kd, lv | positive regulation of interleukin-12 production (7.8e-03/1.8e-02/ 2/ 3) | |||||
| 51 | 3/2.2 | 32 | 7 | mmu, mdo, oan | ht | mitochondrial electron transport, NADH to ubiquinone (3.7e-03/7.1e-02/ 3/ 12) | myofibril (1.2e-05/2.7e-01/ 6/ 45) | NADH dehydrogenase activity (3.2e-03/7.1e-02/ 3/ 12) | Alzheimer's disease (7.9e-04/ 0.3185/ 5/44) | ||
| 52 | 3/2.2 | 72 | 13 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | ht | muscle contraction (3.4e-08/9.0e-01/ 12/ 74) | myofibril (3.3e-16/5.1e-01/ 15/ 45) | structural constituent of muscle (1.3e-04/1.8e-01/ 5/ 14) | Dilated cardiomyopathy (1.7e-06/ 0.4717/ 8/34) | ||
| 53 | 3/2 | 57 | 17 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | ht | cardiac muscle tissue development (7.5e-09/3.1e-01/ 9/ 34) | myofibril (1.7e-17/4.1e-01/ 15/ 45) | actin binding (1.1e-05/1.3e+00/ 11/ 124) | Dilated cardiomyopathy (4.1e-08/ 0.3076/ 8/34) | ||
| 54 | 3/2 | 31 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | lv | wound healing (1.6e-06/6.0e-01/ 9/ 88) | extracellular region (1.4e-07/3.3e+00/ 17/ 533) | endopeptidase inhibitor activity (4.9e-07/2.0e-01/ 7/ 34) | Complement and coagulation cascades (1.3e-10/ 0.2407/ 9/21) | ||
| 55 | 3/2 | 56 | 18 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | kd | excretion (8.6e-08/2.8e-01/ 8/ 24) | apical plasma membrane (4.2e-09/6.5e-01/ 11/ 59) | transmembrane transporter activity (1.1e-05/4.1e+00/ 18/ 368) | Aldosterone-regulated sodium reabsorption (4.6e-05/ 0.1641/ 5/16) | ||
| 56 | 3/2 | 22 | 5 | oan, gga | ts | meiotic chromosome segregation (4.3e-03/1.2e-02/ 2/ 3) | chromosome, centromeric region (1.7e-02/2.0e-01/ 3/ 54) | X (1.9e-03/ 0.561/ 7/145) | |||
| 57 | 3/2 | 32 | 6 | gga | kd, lv, ts | regulation of response to biotic stimulus (1.9e-03/5.4e-02/ 3/ 10) | cytokine binding (4.0e-02/2.1e-01/ 3/ 43) | Allograft rejection (8.0e-04/ 0.0483/ 3/5) | |||
| 58 | 3/2 | 21 | 4 | mdo, gga | ts | nucleic acid metabolic process (1.2e-02/4.4e+00/ 12/1075) | nucleus (1.8e-03/5.6e+00/ 14/1528) | DNA binding (2.5e-03/1.9e+00/ 9/ 529) | |||
| 59 | 3/2 | 52 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mdo | kd | excretion (1.4e-06/2.6e-01/ 7/ 24) | apical plasma membrane (3.6e-08/6.0e-01/ 10/ 59) | transmembrane transporter activity (1.2e-04/3.9e+00/ 16/ 368) | Aldosterone-regulated sodium reabsorption (6.0e-05/ 0.1737/ 5/16) | ||
| 60 | 3/1.8 | 52 | 13 | mml | br, cb, ht, kd, lv, ts | ||||||
| 61 | 3/1.8 | 19 | 17 | hsa, ptr, ppa, ggo, ppy, mml, mdo, oan, gga | cb | system development (3.4e-02/3.0e+00/ 9/ 958) | |||||
| 62 | 3/1.8 | 23 | 5 | mmu, mdo | lv, ts | cytokine binding (2.9e-02/1.8e-01/ 3/ 43) | |||||
| 63 | 3/1.8 | 18 | 8 | mmu, mdo, oan, gga | br | synaptic transmission, cholinergic (3.3e-02/4.0e-02/ 2/ 11) | plasma membrane (1.2e-02/4.1e+00/ 11/1133) | neuropeptide receptor activity (1.1e-03/4.6e-02/ 3/ 12) | |||
| 64 | 3/1.6 | 24 | 15 | mmu | br, cb, ht, kd, lv | ||||||
| 65 | 3/1.6 | 21 | 12 | mmu | cb, ht, kd, lv | ||||||
| 66 | 3/1.6 | 18 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb | ||||||
| 67 | 3/1.6 | 27 | 17 | mmu | br, cb, ht, kd, lv, ts | ||||||
| 68 | 3/1.6 | 17 | 17 | ptr, ppa, mml, mmu | ts, br, cb, ht, kd, lv | CUL4 RING ubiquitin ligase complex (8.5e-03/3.1e-02/ 2/ 10) | |||||
| 69 | 3/1.2 | 23 | 26 | ptr, ppa, oan | br, cb, ht, kd, lv, br | organellar ribosome (2.4e-02/5.8e-02/ 2/ 15) | |||||
| 70 | 3/1 | 27 | 32 | ptr, ppa, mdo, oan | br, cb, ht, kd, lv, ts | organellar ribosome (3.3e-02/7.0e-02/ 2/ 15) | DNA binding (1.7e-02/2.5e+00/ 9/ 529) | Purine metabolism (4.5e-02/ 0.2449/ 3/58) | |||
| 71 | 3/1 | 43 | 14 | ggo, mdo | ht, br, cb, ht, kd, lv, ts | ATP synthesis coupled electron transport (1.2e-02/1.2e-01/ 3/ 17) | respiratory chain (6.5e-03/1.3e-01/ 3/ 18) | Parkinson's disease (2.8e-04/ 0.2443/ 5/27) | MT (2.0e-04/ 0.046/ 4/ 6) | ||
| 72 | 2.8/3 | 43 | 3 | mmu | ht | sarcolemma (2.1e-03/2.3e-01/ 4/ 30) | |||||
| 73 | 2.8/3 | 43 | 3 | mmu | kd | carbohydrate metabolic process (4.2e-02/1.6e+00/ 7/ 205) | extracellular region (1.6e-04/4.6e+00/ 16/ 533) | beta-glucosidase activity (4.1e-03/1.5e-02/ 2/ 2) | Glycosphingolipid biosynthesis - lacto and neolacto series (3.7e-02/ 0.0507/ 2/7) | ||
| 74 | 2.8/3 | 44 | 3 | oan | ts | meiotic chromosome segregation (1.4e-02/2.6e-02/ 2/ 3) | nucleus (4.4e-02/1.3e+01/ 22/1528) | DNA binding (2.6e-02/4.3e+00/ 12/ 529) | |||
| 75 | 2.8/3 | 33 | 3 | mmu | lv | ||||||
| 76 | 2.8/3 | 39 | 4 | mdo | br, cb | attachment of GPI anchor to protein (9.1e-05/2.3e-02/ 3/ 3) | GPI-anchor transamidase complex (2.4e-05/2.2e-02/ 3/ 3) | GPI-anchor transamidase activity (8.8e-05/2.2e-02/ 3/ 3) | Parkinson's disease (3.8e-04/ 0.2606/ 5/27) | MT (5.6e-03/ 0.043/ 3/ 6) | |
| 77 | 2.8/3 | 37 | 5 | hsa, ptr, ppa, ggo | ts | DNA damage checkpoint (1.6e-02/1.3e-01/ 3/ 19) | |||||
| 78 | 2.8/3 | 24 | 7 | hsa, ptr, ppa, ggo, mml | ts | nuclear membrane (2.0e-02/2.1e-01/ 3/ 47) | |||||
| 79 | 2.8/3 | 34 | 4 | mmu, gga | ts | organ development (1.6e-02/3.6e+00/ 11/ 718) | nucleus (1.5e-02/7.2e+00/ 15/1528) | sequence-specific DNA binding transcription factor activity (4.3e-02/1.3e+00/ 6/ 290) | |||
| 80 | 2.8/2.8 | 34 | 4 | oan | br, cb | regulation of neurotransmitter secretion (4.8e-02/5.3e-02/ 2/ 8) | |||||
| 81 | 2.8/2.8 | 21 | 5 | mmu, gga | lv | learning or memory (3.9e-02/1.9e-01/ 3/ 45) | apical cortex (5.4e-04/7.7e-03/ 2/ 2) | cytokine receptor activity (1.1e-02/1.2e-01/ 3/ 29) | |||
| 82 | 2.8/2.8 | 44 | 4 | gga | kd, lv | positive regulation of interferon-gamma production (1.1e-03/4.8e-02/ 3/ 6) | extracellular region (1.2e-02/4.2e+00/ 12/ 533) | receptor activity (4.4e-02/2.8e+00/ 9/ 402) | Allograft rejection (1.1e-03/ 0.0543/ 3/5) | ||
| 83 | 2.8/2.8 | 41 | 5 | mdo, oan | ts | meiotic chromosome segregation (1.0e-02/2.1e-02/ 2/ 3) | chromosomal part (2.2e-02/8.3e-01/ 5/ 124) | ||||
| 84 | 2.8/2.8 | 34 | 5 | ppa, ggo, ppy | lv | wound healing (2.3e-03/6.0e-01/ 6/ 88) | vesicle lumen (1.0e-04/9.8e-02/ 4/ 16) | cytokine receptor activity (2.7e-03/1.9e-01/ 4/ 29) | Complement and coagulation cascades (3.9e-03/ 0.2280/ 4/21) | ||
| 85 | 2.8/2.6 | 43 | 6 | gga | ht, kd, lv | positive regulation of interferon-gamma production (9.0e-04/4.3e-02/ 3/ 6) | Allograft rejection (8.0e-04/ 0.0483/ 3/5) | ||||
| 86 | 2.8/2.6 | 20 | 9 | hsa, ptr, ppa, ggo, mml, gga | ts | mitotic sister chromatid segregation (3.7e-02/4.3e-02/ 2/ 12) | |||||
| 87 | 2.8/2.6 | 48 | 6 | hsa, ptr, ppa, ggo, ppy | ht | striated muscle contraction (1.8e-06/1.5e-01/ 6/ 20) | contractile fiber part (9.0e-13/3.0e-01/ 11/ 41) | structural constituent of muscle (6.0e-04/1.2e-01/ 4/ 14) | Hypertrophic cardiomyopathy (HCM) (2.7e-04/ 0.2461/ 5/34) | ||
| 88 | 2.8/2.6 | 29 | 5 | ppa, ggo, ppy, mml | lv | response to wounding (2.1e-04/1.2e+00/ 9/ 211) | external side of plasma membrane (2.4e-04/2.7e-01/ 5/ 49) | cytokine receptor activity (1.6e-03/1.6e-01/ 4/ 29) | Complement and coagulation cascades (3.9e-03/ 0.2280/ 4/21) | ||
| 89 | 2.8/2.6 | 43 | 4 | mdo, gga | ts | meiotic chromosome segregation (9.8e-03/2.0e-02/ 2/ 3) | chromosomal part (4.4e-04/8.1e-01/ 7/ 124) | ||||
| 90 | 2.8/2.6 | 57 | 5 | mmu, mdo | ht | cellular respiration (2.7e-03/3.7e-01/ 5/ 36) | myofibril (1.5e-05/4.5e-01/ 7/ 45) | oxidoreductase activity, acting on the aldehyde or oxo group of donors, disulfide as acceptor (3.7e-02/5.1e-02/ 2/ 5) | Alzheimer's disease (7.7e-03/ 0.5308/ 5/44) | ||
| 91 | 2.8/2.6 | 47 | 6 | gga | kd, lv, ts | response to tumor cell (6.0e-04/3.8e-02/ 3/ 5) | receptor activity (1.7e-02/2.9e+00/ 10/ 402) | Allograft rejection (1.6e-03/ 0.0633/ 3/5) | |||
| 92 | 2.8/2.6 | 22 | 4 | mmu, mdo | ts | chromosome (2.4e-02/5.2e-01/ 4/ 150) | |||||
| 93 | 2.8/2.6 | 19 | 6 | mml, mdo, gga | ts | ||||||
| 94 | 2.8/2.6 | 42 | 7 | hsa, ptr, ppa | kd | excretion (2.1e-04/2.0e-01/ 5/ 24) | apical part of cell (5.7e-06/5.8e-01/ 8/ 75) | metallopeptidase activity (9.7e-03/5.3e-01/ 5/ 63) | Aldosterone-regulated sodium reabsorption (6.2e-04/ 0.1351/ 4/16) | ||
| 95 | 2.8/2.6 | 11 | 9 | hsa, ptr, ppa, ggo, mml, mmu | ts | cell cycle (3.2e-02/5.0e-01/ 4/ 370) | nuclear membrane (3.6e-02/7.7e-02/ 2/ 47) | ||||
| 96 | 2.8/2.6 | 59 | 7 | mmu, oan, gga | ts | M phase (2.2e-07/1.1e+00/ 12/ 152) | microtubule cytoskeleton (1.3e-03/1.8e+00/ 9/ 227) | microtubule motor activity (5.8e-03/2.4e-01/ 4/ 30) | Homologous recombination (1.9e-02/ 0.0332/ 2/11) | ||
| 97 | 2.8/2.6 | 39 | 5 | mmu, oan | ts | meiosis (6.1e-05/2.9e-01/ 6/ 47) | nucleus (3.1e-02/9.0e+00/ 17/1528) | DNA binding (3.1e-02/3.2e+00/ 10/ 529) | Homologous recombination (1.9e-02/ 0.0332/ 2/11) | ||
| 98 | 2.8/2.6 | 32 | 6 | ppa, ggo, ppy, mml | lv | response to wounding (5.1e-04/1.3e+00/ 9/ 211) | vesicle lumen (9.0e-05/9.4e-02/ 4/ 16) | eukaryotic cell surface binding (1.7e-02/3.1e-02/ 2/ 5) | Complement and coagulation cascades (3.3e-03/ 0.2153/ 4/21) | ||
| 99 | 2.8/2.6 | 41 | 4 | gga | lv, ts | negative regulation of transcription (1.5e-02/1.3e+00/ 7/ 173) | PcG protein complex (1.1e-02/3.8e-02/ 2/ 5) | transcription repressor activity (6.6e-03/7.8e-01/ 6/ 108) | |||
| 100 | 2.8/2.4 | 30 | 10 | hsa, ptr, ppa, ggo, ppy, mml | lv | wound healing (3.3e-08/5.4e-01/ 10/ 88) | extracellular region (1.7e-08/3.3e+00/ 18/ 533) | serine-type endopeptidase inhibitor activity (8.3e-04/1.3e-01/ 4/ 23) | Complement and coagulation cascades (6.9e-09/ 0.2407/ 8/21) | ||
| 101 | 2.8/2.4 | 19 | 6 | hsa, ptr | br | ||||||
| 102 | 2.8/2.4 | 55 | 7 | hsa, ptr, ppa, ggo, ppy, mml | ht | striated muscle contraction (3.8e-06/1.7e-01/ 6/ 20) | contractile fiber part (4.8e-12/3.5e-01/ 11/ 41) | structural constituent of muscle (9.3e-04/1.4e-01/ 4/ 14) | Dilated cardiomyopathy (1.0e-05/ 0.2461/ 6/34) | ||
| 103 | 2.8/2.4 | 19 | 9 | ptr, ppa, mml, mmu, oan | ts | central element (3.4e-02/2.2e-03/ 1/ 1) | |||||
| 104 | 2.8/2.4 | 25 | 6 | mmu | kd, lv | lactation (4.3e-02/4.8e-02/ 2/ 10) | microbody part (4.9e-02/9.2e-02/ 2/ 18) | cytokine binding (4.0e-02/2.1e-01/ 3/ 43) | |||
| 105 | 2.8/2.4 | 53 | 13 | oan | br, cb, ht, kd, lv, ts | regulation of transcription involved in G1/S phase of mitotic cell cycle (1.4e-02/2.5e-02/ 2/ 3) | nuclear part (2.0e-02/5.8e+00/ 14/ 637) | ||||
| 106 | 2.8/2.4 | 29 | 9 | hsa, ptr, ppa, ggo, ppy | cb | neurogenesis (2.6e-03/1.3e+00/ 8/ 255) | sequence-specific DNA binding transcription factor activity (1.3e-02/1.4e+00/ 7/ 290) | ||||
| 107 | 2.8/2.4 | 67 | 10 | gga | br, cb, ht, kd, lv | nucleic acid metabolic process (1.0e-03/1.2e+01/ 26/1075) | nucleus (9.2e-03/1.7e+01/ 29/1528) | ||||
| 108 | 2.8/2.4 | 33 | 8 | mml, mmu, mdo, oan | lv | organic acid metabolic process (9.8e-07/1.7e+00/ 13/ 228) | amino acid binding (8.5e-05/1.6e-01/ 5/ 25) | Primary bile acid biosynthesis (1.9e-02/ 0.0344/ 2/3) | |||
| 109 | 2.8/2.4 | 24 | 4 | mdo, oan | lv | amine metabolic process (2.5e-02/6.8e-01/ 5/ 151) | Nitrogen metabolism (1.6e-02/ 0.0290/ 2/8) | ||||
| 110 | 2.8/2.4 | 24 | 11 | hsa, ptr, ppa, ggo, mml, mmu, oan | ts | sexual reproduction (2.8e-05/4.6e-01/ 7/ 145) | P granule (3.9e-03/2.0e-02/ 2/ 6) | ||||
| 111 | 2.8/2.4 | 18 | 10 | ptr, ppa, ggo, mml, mmu, oan | ts | mitotic spindle organization (1.3e-02/2.2e-02/ 2/ 9) | microtubule cytoskeleton (2.7e-02/5.5e-01/ 4/ 227) | ||||
| 112 | 2.8/2.4 | 39 | 5 | oan, gga | ts | M phase (2.1e-03/8.9e-01/ 7/ 152) | chromosome, centromeric region (6.1e-03/3.2e-01/ 4/ 54) | X (1.8e-02/ 0.969/ 7/145) | |||
| 113 | 2.8/2.4 | 33 | 7 | mmu, mdo, oan | lv | organic acid metabolic process (6.6e-07/1.6e+00/ 13/ 228) | cell fraction (1.0e-02/2.5e+00/ 9/ 377) | organic acid transmembrane transporter activity (3.8e-04/2.3e-01/ 5/ 39) | Primary bile acid biosynthesis (1.9e-02/ 0.0344/ 2/3) | ||
| 114 | 2.8/2.4 | 76 | 12 | mdo | br, cb, ht, kd, lv, ts | attachment of GPI anchor to protein (2.9e-02/4.1e-02/ 2/ 3) | GPI-anchor transamidase complex (1.1e-02/4.1e-02/ 2/ 3) | GPI-anchor transamidase activity (2.2e-02/3.9e-02/ 2/ 3) | Parkinson's disease (1.3e-03/ 0.3420/ 5/27) | MT (1.7e-03/ 0.083/ 4/ 6) | |
| 115 | 2.8/2.4 | 15 | 6 | mdo, oan, gga | lv | extracellular region (3.4e-02/1.5e+00/ 6/ 533) | Nitrogen metabolism (1.6e-02/ 0.0290/ 2/8) | ||||
| 116 | 2.8/2.4 | 74 | 10 | mdo | br, cb, ht, kd, lv | glycerophospholipid biosynthetic process (1.6e-02/3.2e-01/ 4/ 24) | GPI-anchor transamidase complex (1.1e-02/4.0e-02/ 2/ 3) | GPI-anchor transamidase activity (2.0e-02/3.6e-02/ 2/ 3) | Parkinson's disease (1.3e-02/ 0.3257/ 4/27) | MT (1.9e-02/ 0.079/ 3/ 6) | |
| 117 | 2.8/2.2 | 47 | 15 | hsa, ptr, ppa, ppy, mml, mmu, mdo, oan | lv | response to wounding (6.8e-09/2.1e+00/ 17/ 211) | extracellular region (1.4e-12/5.0e+00/ 27/ 533) | endopeptidase inhibitor activity (8.7e-06/3.2e-01/ 7/ 34) | Complement and coagulation cascades (1.1e-11/ 0.3800/11/21) | ||
| 118 | 2.8/2.2 | 14 | 8 | hsa, ptr | br | ||||||
| 119 | 2.8/2.2 | 77 | 9 | hsa, ptr, ppa, ggo, ppy, mml, mmu | ht | muscle contraction (2.8e-09/9.2e-01/ 13/ 74) | myofibril (2.5e-17/5.4e-01/ 16/ 45) | actin binding (4.1e-06/1.7e+00/ 13/ 124) | Dilated cardiomyopathy (5.3e-07/ 0.4101/ 8/34) | ||
| 120 | 2.8/2.2 | 47 | 10 | hsa, ptr, ppa, ggo, ppy, mml | ht | striated muscle contraction (1.8e-06/1.5e-01/ 6/ 20) | contractile fiber part (9.0e-13/3.0e-01/ 11/ 41) | structural constituent of muscle (6.0e-04/1.2e-01/ 4/ 14) | Hypertrophic cardiomyopathy (HCM) (2.7e-04/ 0.2461/ 5/34) | ||
| 121 | 2.8/2.2 | 44 | 13 | ptr, ppa, mml, mmu, mdo, oan, gga | ts | M phase (2.5e-05/6.5e-01/ 8/ 152) | microtubule cytoskeleton (1.3e-03/1.0e+00/ 7/ 227) | microtubule motor activity (1.4e-03/1.5e-01/ 4/ 30) | |||
| 122 | 2.8/2.2 | 55 | 5 | mmu, mdo | kd | cation transport (6.0e-03/2.3e+00/ 10/ 228) | brush border (4.5e-05/1.9e-01/ 5/ 18) | active transmembrane transporter activity (2.5e-03/1.3e+00/ 8/ 130) | |||
| 123 | 2.8/2.2 | 76 | 12 | hsa, ptr, ggo, mml, mmu, mdo | kd | cation transport (1.5e-08/3.6e+00/ 21/ 228) | apical plasma membrane (2.0e-11/8.8e-01/ 14/ 59) | transmembrane transporter activity (1.5e-09/5.5e+00/ 27/ 368) | Aldosterone-regulated sodium reabsorption (2.7e-04/ 0.2413/ 5/16) | ||
| 124 | 2.8/2.2 | 60 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | excretion (3.3e-06/2.9e-01/ 7/ 24) | apical plasma membrane (2.4e-10/6.6e-01/ 12/ 59) | transmembrane transporter activity (1.5e-04/4.4e+00/ 17/ 368) | Aldosterone-regulated sodium reabsorption (9.8e-05/ 0.1930/ 5/16) | ||
| 125 | 2.8/2.2 | 46 | 11 | ptr, ppa, mml, mmu, oan, gga | ts | M phase (3.8e-05/6.9e-01/ 8/ 152) | microtubule cytoskeleton (2.2e-04/1.1e+00/ 8/ 227) | microtubule motor activity (7.1e-05/1.5e-01/ 5/ 30) | |||
| 126 | 2.8/2 | 49 | 15 | hsa, ptr, ppa, ggo, mml, mmu, mdo, oan, gga | ts | M phase (1.6e-07/6.9e-01/ 10/ 152) | microtubule cytoskeleton (4.1e-04/1.2e+00/ 8/ 227) | microtubule motor activity (1.8e-03/1.7e-01/ 4/ 30) | |||
| 127 | 2.8/2 | 50 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | lv | wound healing (3.3e-10/9.8e-01/ 14/ 88) | extracellular region (1.4e-10/5.4e+00/ 26/ 533) | endopeptidase inhibitor activity (1.2e-05/3.5e-01/ 7/ 34) | Complement and coagulation cascades (6.4e-12/ 0.3546/11/21) | ||
| 128 | 2.8/2 | 48 | 16 | hsa, ptr, ppa, ggo, mml, mmu, mdo, oan, gga | ts | M phase (7.4e-08/8.3e-01/ 11/ 152) | microtubule cytoskeleton (2.3e-05/1.3e+00/ 10/ 227) | microtubule motor activity (2.0e-03/1.7e-01/ 4/ 30) | |||
| 129 | 2.8/2 | 81 | 17 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | ht | muscle contraction (8.1e-09/1.0e+00/ 13/ 74) | myofibril (9.9e-17/6.0e-01/ 16/ 45) | actin binding (4.4e-05/1.8e+00/ 12/ 124) | Dilated cardiomyopathy (2.5e-09/ 0.4717/10/34) | ||
| 130 | 2.8/2 | 76 | 18 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo | kd | excretion (7.6e-07/3.7e-01/ 8/ 24) | apical plasma membrane (3.2e-10/8.6e-01/ 13/ 59) | transmembrane transporter activity (4.8e-05/5.5e+00/ 20/ 368) | Aldosterone-regulated sodium reabsorption (2.7e-04/ 0.2413/ 5/16) | ||
| 131 | 2.8/2 | 12 | 9 | hsa, ptr | br | 1-phosphatidylinositol-5-phosphate 4-kinase activity (4.9e-02/1.5e-03/ 1/ 1) | |||||
| 132 | 2.8/2 | 31 | 6 | mmu, mdo, oan, gga | br | G-protein signaling, coupled to cyclic nucleotide second messenger (5.0e-04/2.4e-01/ 5/ 40) | plasma membrane (2.4e-04/7.1e+00/ 19/1133) | transmembrane receptor activity (1.2e-04/1.8e+00/ 11/ 271) | Neuroactive ligand-receptor interaction (4.2e-04/ 0.7998/ 7/102) | ||
| 133 | 2.8/2 | 31 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | nervous system development (2.0e-03/2.6e+00/ 11/ 467) | sequence-specific DNA binding transcription factor activity (2.0e-02/1.5e+00/ 7/ 290) | ||||
| 134 | 2.8/2 | 42 | 4 | gga | br, cb | Neuroactive ligand-receptor interaction (4.6e-02/ 0.5537/ 4/102) | |||||
| 135 | 2.8/2 | 21 | 9 | mmu | ht, kd, lv | ||||||
| 136 | 2.8/2 | 70 | 12 | gga | br, cb, ht, kd, lv, ts | mRNA metabolic process (4.0e-03/1.3e+00/ 8/ 118) | transcription factor TFIID complex (1.4e-02/4.5e-02/ 2/ 4) | translation regulator activity, nucleic acid binding (1.9e-02/3.5e-02/ 2/ 3) | |||
| 137 | 2.8/1.8 | 21 | 7 | hsa | ht, kd, lv | ||||||
| 138 | 2.8/1.8 | 28 | 9 | mmu, mdo, oan, gga | br | G-protein coupled receptor protein signaling pathway (1.7e-02/9.5e-01/ 6/ 175) | plasma membrane (8.6e-05/6.2e+00/ 18/1133) | neuropeptide receptor activity (3.0e-03/6.9e-02/ 3/ 12) | Neuroactive ligand-receptor interaction (3.1e-02/ 0.4922/ 4/102) | ||
| 139 | 2.8/1.8 | 30 | 8 | mmu, mdo, oan, gga | br | G-protein coupled receptor protein signaling pathway (2.7e-03/9.5e-01/ 7/ 175) | plasma membrane (1.3e-03/6.7e+00/ 17/1133) | transmembrane receptor activity (2.0e-03/1.7e+00/ 9/ 271) | Neuroactive ligand-receptor interaction (4.2e-03/ 0.7998/ 6/102) | ||
| 140 | 2.8/1.8 | 23 | 9 | mml, mmu, oan, gga | br | ion transport (4.7e-03/1.5e+00/ 8/ 332) | ion channel complex (2.1e-02/4.8e-01/ 4/ 108) | transporter activity (9.2e-03/2.2e+00/ 9/ 454) | |||
| 141 | 2.8/1.8 | 46 | 7 | mmu, mdo | ht, ts | sarcolemma (1.2e-04/2.3e-01/ 5/ 30) | Calcium signaling pathway (2.1e-02/ 0.4101/ 4/68) | ||||
| 142 | 2.8/1.6 | 31 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb | Long-term depression (2.3e-03/ 0.1990/ 4/30) | |||||
| 143 | 2.8/1.6 | 34 | 22 | ptr, ppa | br, ht, kd, lv, cb | ||||||
| 144 | 2.8/1.6 | 27 | 14 | hsa, ptr, ppa, ggo, ppy, mml, mmu | cb | system development (2.6e-03/4.8e+00/ 14/ 958) | |||||
| 145 | 2.8/1.6 | 15 | 15 | hsa, ppy, mml, mmu, mdo, oan, gga | br | associative learning (7.5e-04/3.8e-02/ 3/ 12) | integral to plasma membrane (3.8e-05/1.3e+00/ 9/ 413) | cation channel activity (2.2e-04/4.0e-01/ 6/ 125) | |||
| 146 | 2.8/1.4 | 52 | 17 | mmu | br, cb, ht, kd, lv, ts | ||||||
| 147 | 2.8/1.2 | 50 | 18 | hsa, ptr, ppa, ggo, oan | ts, br, cb, ht, kd, lv, kd, lv | cell cycle (1.2e-02/3.7e+00/ 12/ 370) | |||||
| 148 | 2.8/1 | 13 | 22 | hsa, ptr, ppa, ggo, ppy | ht, kd, br, cb, lv, ts | proton-transporting ATP synthase complex, coupling factor F(o) (3.2e-02/2.0e-03/ 1/ 1) | |||||
| 149 | 2.8/1 | 11 | 29 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | kd, lv | organic acid metabolic process (6.0e-03/5.2e-01/ 5/ 228) | carboxy-lyase activity (1.0e-02/2.1e-02/ 2/ 10) | Metabolic pathways (2.0e-02/ 1.0645/ 5/353) | |||
| 150 | 2.6/3 | 45 | 4 | mmu, mdo | ts | glycolysis (9.1e-03/1.0e-01/ 3/ 16) | nucleus (2.0e-03/8.7e+00/ 19/1528) | microtubule motor activity (3.0e-02/1.8e-01/ 3/ 30) | |||
| 151 | 2.6/3 | 65 | 3 | ppa, ppy | lv | immune response (1.1e-03/2.2e+00/ 11/ 174) | vesicle lumen (9.3e-04/1.9e-01/ 4/ 16) | eukaryotic cell surface binding (4.9e-02/6.2e-02/ 2/ 5) | Complement and coagulation cascades (1.8e-03/ 0.3673/ 5/21) | ||
| 152 | 2.6/3 | 40 | 4 | ptr, ppa, mml | ts | nuclear membrane (5.0e-02/3.2e-01/ 3/ 47) | |||||
| 153 | 2.6/3 | 68 | 5 | oan, gga | ts | M phase (2.7e-04/1.5e+00/ 10/ 152) | chromosome, centromeric region (5.0e-04/5.4e-01/ 6/ 54) | DNA binding (4.1e-02/5.2e+00/ 13/ 529) | |||
| 154 | 2.6/3 | 49 | 4 | oan | br, cb | ||||||
| 155 | 2.6/3 | 66 | 3 | oan | ts | meiotic chromosome segregation (2.3e-02/3.5e-02/ 2/ 3) | nucleus (8.1e-03/1.7e+01/ 30/1528) | DNA binding (5.5e-03/6.3e+00/ 17/ 529) | Neuroactive ligand-receptor interaction (3.9e-02/ 0.8613/ 5/102) | ||
| 156 | 2.6/3 | 55 | 3 | mmu | lv | intestinal absorption (1.8e-02/3.0e-02/ 2/ 3) | apical part of cell (2.1e-02/8.1e-01/ 5/ 75) | cytokine binding (3.6e-02/4.5e-01/ 4/ 43) | ABC transporters (3.4e-02/ 0.2027/ 3/14) | ||
| 157 | 2.6/3 | 68 | 3 | ptr, ppa | kd | multicellular organismal process (1.4e-03/2.0e+01/ 36/1507) | vacuolar proton-transporting V-type ATPase complex (4.1e-03/2.6e-02/ 2/ 2) | sequence-specific DNA binding transcription factor activity (1.2e-03/3.7e+00/ 14/ 290) | Phagosome (2.1e-02/ 0.3848/ 4/29) | ||
| 158 | 2.6/3 | 40 | 5 | hsa, ptr, ppa, ggo | cb | neurogenesis (1.6e-04/1.8e+00/ 11/ 255) | |||||
| 159 | 2.6/3 | 49 | 4 | mml, mdo | ts | ||||||
| 160 | 2.6/3 | 74 | 3 | mmu | kd | glomerular basement membrane development (1.2e-02/2.7e-02/ 2/ 2) | extracellular region part (9.2e-04/4.5e+00/ 15/ 320) | beta-glucosidase activity (1.0e-02/2.7e-02/ 2/ 2) | Glycosphingolipid biosynthesis - lacto and neolacto series (3.4e-03/ 0.0802/ 3/7) | ||
| 161 | 2.6/3 | 68 | 3 | mmu | ht | muscle structure development (4.2e-02/1.6e+00/ 7/ 141) | myofibril (3.6e-04/5.0e-01/ 6/ 45) | oxidoreductase activity, acting on the aldehyde or oxo group of donors, disulfide as acceptor (4.4e-02/5.8e-02/ 2/ 5) | |||
| 162 | 2.6/2.8 | 45 | 7 | hsa, ptr, ppa, ggo, mml | ts | nuclear export (1.9e-02/1.4e-01/ 3/ 19) | kinetochore microtubule (3.8e-03/2.1e-02/ 2/ 3) | ||||
| 163 | 2.6/2.8 | 39 | 6 | mml, mmu, mdo | ts | ||||||
| 164 | 2.6/2.8 | 42 | 6 | hsa, ptr, ppa, ggo, mml | ts | cell cycle (9.8e-03/2.6e+00/ 10/ 370) | kinetochore microtubule (3.7e-03/2.1e-02/ 2/ 3) | ||||
| 165 | 2.6/2.8 | 62 | 4 | gga | kd, lv | hemopoiesis (7.0e-04/1.3e+00/ 9/ 123) | extracellular region (2.4e-02/5.9e+00/ 14/ 533) | cytokine binding (3.4e-02/4.4e-01/ 4/ 43) | Allograft rejection (2.8e-03/ 0.0784/ 3/5) | ||
| 166 | 2.6/2.8 | 62 | 3 | hsa | ht | negative regulation of collagen metabolic process (9.0e-03/2.2e-02/ 2/ 2) | sarcomere (1.2e-02/3.9e-01/ 4/ 37) | structural constituent of muscle (2.2e-02/1.6e-01/ 3/ 14) | Tyrosine metabolism (2.6e-02/ 0.1773/ 3/14) | ||
| 167 | 2.6/2.8 | 67 | 4 | mmu, gga | ts | spermatogenesis (7.6e-03/7.7e-01/ 6/ 92) | nucleus (8.7e-03/1.3e+01/ 24/1528) | nucleic acid binding (4.9e-02/6.8e+00/ 15/ 802) | |||
| 168 | 2.6/2.8 | 45 | 4 | oan | kd, lv | urea cycle (5.3e-03/1.6e-02/ 2/ 2) | coreceptor activity (2.9e-02/4.3e-02/ 2/ 5) | ||||
| 169 | 2.6/2.8 | 68 | 5 | mmu, oan | ts | M phase (2.7e-05/1.4e+00/ 11/ 152) | chromatoid body (2.2e-02/5.7e-02/ 2/ 6) | nucleic acid binding (1.2e-02/8.3e+00/ 19/ 802) | |||
| 170 | 2.6/2.8 | 62 | 6 | oan | br, cb, ht | COPI vesicle coat (2.7e-02/6.5e-02/ 2/ 6) | RNA binding (1.4e-02/2.2e+00/ 9/ 212) | ||||
| 171 | 2.6/2.8 | 89 | 6 | mdo | br, cb, ht | attachment of GPI anchor to protein (5.8e-04/4.8e-02/ 3/ 3) | GPI-anchor transamidase complex (2.1e-04/5.0e-02/ 3/ 3) | GPI-anchor transamidase activity (4.8e-04/4.6e-02/ 3/ 3) | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (1.6e-03/ 0.1791/ 4/11) | MT (3.0e-02/ 0.098/ 3/ 6) | |
| 172 | 2.6/2.6 | 54 | 4 | mdo | br, cb | attachment of GPI anchor to protein (1.9e-04/3.1e-02/ 3/ 3) | GPI-anchor transamidase complex (5.7e-05/3.1e-02/ 3/ 3) | GPI-anchor transamidase activity (1.5e-04/2.8e-02/ 3/ 3) | Parkinson's disease (5.1e-04/ 0.2768/ 5/27) | MT (9.3e-03/ 0.059/ 3/ 6) | |
| 173 | 2.6/2.6 | 62 | 5 | mdo, oan | ts | nucleic acid metabolic process (2.6e-03/1.1e+01/ 24/1075) | nucleus (3.5e-03/1.5e+01/ 28/1528) | DNA binding (8.8e-03/5.4e+00/ 15/ 529) | |||
| 174 | 2.6/2.6 | 95 | 5 | mmu, mdo | ht | cellular respiration (7.3e-09/6.1e-01/ 11/ 36) | myofibril (2.2e-12/7.5e-01/ 14/ 45) | structural constituent of muscle (3.7e-04/2.4e-01/ 5/ 14) | Oxidative phosphorylation (8.5e-06/ 0.5790/ 8/30) | ||
| 175 | 2.6/2.6 | 90 | 7 | mmu, oan, gga | ts | M phase (4.9e-12/1.6e+00/ 18/ 152) | chromosome (2.5e-04/1.7e+00/ 10/ 150) | microtubule motor activity (1.8e-03/3.4e-01/ 5/ 30) | |||
| 176 | 2.6/2.6 | 35 | 4 | hsa, mml | lv | lipid homeostasis (5.1e-04/1.1e-01/ 4/ 17) | membrane attack complex (6.2e-03/2.7e-02/ 2/ 4) | apolipoprotein binding (2.2e-02/3.6e-02/ 2/ 6) | Complement and coagulation cascades (5.0e-02/ 0.2407/ 3/21) | ||
| 177 | 2.6/2.6 | 100 | 11 | ptr, ppa, mml, mmu, oan, gga | ts | M phase (2.0e-13/1.5e+00/ 19/ 152) | non-membrane-bounded organelle (3.2e-06/9.4e+00/ 27/ 855) | microtubule motor activity (1.9e-04/3.6e-01/ 6/ 30) | |||
| 178 | 2.6/2.6 | 62 | 6 | ppa, ggo, ppy | lv | response to wounding (1.5e-06/2.7e+00/ 16/ 211) | extracellular region (6.8e-08/6.0e+00/ 24/ 533) | endopeptidase inhibitor activity (2.9e-04/3.9e-01/ 6/ 34) | Complement and coagulation cascades (3.7e-10/ 0.3926/10/21) | ||
| 179 | 2.6/2.6 | 80 | 7 | mmu, mdo, oan | ts | spermatogenesis (1.1e-04/1.0e+00/ 9/ 92) | P granule (8.3e-04/6.5e-02/ 3/ 6) | nucleic acid binding (8.2e-03/9.3e+00/ 21/ 802) | |||
| 180 | 2.6/2.6 | 62 | 4 | mdo, oan | ht | generation of precursor metabolites and energy (7.5e-04/1.3e+00/ 9/ 112) | mitochondrial membrane part (3.5e-06/3.6e-01/ 7/ 33) | NADH dehydrogenase activity (1.0e-03/1.4e-01/ 4/ 12) | Alzheimer's disease (1.9e-02/ 0.6634/ 5/44) | ||
| 181 | 2.6/2.6 | 98 | 10 | gga | br, cb, ht, kd, lv | nucleic acid metabolic process (4.3e-04/1.8e+01/ 36/1075) | nucleus (1.3e-02/2.5e+01/ 39/1528) | translation regulator activity, nucleic acid binding (3.3e-02/5.1e-02/ 2/ 3) | |||
| 182 | 2.6/2.6 | 41 | 5 | mmu | lv, ts | ||||||
| 183 | 2.6/2.6 | 58 | 5 | ppa, ggo, ppy | lv | wound healing (1.7e-05/1.1e+00/ 10/ 88) | extracellular region (8.0e-07/5.7e+00/ 22/ 533) | serine-type endopeptidase inhibitor activity (5.7e-04/2.6e-01/ 5/ 23) | Complement and coagulation cascades (3.1e-06/ 0.3293/ 7/21) | ||
| 184 | 2.6/2.6 | 47 | 8 | ptr, ppa, mml, mmu, gga | ts | microtubule-based process (8.5e-04/5.0e-01/ 6/ 105) | microtubule (3.9e-04/5.3e-01/ 6/ 108) | microtubule motor activity (1.2e-04/1.7e-01/ 5/ 30) | |||
| 185 | 2.6/2.6 | 104 | 3 | mml, oan | kd | excretion (3.2e-07/5.0e-01/ 9/ 24) | apical plasma membrane (3.2e-12/1.2e+00/ 16/ 59) | substrate-specific transporter activity (3.3e-05/7.9e+00/ 25/ 388) | Aldosterone-regulated sodium reabsorption (1.2e-03/ 0.3378/ 5/16) | ||
| 186 | 2.6/2.6 | 74 | 4 | ptr, ppa, ggo, ppy | ht | striated muscle contraction (1.6e-05/2.3e-01/ 6/ 20) | myofibril (9.3e-12/5.0e-01/ 12/ 45) | structural constituent of muscle (2.2e-03/1.8e-01/ 4/ 14) | Dilated cardiomyopathy (2.7e-05/ 0.2871/ 6/34) | ||
| 187 | 2.6/2.4 | 40 | 9 | hsa, ptr, ppa, ggo, mml, mmu | ts | cell cycle (6.0e-03/2.4e+00/ 10/ 370) | spindle microtubule (1.2e-03/6.9e-02/ 3/ 11) | ||||
| 188 | 2.6/2.4 | 56 | 8 | hsa, ptr, ppa, ppy, mml | lv | response to wounding (7.2e-08/2.5e+00/ 17/ 211) | extracellular region (2.9e-10/6.0e+00/ 27/ 533) | endopeptidase inhibitor activity (2.6e-04/3.8e-01/ 6/ 34) | Complement and coagulation cascades (2.2e-11/ 0.4180/11/21) | ||
| 189 | 2.6/2.4 | 72 | 8 | hsa, ptr, ppa, ggo | kd | excretion (7.7e-06/3.4e-01/ 7/ 24) | apical plasma membrane (1.7e-09/7.8e-01/ 12/ 59) | amiloride-sensitive sodium channel activity (1.1e-03/5.5e-02/ 3/ 4) | Aldosterone-regulated sodium reabsorption (2.3e-04/ 0.2316/ 5/16) | ||
| 190 | 2.6/2.4 | 84 | 13 | oan | br, cb, ht, kd, lv, ts | nucleic acid metabolic process (2.6e-02/1.6e+01/ 28/1075) | intracellular organelle lumen (5.2e-04/9.1e+00/ 23/ 621) | RNA binding (3.2e-02/3.1e+00/ 10/ 212) | |||
| 191 | 2.6/2.4 | 56 | 10 | hsa, ptr, ppa, ggo, ppy, mml | lv | response to wounding (3.4e-12/2.4e+00/ 21/ 211) | extracellular region (7.4e-14/6.0e+00/ 31/ 533) | endopeptidase inhibitor activity (2.2e-04/3.7e-01/ 6/ 34) | Complement and coagulation cascades (2.1e-12/ 0.4306/12/21) | ||
| 192 | 2.6/2.4 | 101 | 6 | hsa, ptr, mml, mmu | ht | muscle system process (4.8e-09/1.4e+00/ 15/ 81) | myofibril (1.5e-20/7.6e-01/ 20/ 45) | structural constituent of muscle (1.4e-06/2.6e-01/ 7/ 14) | Dilated cardiomyopathy (4.4e-06/ 0.5332/ 8/34) | ||
| 193 | 2.6/2.4 | 46 | 6 | mdo, oan, gga | lv | bile acid metabolic process (3.3e-04/1.0e-01/ 4/ 11) | extracellular space (4.2e-03/2.1e+00/ 9/ 226) | oxysterol 7-alpha-hydroxylase activity (5.8e-03/1.9e-02/ 2/ 2) | Primary bile acid biosynthesis (1.9e-04/ 0.0344/ 3/3) | ||
| 194 | 2.6/2.4 | 106 | 13 | ptr, ppa, mml, mmu, mdo, oan, gga | ts | M phase (3.4e-16/1.7e+00/ 22/ 152) | microtubule cytoskeleton (7.3e-11/2.6e+00/ 20/ 227) | microtubule motor activity (2.7e-09/3.6e-01/ 10/ 30) | |||
| 195 | 2.6/2.4 | 34 | 4 | hsa | br | ||||||
| 196 | 2.6/2.4 | 88 | 4 | ggo, mml, mdo | ht | muscle contraction (2.9e-09/1.1e+00/ 14/ 74) | myofibril (2.4e-17/6.7e-01/ 17/ 45) | structural constituent of muscle (1.4e-05/2.2e-01/ 6/ 14) | Cardiac muscle contraction (4.2e-07/ 0.3920/ 8/25) | ||
| 197 | 2.6/2.4 | 102 | 10 | mdo | br, cb, ht, kd, lv | glycerolipid biosynthetic process (1.4e-02/5.7e-01/ 5/ 32) | GPI-anchor transamidase complex (1.8e-02/5.4e-02/ 2/ 3) | GPI-anchor transamidase activity (3.3e-02/5.1e-02/ 2/ 3) | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (3.2e-02/ 0.1990/ 3/11) | MT (3.8e-02/ 0.110/ 3/ 6) | |
| 198 | 2.6/2.4 | 83 | 4 | mml, mdo, gga | ht | muscle contraction (2.6e-05/1.1e+00/ 10/ 74) | myofibril (3.2e-13/6.5e-01/ 14/ 45) | actin binding (3.6e-04/1.9e+00/ 11/ 124) | Cardiac muscle contraction (1.3e-05/ 0.4071/ 7/25) | ||
| 199 | 2.6/2.4 | 56 | 11 | hsa, ptr, ppa, ggo, mml, mmu, gga | ts | sexual reproduction (1.2e-05/1.1e+00/ 10/ 145) | microtubule cytoskeleton (7.3e-04/1.6e+00/ 9/ 227) | microtubule motor activity (4.9e-03/2.3e-01/ 4/ 30) | |||
| 200 | 2.6/2.4 | 54 | 5 | mmu, oan | lv | organic acid metabolic process (1.7e-07/2.3e+00/ 16/ 228) | cell fraction (2.3e-02/3.9e+00/ 11/ 377) | amino acid binding (5.5e-03/2.4e-01/ 4/ 25) | ABC transporters (4.7e-02/ 0.2364/ 3/14) | ||
| 201 | 2.6/2.2 | 70 | 6 | gga | ht, kd, lv | leukocyte differentiation (3.8e-05/8.8e-01/ 9/ 72) | origin recognition complex (4.2e-02/8.5e-02/ 2/ 7) | DNA replication origin binding (4.7e-02/6.0e-02/ 2/ 5) | Allograft rejection (2.8e-03/ 0.0784/ 3/5) | ||
| 202 | 2.6/2.2 | 104 | 12 | mdo | br, cb, ht, kd, lv, ts | attachment of GPI anchor to protein (4.5e-02/5.6e-02/ 2/ 3) | GPI-anchor transamidase complex (1.8e-02/5.6e-02/ 2/ 3) | GPI-anchor transamidase activity (3.5e-02/5.3e-02/ 2/ 3) | Parkinson's disease (5.0e-03/ 0.4723/ 5/27) | MT (2.3e-03/ 0.113/ 4/ 6) | |
| 203 | 2.6/2.2 | 42 | 6 | mmu | kd, lv | digestion (3.1e-02/1.7e-01/ 3/ 23) | apical cortex (1.9e-03/1.6e-02/ 2/ 2) | ||||
| 204 | 2.6/2.2 | 50 | 11 | hsa, ptr, ppa, ggo, mml, mmu, mdo | ts | cell cycle process (5.0e-05/1.6e+00/ 11/ 259) | microtubule cytoskeleton (5.9e-04/1.6e+00/ 9/ 227) | microtubule motor activity (4.2e-02/2.2e-01/ 3/ 30) | |||
| 205 | 2.6/2.2 | 54 | 4 | oan, gga | kd | apical part of cell (2.0e-03/7.2e-01/ 6/ 75) | protein dimerization activity (3.3e-02/2.1e+00/ 8/ 206) | ||||
| 206 | 2.6/2.2 | 46 | 10 | hsa, ptr, ppa, ggo, mml, mmu, mdo | ts | cell cycle process (2.5e-04/1.6e+00/ 10/ 259) | spindle microtubule (1.2e-03/6.9e-02/ 3/ 11) | ||||
| 207 | 2.6/2.2 | 69 | 10 | hsa, ptr, ppa, ppy, mml, mmu | lv | wound healing (1.5e-06/1.3e+00/ 12/ 88) | extracellular region (3.6e-08/7.2e+00/ 27/ 533) | endopeptidase inhibitor activity (4.7e-05/4.4e-01/ 7/ 34) | Complement and coagulation cascades (1.1e-10/ 0.4940/11/21) | ||
| 208 | 2.6/2.2 | 83 | 13 | hsa, ptr, ppa, mml, mmu, mdo, oan | lv | organic acid metabolic process (7.1e-11/4.1e+00/ 25/ 228) | extracellular region (3.9e-10/8.7e+00/ 33/ 533) | vitamin binding (6.6e-07/9.1e-01/ 11/ 55) | Complement and coagulation cascades (4.5e-11/ 0.6206/12/21) | ||
| 209 | 2.6/2.2 | 82 | 7 | mmu, mdo, gga | kd | sodium ion transport (9.8e-05/7.3e-01/ 8/ 47) | apical plasma membrane (1.2e-06/8.9e-01/ 10/ 59) | symporter activity (4.6e-05/8.9e-01/ 9/ 56) | Aldosterone-regulated sodium reabsorption (2.8e-02/ 0.1834/ 3/16) | ||
| 210 | 2.6/2.2 | 75 | 9 | mml, mmu, mdo, oan | lv | organic acid metabolic process (2.0e-07/3.8e+00/ 20/ 228) | platelet alpha granule lumen (1.2e-07/2.3e-01/ 7/ 15) | endopeptidase inhibitor activity (1.0e-04/5.0e-01/ 7/ 34) | Complement and coagulation cascades (2.3e-07/ 0.5446/ 9/21) | ||
| 211 | 2.6/2.2 | 85 | 10 | hsa, ptr, ppa, ggo, ppy, mml | ht | cardiac muscle tissue development (2.2e-08/5.0e-01/ 10/ 34) | contractile fiber part (1.4e-15/5.7e-01/ 15/ 41) | structural constituent of muscle (1.4e-05/2.2e-01/ 6/ 14) | Dilated cardiomyopathy (8.1e-07/ 0.4306/ 8/34) | ||
| 212 | 2.6/2.2 | 81 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | excretion (1.0e-06/3.9e-01/ 8/ 24) | apical plasma membrane (4.5e-10/8.9e-01/ 13/ 59) | inorganic cation transmembrane transporter activity (4.4e-04/1.2e+00/ 9/ 77) | Aldosterone-regulated sodium reabsorption (5.2e-04/ 0.2799/ 5/16) | ||
| 213 | 2.6/2.2 | 43 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | nervous system development (5.1e-04/3.6e+00/ 14/ 467) | hedgehog receptor activity (9.5e-03/2.2e-02/ 2/ 3) | ||||
| 214 | 2.6/2.2 | 78 | 7 | hsa, mdo, oan, gga | kd | excretion (2.8e-08/3.7e-01/ 9/ 24) | apical part of cell (7.7e-08/1.1e+00/ 12/ 75) | transmembrane transporter activity (2.0e-05/5.6e+00/ 21/ 368) | Aldosterone-regulated sodium reabsorption (7.7e-05/ 0.1834/ 5/16) | ||
| 215 | 2.6/2.2 | 59 | 12 | hsa, ptr, ppa, ggo, ppy, mml, mdo | lv | response to wounding (4.3e-10/2.7e+00/ 20/ 211) | extracellular region (3.7e-12/6.3e+00/ 30/ 533) | endopeptidase inhibitor activity (2.7e-05/4.0e-01/ 7/ 34) | Complement and coagulation cascades (1.2e-09/ 0.4433/10/21) | ||
| 216 | 2.6/2.2 | 45 | 5 | mmu, mdo | kd, lv | extracellular region (1.8e-02/4.4e+00/ 12/ 533) | Peroxisome (3.2e-02/ 0.1990/ 3/30) | ||||
| 217 | 2.6/2.2 | 62 | 10 | hsa, ptr, ppa, ppy, mml, oan | lv | response to wounding (1.8e-08/2.9e+00/ 19/ 211) | extracellular region (4.3e-12/6.7e+00/ 31/ 533) | endopeptidase inhibitor activity (4.4e-05/4.3e-01/ 7/ 34) | Complement and coagulation cascades (6.4e-12/ 0.4940/12/21) | ||
| 218 | 2.6/2.2 | 112 | 9 | hsa, ptr, ppa, ggo, ppy, mml, mmu | ht | muscle contraction (2.3e-08/1.3e+00/ 14/ 74) | sarcomere (1.6e-17/6.6e-01/ 17/ 37) | actin binding (6.4e-06/2.5e+00/ 15/ 124) | Cardiac muscle contraction (5.0e-08/ 0.4524/ 9/25) | ||
| 219 | 2.6/2 | 75 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | lv | organic acid metabolic process (5.0e-09/3.8e+00/ 22/ 228) | extracellular region (3.4e-12/7.9e+00/ 34/ 533) | endopeptidase inhibitor activity (1.0e-05/5.1e-01/ 8/ 34) | Complement and coagulation cascades (8.0e-13/ 0.5320/13/21) | ||
| 220 | 2.6/2 | 103 | 12 | gga | br, cb, ht, kd, lv, ts | nucleic acid metabolic process (4.0e-05/1.8e+01/ 38/1075) | nucleus (1.3e-02/2.6e+01/ 41/1528) | nucleic acid binding (1.5e-02/1.4e+01/ 27/ 802) | |||
| 221 | 2.6/2 | 27 | 6 | mml, oan | lv, kd | organic acid metabolic process (6.4e-03/1.1e+00/ 7/ 228) | |||||
| 222 | 2.6/2 | 86 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mdo | kd | excretion (7.5e-08/4.2e-01/ 9/ 24) | apical plasma membrane (3.8e-12/9.6e-01/ 15/ 59) | transmembrane transporter activity (9.7e-05/6.2e+00/ 21/ 368) | Aldosterone-regulated sodium reabsorption (4.4e-04/ 0.2702/ 5/16) | ||
| 223 | 2.6/2 | 34 | 9 | mmu | ht, kd, lv | ||||||
| 224 | 2.6/1.8 | 40 | 9 | mmu, mdo, oan, gga | br | G-protein coupled receptor protein signaling pathway (5.0e-04/1.3e+00/ 9/ 175) | plasma membrane (4.4e-05/8.8e+00/ 23/1133) | neurotransmitter binding (4.6e-04/2.4e-01/ 5/ 30) | Neuroactive ligand-receptor interaction (1.2e-03/ 0.9228/ 7/102) | ||
| 225 | 2.6/1.8 | 28 | 12 | hsa, ptr, ppa, ggo, ppy, mml, gga | br | memory (8.8e-04/1.3e-01/ 4/ 25) | voltage-gated potassium channel complex (2.8e-03/2.5e-01/ 4/ 46) | serotonin receptor activity (5.2e-03/1.5e-02/ 2/ 3) | Long-term depression (2.0e-02/ 0.1628/ 3/30) | ||
| 226 | 2.6/1.8 | 45 | 13 | hsa, ptr, ppa, ggo, ppy, mml, mdo | cb | system development (2.5e-03/7.6e+00/ 19/ 958) | hedgehog receptor activity (1.0e-02/2.4e-02/ 2/ 3) | ||||
| 227 | 2.6/1.8 | 43 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mdo, oan | cb | developmental process (1.6e-02/9.1e+00/ 19/1216) | hedgehog receptor activity (9.8e-03/2.3e-02/ 2/ 3) | Long-term depression (3.9e-02/ 0.2171/ 3/30) | |||
| 228 | 2.6/1.8 | 13 | 19 | hsa, ptr, ppa, ggo, ppy, mml | br | potassium ion transport (1.6e-02/1.3e-01/ 3/ 59) | voltage-gated potassium channel complex (4.1e-03/1.1e-01/ 3/ 46) | voltage-gated potassium channel activity (8.0e-03/1.1e-01/ 3/ 50) | |||
| 229 | 2.6/1.6 | 45 | 9 | mdo, gga | ts, ht, kd, lv | ||||||
| 230 | 2.6/1.6 | 12 | 20 | hsa, ptr, ppa, ggo, ppy, mml | br | potassium ion transport (2.0e-02/1.5e-01/ 3/ 59) | voltage-gated potassium channel complex (4.1e-03/1.1e-01/ 3/ 46) | voltage-gated potassium channel activity (1.0e-02/1.2e-01/ 3/ 50) | |||
| 231 | 2.6/1.6 | 83 | 17 | mmu | br, cb, ht, kd, lv, ts | ||||||
| 232 | 2.6/1.6 | 37 | 17 | ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | learning (1.0e-03/1.4e-01/ 4/ 19) | ion channel complex (3.4e-06/7.7e-01/ 9/ 108) | ion channel activity (6.2e-05/1.3e+00/ 10/ 176) | Gastric acid secretion (4.7e-02/ 0.2352/ 3/30) | ||
| 233 | 2.6/1.6 | 42 | 15 | hsa, ppa, ppy, mml, mmu, mdo, oan, gga | br | ion transport (1.7e-04/2.7e+00/ 13/ 332) | ion channel complex (9.3e-07/8.8e-01/ 10/ 108) | ion channel activity (3.2e-06/1.4e+00/ 12/ 176) | Neuroactive ligand-receptor interaction (9.1e-03/ 0.9228/ 6/102) | ||
| 234 | 2.6/1.6 | 37 | 15 | ppa, ppy, mml, mmu, mdo, oan, gga | br | ion transport (2.6e-04/2.4e+00/ 12/ 332) | ion channel complex (2.7e-07/7.7e-01/ 10/ 108) | ion channel activity (9.9e-07/1.3e+00/ 12/ 176) | Neuroactive ligand-receptor interaction (9.1e-03/ 0.9228/ 6/102) | ||
| 235 | 2.6/1.4 | 17 | 29 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | central nervous system development (1.7e-02/6.3e-01/ 5/ 186) | voltage-gated potassium channel complex (5.6e-04/1.6e-01/ 4/ 46) | voltage-gated potassium channel activity (1.4e-03/1.6e-01/ 4/ 50) | |||
| 236 | 2.6/1.4 | 47 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb | synaptic transmission, glutamatergic (1.6e-02/1.3e-01/ 3/ 16) | hedgehog receptor activity (1.2e-02/2.6e-02/ 2/ 3) | Long-term depression (6.8e-03/ 0.2714/ 4/30) | |||
| 237 | 2.6/1.4 | 14 | 24 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo | br | potassium ion transport (2.0e-02/1.5e-01/ 3/ 59) | voltage-gated potassium channel complex (5.1e-03/1.2e-01/ 3/ 46) | voltage-gated potassium channel activity (1.0e-02/1.2e-01/ 3/ 50) | |||
| 238 | 2.6/1.4 | 46 | 13 | hsa | br, ht, kd, lv, ts | autophagy (3.1e-02/1.7e-01/ 3/ 20) | Selenoamino acid metabolism (4.8e-02/ 0.0603/ 2/10) | ||||
| 239 | 2.4/3 | 97 | 6 | hsa, ptr, ppa, ggo, mml | ts | cell cycle (2.0e-05/6.2e+00/ 22/ 370) | microtubule cytoskeleton (1.3e-03/3.6e+00/ 13/ 227) | nucleic acid binding (2.2e-02/1.2e+01/ 24/ 802) | |||
| 240 | 2.4/3 | 84 | 4 | ptr, ppa, mml | ts | M phase (3.0e-03/2.1e+00/ 10/ 152) | microtubule organizing center (6.1e-04/1.5e+00/ 9/ 113) | nucleic acid binding (7.0e-03/1.1e+01/ 23/ 802) | |||
| 241 | 2.4/3 | 115 | 5 | mdo, oan | ts | M phase (1.2e-08/2.8e+00/ 19/ 152) | non-membrane-bounded organelle (3.4e-04/1.5e+01/ 32/ 855) | nucleic acid binding (1.1e-03/1.4e+01/ 30/ 802) | |||
| 242 | 2.4/3 | 107 | 3 | ppa, ppy | lv | response to wounding (2.8e-07/4.6e+00/ 22/ 211) | extracellular region (3.5e-07/1.1e+01/ 32/ 533) | enzyme inhibitor activity (4.5e-03/1.4e+00/ 8/ 69) | Complement and coagulation cascades (1.4e-09/ 0.6333/11/21) | ||
| 243 | 2.4/3 | 132 | 5 | mmu, oan | ts | M phase (1.9e-10/2.8e+00/ 21/ 152) | chromosome, centromeric region (3.5e-06/1.0e+00/ 10/ 54) | motor activity (4.5e-03/1.0e+00/ 7/ 55) | |||
| 244 | 2.4/3 | 126 | 3 | mmu | ht | muscle organ development (1.3e-03/2.7e+00/ 12/ 116) | myofibril (2.1e-08/9.9e-01/ 12/ 45) | structural constituent of muscle (1.1e-02/3.1e-01/ 4/ 14) | Dilated cardiomyopathy (1.1e-03/ 0.8408/ 7/34) | ||
| 245 | 2.4/3 | 91 | 4 | oan | br, cb | ||||||
| 246 | 2.4/3 | 101 | 3 | oan | ts | M phase (6.4e-05/2.7e+00/ 14/ 152) | nucleus (1.7e-02/2.5e+01/ 39/1528) | nucleic acid binding (1.5e-02/1.4e+01/ 27/ 802) | |||
| 247 | 2.4/3 | 96 | 3 | mmu | lv | organic acid metabolic process (5.4e-06/4.2e+00/ 19/ 228) | integral to organelle membrane (4.0e-04/1.1e+00/ 8/ 58) | carboxylic acid binding (2.9e-03/9.4e-01/ 7/ 53) | |||
| 248 | 2.4/3 | 92 | 4 | mdo | br, cb | attachment of GPI anchor to protein (6.0e-04/4.9e-02/ 3/ 3) | GPI-anchor transamidase complex (2.0e-04/4.9e-02/ 3/ 3) | GPI-anchor transamidase activity (4.9e-04/4.6e-02/ 3/ 3) | Parkinson's disease (5.0e-03/ 0.4723/ 5/27) | MT (3.2e-02/ 0.100/ 3/ 6) | |
| 249 | 2.4/2.8 | 80 | 3 | hsa | kd | excretion (1.3e-05/3.7e-01/ 7/ 24) | apical plasma membrane (7.1e-06/8.3e-01/ 9/ 59) | amiloride-sensitive sodium channel activity (1.2e-03/5.8e-02/ 3/ 4) | Aldosterone-regulated sodium reabsorption (1.9e-04/ 0.2220/ 5/16) | ||
| 250 | 2.4/2.8 | 72 | 3 | mmu | cb | neurotransmitter transport (1.7e-02/5.9e-01/ 5/ 42) | integral to plasma membrane (1.3e-02/5.4e+00/ 14/ 413) | amine transmembrane transporter activity (5.3e-03/4.5e-01/ 5/ 33) | |||
| 251 | 2.4/2.8 | 89 | 4 | mdo | kd, lv | sphingosine biosynthetic process (3.5e-02/4.8e-02/ 2/ 3) | cytoplasm (2.0e-02/4.2e+01/ 56/2671) | oxidoreductase activity, acting on sulfur group of donors (3.6e-02/2.0e-01/ 3/ 14) | Parkinson's disease (2.5e-02/ 0.4071/ 4/27) | MT (2.8e-02/ 0.094/ 3/ 6) | |
| 252 | 2.4/2.8 | 117 | 4 | mmu, gga | ts | microtubule-based process (9.8e-06/1.6e+00/ 12/ 105) | microtubule cytoskeleton (4.6e-05/3.4e+00/ 15/ 227) | microtubule motor activity (4.1e-06/4.5e-01/ 8/ 30) | |||
| 253 | 2.4/2.8 | 117 | 3 | mmu | kd | sodium ion transport (5.0e-03/1.0e+00/ 7/ 47) | apical plasma membrane (6.1e-03/1.3e+00/ 7/ 59) | active transmembrane transporter activity (5.1e-03/2.7e+00/ 11/ 130) | Glycosphingolipid biosynthesis - lacto and neolacto series (1.4e-02/ 0.1435/ 3/7) | ||
| 254 | 2.4/2.8 | 92 | 7 | hsa, ptr, ppa, ggo, mml | ts | M phase (4.5e-04/2.4e+00/ 12/ 152) | spindle microtubule (5.0e-04/1.6e-01/ 4/ 11) | ||||
| 255 | 2.4/2.8 | 103 | 3 | ppa, ggo, ppy | lv | response to wounding (7.6e-10/4.5e+00/ 25/ 211) | extracellular region (5.9e-07/1.0e+01/ 31/ 533) | cytokine receptor activity (1.9e-04/5.7e-01/ 7/ 29) | Complement and coagulation cascades (7.9e-10/ 0.5953/11/21) | ||
| 256 | 2.4/2.8 | 75 | 3 | hsa | br | small-subunit processome (1.9e-02/5.5e-02/ 2/ 4) | Ras GTPase activator activity (4.9e-02/5.1e-01/ 4/ 42) | ||||
| 257 | 2.4/2.8 | 96 | 6 | ptr, ppa, mml, mmu | ts | cell cycle process (1.4e-04/3.4e+00/ 15/ 259) | piP-body (4.3e-03/2.6e-02/ 2/ 2) | RNA polymerase binding (2.3e-02/4.1e-02/ 2/ 3) | |||
| 258 | 2.4/2.8 | 106 | 6 | mml, mmu, mdo | ts | M phase (3.9e-06/2.1e+00/ 14/ 152) | microtubule cytoskeleton (1.4e-06/2.9e+00/ 16/ 227) | microtubule motor activity (4.6e-04/4.3e-01/ 6/ 30) | Oocyte meiosis (4.5e-02/ 0.2352/ 3/39) | ||
| 259 | 2.4/2.8 | 109 | 3 | ptr, ppa | kd | excretion (7.4e-05/4.9e-01/ 7/ 24) | apical part of cell (8.6e-05/1.5e+00/ 10/ 75) | scavenger receptor activity (1.3e-02/3.3e-01/ 4/ 16) | Aldosterone-regulated sodium reabsorption (1.2e-02/ 0.3185/ 4/16) | ||
| 260 | 2.4/2.8 | 99 | 4 | gga | kd, lv | positive regulation of interferon-gamma production (8.4e-03/1.1e-01/ 3/ 6) | clathrin adaptor complex (3.2e-02/2.6e-01/ 3/ 15) | cytokine binding (3.2e-02/7.5e-01/ 5/ 43) | Allograft rejection (6.6e-03/ 0.1116/ 3/5) | ||
| 261 | 2.4/2.8 | 90 | 5 | mmu, oan | lv | organic acid metabolic process (4.9e-07/4.0e+00/ 20/ 228) | cell fraction (2.0e-03/6.6e+00/ 18/ 377) | carboxylic acid binding (3.5e-04/9.0e-01/ 8/ 53) | Complement and coagulation cascades (1.1e-03/ 0.5700/ 6/21) | ||
| 262 | 2.4/2.8 | 107 | 5 | oan | br, cb, ht | regulation of transcription involved in G1/S phase of mitotic cell cycle (4.1e-02/5.2e-02/ 2/ 3) | Spliceosome (2.3e-02/ 0.3981/ 4/22) | ||||
| 263 | 2.4/2.6 | 103 | 8 | ptr, ppa, mml, mmu, mdo | ts | M phase (2.7e-10/2.0e+00/ 18/ 152) | microtubule cytoskeleton (2.3e-07/2.9e+00/ 17/ 227) | microtubule motor activity (3.9e-03/4.2e-01/ 5/ 30) | |||
| 264 | 2.4/2.6 | 102 | 8 | hsa, ptr, ppa, ggo, mml, mmu | ts | M phase (1.8e-08/2.2e+00/ 17/ 152) | microtubule cytoskeleton (1.9e-07/3.2e+00/ 18/ 227) | microtubule motor activity (5.2e-05/4.5e-01/ 7/ 30) | |||
| 265 | 2.4/2.6 | 88 | 4 | hsa, ppa | kd | excretion (7.5e-08/4.2e-01/ 9/ 24) | apical plasma membrane (1.7e-06/9.2e-01/ 10/ 59) | amiloride-sensitive sodium channel activity (1.8e-03/6.8e-02/ 3/ 4) | Aldosterone-regulated sodium reabsorption (2.7e-04/ 0.2413/ 5/16) | ||
| 266 | 2.4/2.6 | 147 | 10 | gga | br, cb, ht, kd, lv | nucleic acid metabolic process (8.5e-05/2.6e+01/ 49/1075) | nucleus (8.1e-03/3.8e+01/ 56/1528) | nucleic acid binding (1.5e-02/2.1e+01/ 36/ 802) | |||
| 267 | 2.4/2.6 | 104 | 5 | hsa, ggo | kd | excretion (2.7e-07/4.9e-01/ 9/ 24) | apical plasma membrane (9.9e-07/1.1e+00/ 11/ 59) | transmembrane transporter activity (2.2e-04/7.2e+00/ 22/ 368) | Aldosterone-regulated sodium reabsorption (9.1e-04/ 0.3185/ 5/16) | ||
| 268 | 2.4/2.6 | 125 | 5 | oan, gga | ts | M phase (1.6e-09/2.8e+00/ 20/ 152) | condensed chromosome (1.2e-04/9.1e-01/ 8/ 49) | microtubule motor activity (1.0e-02/5.5e-01/ 5/ 30) | |||
| 269 | 2.4/2.6 | 95 | 5 | hsa, ptr, ppa | kd | excretion (1.4e-07/4.5e-01/ 9/ 24) | apical plasma membrane (2.4e-09/1.0e+00/ 13/ 59) | transmembrane transporter activity (4.2e-04/6.9e+00/ 21/ 368) | Aldosterone-regulated sodium reabsorption (6.0e-04/ 0.2895/ 5/16) | ||
| 270 | 2.4/2.6 | 98 | 4 | gga | br, cb | G-protein coupled receptor protein signaling pathway (3.0e-02/2.9e+00/ 10/ 175) | postsynaptic membrane (2.2e-02/1.2e+00/ 6/ 76) | neuropeptide receptor activity (2.4e-03/1.9e-01/ 4/ 12) | Neuroactive ligand-receptor interaction (1.0e-02/ 1.7226/ 8/102) | X (5.6e-03/ 2.499/12/145) | |
| 271 | 2.4/2.6 | 165 | 11 | ptr, mml, mmu, mdo, oan, gga | ts | M phase (4.4e-24/3.1e+00/ 35/ 152) | microtubule cytoskeleton (1.3e-15/4.5e+00/ 31/ 227) | microtubule motor activity (2.0e-08/6.4e-01/ 11/ 30) | Cell cycle (2.9e-04/ 0.4439/ 6/46) | ||
| 272 | 2.4/2.6 | 100 | 4 | mdo, gga | ts | microtubule-based movement (2.8e-03/6.2e-01/ 6/ 44) | chromosome (7.3e-05/2.2e+00/ 12/ 150) | chromatin binding (2.6e-04/8.5e-01/ 8/ 65) | |||
| 273 | 2.4/2.6 | 102 | 5 | ppa, ggo, ppy | lv | response to wounding (3.9e-09/4.4e+00/ 24/ 211) | extracellular region (2.0e-11/1.0e+01/ 38/ 533) | cytokine receptor activity (1.6e-03/5.7e-01/ 6/ 29) | Complement and coagulation cascades (5.4e-11/ 0.6333/12/21) | ||
| 274 | 2.4/2.6 | 86 | 5 | hsa, ptr, ppa | lv | wound healing (1.4e-06/1.6e+00/ 13/ 88) | extracellular region (4.4e-08/8.7e+00/ 30/ 533) | endopeptidase inhibitor activity (1.9e-04/5.7e-01/ 7/ 34) | Complement and coagulation cascades (6.4e-12/ 0.4940/12/21) | ||
| 275 | 2.4/2.6 | 102 | 4 | mdo, gga | ht | cardiac muscle tissue development (2.6e-05/6.1e-01/ 8/ 34) | myofibril (4.3e-07/8.0e-01/ 10/ 45) | cytidine deaminase activity (1.7e-02/3.7e-02/ 2/ 2) | Cardiac muscle contraction (6.4e-05/ 0.5277/ 7/25) | ||
| 276 | 2.4/2.6 | 127 | 5 | hsa, ptr, ppa, ggo, ppy | ht | muscle contraction (2.2e-08/1.6e+00/ 15/ 74) | myofibril (1.1e-17/9.3e-01/ 19/ 45) | structural constituent of muscle (4.4e-06/3.2e-01/ 7/ 14) | Dilated cardiomyopathy (1.5e-06/ 0.6562/ 9/34) | ||
| 277 | 2.4/2.6 | 126 | 8 | ptr, ppa, mml, mmu, gga | ts | M phase (4.4e-11/2.3e+00/ 20/ 152) | microtubule cytoskeleton (5.8e-08/3.4e+00/ 19/ 227) | microtubule motor activity (6.4e-07/5.1e-01/ 9/ 30) | |||
| 278 | 2.4/2.6 | 84 | 3 | mml, mdo | lv | response to wounding (2.8e-09/3.6e+00/ 22/ 211) | extracellular region (3.3e-07/8.9e+00/ 29/ 533) | vitamin binding (3.0e-04/8.7e-01/ 8/ 55) | Complement and coagulation cascades (3.4e-07/ 0.5700/ 9/21) | ||
| 279 | 2.4/2.6 | 67 | 4 | mml | kd, lv | activation of NF-kappaB-inducing kinase activity (4.2e-02/5.1e-02/ 2/ 4) | mitochondrion (4.8e-02/5.0e+00/ 12/ 427) | ||||
| 280 | 2.4/2.4 | 105 | 7 | hsa, ptr, ppa, ggo, mml | kd | excretion (4.8e-10/4.9e-01/ 11/ 24) | apical plasma membrane (5.1e-10/1.1e+00/ 14/ 59) | transmembrane transporter activity (1.1e-03/7.5e+00/ 21/ 368) | Aldosterone-regulated sodium reabsorption (9.1e-04/ 0.3185/ 5/16) | ||
| 281 | 2.4/2.4 | 97 | 4 | oan, gga | ht | heart development (1.4e-04/2.1e+00/ 12/ 117) | myofibril (3.2e-07/7.7e-01/ 10/ 45) | myosin binding (2.9e-02/1.9e-01/ 3/ 11) | Cardiac muscle contraction (3.3e-02/ 0.4524/ 4/25) | ||
| 282 | 2.4/2.4 | 92 | 10 | hsa, ptr, ppa, ggo, ppy, mml | lv | response to wounding (5.7e-10/4.1e+00/ 24/ 211) | extracellular region (2.3e-11/9.8e+00/ 37/ 533) | serine-type endopeptidase inhibitor activity (3.3e-05/4.2e-01/ 7/ 23) | Complement and coagulation cascades (2.8e-13/ 0.6333/14/21) | ||
| 283 | 2.4/2.4 | 129 | 8 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (2.7e-07/1.6e+00/ 14/ 74) | myofibril (4.8e-15/9.4e-01/ 17/ 45) | actin binding (4.7e-05/3.0e+00/ 15/ 124) | Dilated cardiomyopathy (1.8e-06/ 0.6767/ 9/34) | ||
| 284 | 2.4/2.4 | 128 | 3 | ggo, mdo | ht | cellular respiration (1.8e-06/8.2e-01/ 10/ 36) | sarcomere (1.7e-13/8.1e-01/ 15/ 37) | actin binding (3.6e-05/2.9e+00/ 15/ 124) | Cardiac muscle contraction (4.2e-07/ 0.5730/ 9/25) | ||
| 285 | 2.4/2.4 | 97 | 5 | mmu, mdo | lv | organic acid metabolic process (1.7e-11/4.5e+00/ 27/ 228) | endoplasmic reticulum part (4.2e-05/4.2e+00/ 17/ 227) | carboxylic acid binding (1.0e-05/9.7e-01/ 10/ 53) | Primary bile acid biosynthesis (2.3e-03/ 0.0923/ 3/3) | ||
| 286 | 2.4/2.4 | 59 | 4 | hsa | br | Inositol phosphate metabolism (4.6e-02/ 0.2316/ 3/24) | |||||
| 287 | 2.4/2.4 | 97 | 7 | hsa, ptr, ppa, ppy, mml | lv | wound healing (8.5e-10/1.8e+00/ 17/ 88) | extracellular region (8.2e-12/1.0e+01/ 39/ 533) | endopeptidase inhibitor activity (4.4e-05/6.5e-01/ 8/ 34) | Complement and coagulation cascades (8.5e-11/ 0.6586/12/21) | ||
| 288 | 2.4/2.4 | 108 | 8 | hsa, ptr, ppa, ggo | kd | excretion (6.3e-06/5.1e-01/ 8/ 24) | apical part of cell (1.6e-09/1.5e+00/ 15/ 75) | transmembrane transporter activity (5.4e-04/7.6e+00/ 22/ 368) | Aldosterone-regulated sodium reabsorption (9.1e-04/ 0.3185/ 5/16) | ||
| 289 | 2.4/2.4 | 145 | 13 | oan | br, cb, ht, kd, lv, ts | paraxial mesoderm development (1.9e-02/1.5e-01/ 3/ 6) | nuclear part (8.6e-05/1.6e+01/ 36/ 637) | syntaxin binding (3.3e-02/2.1e-01/ 3/ 8) | |||
| 290 | 2.4/2.4 | 94 | 4 | oan | kd, lv | urea cycle (1.8e-02/3.5e-02/ 2/ 2) | pre-snoRNP complex (1.6e-02/5.1e-02/ 2/ 3) | ||||
| 291 | 2.4/2.4 | 141 | 10 | mdo | br, cb, ht, kd, lv | DNA dealkylation involved in DNA repair (2.9e-02/4.8e-02/ 2/ 2) | intracellular membrane-bounded organelle (1.1e-02/6.6e+01/ 84/2681) | Parkinson's disease (1.2e-02/ 0.5862/ 5/27) | MT (5.6e-03/ 0.155/ 4/ 6) | ||
| 292 | 2.4/2.4 | 112 | 4 | mdo, gga | kd | sodium ion transport (7.3e-05/9.7e-01/ 9/ 47) | apical plasma membrane (7.1e-04/1.2e+00/ 8/ 59) | inorganic cation transmembrane transporter activity (4.0e-04/1.6e+00/ 10/ 77) | |||
| 293 | 2.4/2.4 | 98 | 4 | mdo, oan | ht | energy derivation by oxidation of organic compounds (3.9e-06/1.1e+00/ 11/ 60) | organelle inner membrane (1.9e-08/1.7e+00/ 15/ 101) | NADH dehydrogenase activity (2.8e-04/2.3e-01/ 5/ 12) | Cardiac muscle contraction (8.2e-04/ 0.5277/ 6/25) | ||
| 294 | 2.4/2.4 | 98 | 7 | mmu, mdo, oan | lv | organic acid metabolic process (9.2e-14/4.7e+00/ 30/ 228) | platelet alpha granule lumen (1.3e-05/2.9e-01/ 6/ 15) | carboxylic acid binding (1.4e-06/9.9e-01/ 11/ 53) | Complement and coagulation cascades (2.4e-05/ 0.6840/ 8/21) | ||
| 295 | 2.4/2.4 | 101 | 4 | mdo, oan | kd | excretion (5.0e-05/4.6e-01/ 7/ 24) | apical part of cell (1.2e-06/1.4e+00/ 12/ 75) | transporter activity (1.5e-04/8.8e+00/ 25/ 454) | |||
| 296 | 2.4/2.4 | 97 | 9 | ggo | br, cb, ht, kd, lv | regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle (9.7e-03/2.8e-01/ 4/ 17) | Cul3-RING ubiquitin ligase complex (3.6e-02/7.9e-02/ 2/ 5) | ||||
| 297 | 2.4/2.2 | 120 | 9 | mml, mmu, mdo, oan | lv | organic acid metabolic process (2.2e-14/5.9e+00/ 34/ 228) | platelet alpha granule lumen (1.9e-06/3.6e-01/ 7/ 15) | vitamin binding (3.0e-09/1.3e+00/ 15/ 55) | Complement and coagulation cascades (3.0e-09/ 0.9119/12/21) | ||
| 298 | 2.4/2.2 | 121 | 10 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (1.2e-07/1.5e+00/ 14/ 74) | myofibril (1.2e-16/9.2e-01/ 18/ 45) | actin binding (2.4e-05/2.8e+00/ 15/ 124) | Dilated cardiomyopathy (1.8e-06/ 0.6767/ 9/34) | ||
| 299 | 2.4/2.2 | 101 | 13 | hsa, ptr, ppa, ggo, ppy, mml, mdo | lv | response to wounding (1.2e-09/4.6e+00/ 25/ 211) | extracellular region (5.0e-12/1.1e+01/ 40/ 533) | vitamin binding (2.9e-05/1.1e+00/ 10/ 55) | Complement and coagulation cascades (1.1e-11/ 0.6966/13/21) | ||
| 300 | 2.4/2.2 | 121 | 9 | mmu, mdo, oan, gga | kd | sodium ion transport (1.7e-07/1.1e+00/ 12/ 47) | apical part of cell (1.3e-07/1.7e+00/ 14/ 75) | symporter activity (3.3e-07/1.3e+00/ 13/ 56) | Aldosterone-regulated sodium reabsorption (9.1e-04/ 0.3185/ 5/16) | ||
| 301 | 2.4/2.2 | 147 | 12 | mdo | br, cb, ht, kd, lv, ts | ribonucleoprotein complex biogenesis (2.5e-02/1.4e+00/ 7/ 54) | intracellular membrane-bounded organelle (1.2e-02/7.1e+01/ 90/2681) | RNA binding (2.8e-02/5.3e+00/ 14/ 212) | Parkinson's disease (1.8e-02/ 0.6514/ 5/27) | MT (5.6e-03/ 0.161/ 4/ 6) | |
| 302 | 2.4/2.2 | 112 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | excretion (3.0e-08/5.4e-01/ 10/ 24) | apical plasma membrane (1.2e-10/1.2e+00/ 15/ 59) | peptidase activity, acting on L-amino acid peptides (1.8e-03/3.8e+00/ 14/ 171) | Aldosterone-regulated sodium reabsorption (1.8e-03/ 0.3764/ 5/16) | ||
| 303 | 2.4/2.2 | 89 | 4 | oan, gga | lv | zinc ion transport (1.9e-03/1.7e-01/ 4/ 10) | extracellular region (2.5e-02/9.2e+00/ 19/ 533) | ethanolaminephosphotransferase activity (1.5e-02/3.4e-02/ 2/ 2) | Primary bile acid biosynthesis (4.8e-02/ 0.0669/ 2/3) | ||
| 304 | 2.4/2.2 | 109 | 6 | gga | ht, kd, lv | hemopoiesis (3.7e-04/2.3e+00/ 12/ 123) | phosphatidylinositol-4,5-bisphosphate 3-kinase activity (3.7e-02/5.6e-02/ 2/ 3) | Allograft rejection (6.6e-03/ 0.1116/ 3/5) | |||
| 305 | 2.4/2.2 | 109 | 13 | hsa, ptr, ppa, ppy, mml, mmu, mdo | lv | organic acid metabolic process (4.9e-09/5.3e+00/ 26/ 228) | extracellular region (1.0e-10/1.1e+01/ 39/ 533) | vitamin binding (7.0e-06/1.2e+00/ 11/ 55) | Complement and coagulation cascades (2.2e-11/ 0.7726/13/21) | ||
| 306 | 2.4/2.2 | 82 | 5 | mmu, mdo | lv, ts | lung alveolus development (4.0e-02/2.0e-01/ 3/ 14) | |||||
| 307 | 2.4/2.2 | 46 | 7 | hsa, ptr | br | magnesium ion transport (1.1e-02/2.2e-02/ 2/ 3) | |||||
| 308 | 2.4/2.2 | 109 | 11 | hsa, ptr, ppa, ppy, mml, mmu | lv | organic acid metabolic process (5.3e-10/5.2e+00/ 27/ 228) | platelet alpha granule lumen (3.5e-08/3.2e-01/ 8/ 15) | endopeptidase inhibitor activity (7.7e-06/7.1e-01/ 9/ 34) | Complement and coagulation cascades (2.9e-10/ 0.7346/12/21) | ||
| 309 | 2.4/2.2 | 67 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | regulation of transcription, DNA-dependent (2.0e-03/5.6e+00/ 17/ 469) | hedgehog receptor activity (2.0e-02/3.6e-02/ 2/ 3) | ||||
| 310 | 2.4/2.2 | 58 | 5 | mmu, mdo | cb | glycine transmembrane transporter activity (1.5e-02/3.1e-02/ 2/ 3) | |||||
| 311 | 2.4/2 | 137 | 17 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | kd | excretion (5.3e-09/6.3e-01/ 11/ 24) | apical part of cell (6.3e-14/2.0e+00/ 21/ 75) | transmembrane transporter activity (5.8e-07/9.7e+00/ 32/ 368) | Aldosterone-regulated sodium reabsorption (4.2e-03/ 0.4632/ 5/16) | ||
| 312 | 2.4/2 | 78 | 6 | mmu | kd, lv | peroxisome (3.2e-03/5.0e-01/ 5/ 33) | Peroxisome (3.6e-03/ 0.4343/ 5/30) | ||||
| 313 | 2.4/2 | 103 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | lv | organic acid metabolic process (2.6e-10/5.1e+00/ 27/ 228) | extracellular region (5.0e-12/1.1e+01/ 40/ 533) | endopeptidase inhibitor activity (7.3e-05/7.1e-01/ 8/ 34) | Complement and coagulation cascades (2.1e-12/ 0.7853/14/21) | ||
| 314 | 2.4/2 | 131 | 14 | hsa, ptr, ppa, ggo, ppy, mml, mmu | ht | muscle contraction (3.8e-08/1.7e+00/ 15/ 74) | myofibril (1.2e-18/9.8e-01/ 20/ 45) | actin binding (3.0e-06/3.0e+00/ 17/ 124) | Dilated cardiomyopathy (1.9e-07/ 0.7177/10/34) | ||
| 315 | 2.4/2 | 119 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mdo | kd | excretion (4.7e-08/5.7e-01/ 10/ 24) | apical plasma membrane (1.9e-12/1.3e+00/ 17/ 59) | substrate-specific transmembrane transporter activity (1.5e-04/8.0e+00/ 24/ 342) | Aldosterone-regulated sodium reabsorption (2.3e-03/ 0.3957/ 5/16) | ||
| 316 | 2.4/2 | 128 | 8 | gga | ht, kd, lv, ts | response to tumor cell (7.8e-03/1.1e-01/ 3/ 5) | translation regulator activity, nucleic acid binding (4.9e-02/6.8e-02/ 2/ 3) | Allograft rejection (9.5e-03/ 0.1297/ 3/5) | |||
| 317 | 2.4/2 | 61 | 6 | mdo, oan, gga | cb | synaptic transmission, glutamatergic (2.4e-03/1.8e-01/ 4/ 16) | ligand-gated ion channel activity (6.4e-03/7.6e-01/ 6/ 72) | ||||
| 318 | 2.4/2 | 32 | 9 | hsa, ptr | br | ||||||
| 319 | 2.4/1.8 | 24 | 19 | hsa, ptr, ppa, ggo, ppy, mml | br | brain development (1.3e-02/5.7e-01/ 5/ 126) | voltage-gated potassium channel complex (2.1e-02/2.2e-01/ 3/ 46) | phosphoric diester hydrolase activity (2.6e-02/1.7e-01/ 3/ 39) | |||
| 320 | 2.4/1.8 | 67 | 13 | hsa, ppy, mml, mmu, mdo, oan, gga | br | ion transport (3.5e-06/4.2e+00/ 19/ 332) | cation channel complex (5.3e-10/9.0e-01/ 13/ 68) | voltage-gated cation channel activity (3.0e-09/8.5e-01/ 13/ 65) | Gastric acid secretion (3.6e-03/ 0.4343/ 5/30) | ||
| 321 | 2.4/1.8 | 28 | 17 | hsa, ptr, ppa, ggo, ppy, mml | br | brain development (1.9e-02/6.3e-01/ 5/ 126) | voltage-gated potassium channel complex (2.8e-03/2.5e-01/ 4/ 46) | voltage-gated potassium channel activity (6.7e-03/2.5e-01/ 4/ 50) | |||
| 322 | 2.4/1.8 | 60 | 9 | mmu, mdo, oan, gga | br | synaptic transmission (6.5e-05/1.6e+00/ 11/ 146) | plasma membrane (1.8e-06/1.3e+01/ 32/1133) | voltage-gated potassium channel activity (2.4e-05/5.8e-01/ 8/ 50) | Neuroactive ligand-receptor interaction (1.1e-03/ 1.2304/ 8/102) | ||
| 323 | 2.4/1.8 | 93 | 11 | mmu | ht, kd, lv, ts | integral to peroxisomal membrane (4.9e-02/9.5e-02/ 2/ 6) | small conjugating protein binding (3.6e-02/2.0e-01/ 3/ 13) | ||||
| 324 | 2.4/1.8 | 79 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mdo, oan | cb | multicellular organismal process (4.4e-02/2.1e+01/ 33/1507) | postsynaptic density (4.1e-02/6.0e-01/ 4/ 41) | hedgehog receptor activity (2.6e-02/4.4e-02/ 2/ 3) | Long-term depression (2.6e-02/ 0.4162/ 4/30) | ||
| 325 | 2.4/1.6 | 71 | 19 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb | transmission of nerve impulse (1.7e-04/2.1e+00/ 12/ 163) | postsynaptic density (4.3e-03/5.3e-01/ 5/ 41) | gated channel activity (8.1e-03/2.0e+00/ 9/ 146) | Long-term depression (2.0e-03/ 0.3800/ 5/30) | ||
| 326 | 2.4/1.6 | 115 | 15 | mmu | br, cb, ht, kd, lv | subsynaptic reticulum (4.1e-02/4.8e+00/ 12/ 239) | |||||
| 327 | 2.4/1.6 | 60 | 23 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | potassium ion transport (6.0e-05/6.8e-01/ 8/ 59) | voltage-gated potassium channel complex (2.9e-07/5.5e-01/ 9/ 46) | voltage-gated cation channel activity (1.1e-06/7.3e-01/ 10/ 65) | Gastric acid secretion (1.0e-03/ 0.3257/ 5/30) | ||
| 328 | 2.4/1.4 | 52 | 29 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | nervous system development (1.5e-03/4.4e+00/ 15/ 467) | ion channel complex (7.8e-05/1.1e+00/ 9/ 108) | voltage-gated cation channel activity (3.6e-04/6.3e-01/ 7/ 65) | Gastric acid secretion (2.3e-03/ 0.1990/ 4/30) | ||
| 329 | 2.4/1.4 | 134 | 17 | mmu | br, cb, ht, kd, lv, ts | DNA-directed RNA polymerase III complex (4.3e-02/9.2e-02/ 2/ 4) | RNA cap binding (4.7e-02/6.6e-02/ 2/ 3) | ||||
| 330 | 2.4/1.4 | 82 | 9 | mmu | ht, kd, lv | cellular response to abiotic stimulus (4.8e-02/5.6e-02/ 2/ 4) | peroxisome (2.7e-02/5.2e-01/ 4/ 33) | Peroxisome (2.6e-02/ 0.4162/ 4/30) | |||
| 331 | 2.4/1.2 | 30 | 23 | hsa, ptr, ppa, ggo, ppy, mml | kd, lv | organic acid metabolic process (8.7e-04/1.4e+00/ 9/ 228) | cofactor binding (4.5e-02/4.9e-01/ 4/ 83) | ||||
| 332 | 2.4/1.2 | 21 | 22 | ppa, mml, mmu, mdo, oan, gga | br, cb | anchored to membrane (6.0e-03/1.3e-01/ 3/ 35) | Phosphatidylinositol signaling system (7.9e-03/ 0.1158/ 3/32) | ||||
| 333 | 2.4/1 | 40 | 35 | hsa, ptr, ppa, ggo, ppy, mmu, mdo, oan, gga | br, cb, ts, ht, kd, lv | peroxisome organization (2.6e-03/6.3e-02/ 3/ 8) | peroxisome (2.7e-03/2.5e-01/ 4/ 33) | Peroxisome (6.8e-03/ 0.2714/ 4/30) | |||
| 334 | 2.4/1 | 87 | 34 | ptr, ppa, mdo, mdo, oan | br, cb, ht, kd, lv, ts | cellular macromolecule metabolic process (9.1e-03/2.7e+01/ 42/1795) | cis-Golgi network (7.6e-03/1.5e-01/ 3/ 10) | ||||
| 335 | 2.2/3 | 203 | 5 | oan, gga | ts | M phase (1.0e-14/4.6e+00/ 31/ 152) | non-membrane-bounded organelle (3.3e-07/2.5e+01/ 55/ 855) | nucleic acid binding (1.2e-04/2.4e+01/ 48/ 802) | |||
| 336 | 2.2/3 | 163 | 3 | mmu | kd | sodium ion transport (2.4e-02/1.4e+00/ 7/ 47) | integral to membrane (2.8e-03/4.8e+01/ 70/1584) | active transmembrane transporter activity (6.2e-04/3.8e+00/ 15/ 130) | Glycosphingolipid biosynthesis - lacto and neolacto series (2.8e-02/ 0.1942/ 3/7) | ||
| 337 | 2.2/3 | 206 | 4 | mmu, oan | ts | M phase (2.8e-14/4.4e+00/ 30/ 152) | P granule (7.5e-06/1.7e-01/ 5/ 6) | microtubule motor activity (2.3e-03/9.2e-01/ 7/ 30) | Homologous recombination (3.2e-02/ 0.1990/ 3/11) | ||
| 338 | 2.2/3 | 146 | 4 | oan, gga | lv | complement activation, alternative pathway (4.6e-04/1.4e-01/ 4/ 5) | extracellular region (2.2e-05/1.5e+01/ 36/ 533) | endopeptidase inhibitor activity (2.8e-03/9.5e-01/ 7/ 34) | Complement and coagulation cascades (4.3e-07/ 0.8233/10/21) | ||
| 339 | 2.2/3 | 180 | 4 | mmu, mdo | ts | spermatogenesis (7.5e-07/2.5e+00/ 16/ 92) | microtubule cytoskeleton (8.5e-05/5.5e+00/ 19/ 227) | microtubule motor activity (7.5e-03/8.1e-01/ 6/ 30) | |||
| 340 | 2.2/3 | 179 | 3 | oan | ts | M phase (8.8e-07/4.5e+00/ 21/ 152) | nucleus (4.7e-06/4.3e+01/ 73/1528) | nucleic acid binding (2.5e-05/2.3e+01/ 49/ 802) | |||
| 341 | 2.2/3 | 154 | 4 | oan | br, cb | mRNA processing (3.9e-02/2.5e+00/ 9/ 96) | |||||
| 342 | 2.2/3 | 133 | 3 | hsa | br | eukaryotic translation initiation factor 4F complex (1.2e-02/4.9e-02/ 2/ 2) | small GTPase regulator activity (2.4e-03/2.4e+00/ 11/ 110) | 10 (3.2e-02/ 6.625/18/277) | |||
| 343 | 2.2/3 | 175 | 4 | mdo, gga | ts | M phase (3.5e-06/4.0e+00/ 19/ 152) | nucleus (3.6e-05/3.9e+01/ 66/1528) | chromatin binding (4.8e-04/1.6e+00/ 10/ 65) | |||
| 344 | 2.2/3 | 185 | 6 | ptr, ppa, mml, mmu | ts | M phase (7.3e-09/4.1e+00/ 23/ 152) | microtubule cytoskeleton (2.6e-07/5.9e+00/ 24/ 227) | microtubule motor activity (1.3e-03/8.2e-01/ 7/ 30) | |||
| 345 | 2.2/3 | 169 | 4 | ptr, ppa, mml | ts | M phase (1.1e-09/4.1e+00/ 24/ 152) | microtubule cytoskeleton (1.4e-06/6.0e+00/ 23/ 227) | microtubule motor activity (6.3e-03/7.8e-01/ 6/ 30) | |||
| 346 | 2.2/3 | 156 | 4 | mdo | br, cb | attachment of GPI anchor to protein (2.2e-03/8.3e-02/ 3/ 3) | GPI-anchor transamidase complex (7.8e-04/8.4e-02/ 3/ 3) | GPI-anchor transamidase activity (1.7e-03/7.9e-02/ 3/ 3) | Parkinson's disease (3.0e-02/ 0.7654/ 5/27) | ||
| 347 | 2.2/3 | 194 | 4 | mmu, gga | ts | M phase (2.7e-08/4.0e+00/ 22/ 152) | nucleus (3.1e-06/4.1e+01/ 71/1528) | microtubule motor activity (1.9e-04/8.3e-01/ 8/ 30) | |||
| 348 | 2.2/3 | 156 | 3 | mmu | lv | organic acid metabolic process (9.3e-06/6.7e+00/ 24/ 228) | endoplasmic reticulum part (9.5e-05/6.6e+00/ 21/ 227) | carboxylic acid binding (1.2e-03/1.5e+00/ 9/ 53) | |||
| 349 | 2.2/3 | 155 | 3 | hsa | kd | excretion (4.9e-05/7.0e-01/ 8/ 24) | apical plasma membrane (3.0e-06/1.6e+00/ 12/ 59) | active transmembrane transporter activity (4.0e-03/3.6e+00/ 13/ 130) | Aldosterone-regulated sodium reabsorption (3.8e-03/ 0.4536/ 5/16) | ||
| 350 | 2.2/2.8 | 172 | 6 | hsa, ptr, ppa, ggo, mml | ts | M phase (4.7e-11/4.3e+00/ 26/ 152) | spindle (3.7e-08/1.9e+00/ 15/ 70) | microtubule motor activity (7.2e-03/8.0e-01/ 6/ 30) | |||
| 351 | 2.2/2.8 | 154 | 4 | gga | kd, lv | leukocyte differentiation (2.0e-03/1.9e+00/ 10/ 72) | Allograft rejection (1.6e-02/ 0.1628/ 3/5) | ||||
| 352 | 2.2/2.8 | 217 | 6 | mml, mmu, gga | ts | M phase (7.1e-20/4.4e+00/ 36/ 152) | microtubule cytoskeleton (3.2e-11/6.5e+00/ 31/ 227) | microtubule motor activity (4.4e-07/9.2e-01/ 11/ 30) | Cell cycle (1.0e-03/ 0.8323/ 7/46) | ||
| 353 | 2.2/2.8 | 148 | 4 | mdo | kd, lv | cytoplasm (5.4e-03/7.3e+01/ 93/2671) | Huntington's disease (4.5e-02/ 1.2708/ 6/49) | ||||
| 354 | 2.2/2.8 | 162 | 3 | hsa, mml | kd | excretion (6.5e-06/7.4e-01/ 9/ 24) | apical plasma membrane (1.0e-10/1.7e+00/ 17/ 59) | active transmembrane transporter activity (2.0e-04/3.9e+00/ 16/ 130) | Aldosterone-regulated sodium reabsorption (4.5e-03/ 0.4729/ 5/16) | ||
| 355 | 2.2/2.6 | 167 | 4 | mdo, gga | kd | sodium ion transport (1.9e-04/1.4e+00/ 10/ 47) | apical plasma membrane (3.9e-04/1.8e+00/ 10/ 59) | inorganic cation transmembrane transporter activity (3.8e-04/2.3e+00/ 12/ 77) | Aldosterone-regulated sodium reabsorption (2.7e-02/ 0.4246/ 4/16) | ||
| 356 | 2.2/2.6 | 108 | 4 | oan, gga | br | G-protein coupled receptor protein signaling pathway (3.2e-06/3.6e+00/ 18/ 175) | integral to plasma membrane (9.5e-07/8.6e+00/ 28/ 413) | neurotransmitter binding (2.3e-06/6.0e-01/ 9/ 30) | Neuroactive ligand-receptor interaction (7.5e-09/ 2.3993/17/102) | ||
| 357 | 2.2/2.6 | 175 | 6 | mdo | br, cb, ht | GPI anchor biosynthetic process (2.4e-03/3.9e-01/ 5/ 13) | GPI-anchor transamidase complex (1.0e-03/9.3e-02/ 3/ 3) | GPI-anchor transamidase activity (2.2e-03/8.7e-02/ 3/ 3) | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (1.5e-02/ 0.3583/ 4/11) | ||
| 358 | 2.2/2.6 | 137 | 4 | hsa, ptr, ppa | lv | wound healing (5.8e-07/2.4e+00/ 16/ 88) | extracellular region (1.1e-07/1.4e+01/ 39/ 533) | endopeptidase inhibitor activity (4.1e-06/8.9e-01/ 10/ 34) | Complement and coagulation cascades (1.7e-11/ 0.7473/13/21) | ||
| 359 | 2.2/2.6 | 209 | 8 | ptr, ppa, mml, mmu, oan | ts | M phase (2.3e-21/4.3e+00/ 37/ 152) | microtubule cytoskeleton (1.2e-15/6.3e+00/ 36/ 227) | microtubule motor activity (3.8e-06/8.9e-01/ 10/ 30) | Cell cycle (1.6e-03/ 0.6104/ 6/46) | ||
| 360 | 2.2/2.6 | 147 | 3 | hsa, ptr | lv | alcohol metabolic process (3.1e-05/5.1e+00/ 20/ 172) | extracellular region (2.4e-06/1.5e+01/ 38/ 533) | endopeptidase inhibitor activity (5.9e-05/9.5e-01/ 9/ 34) | Complement and coagulation cascades (5.9e-10/ 0.7853/12/21) | ||
| 361 | 2.2/2.6 | 170 | 5 | mmu, mdo | lv | organic acid metabolic process (5.0e-13/7.7e+00/ 37/ 228) | platelet alpha granule lumen (1.0e-05/4.7e-01/ 7/ 15) | carboxylic acid binding (3.8e-07/1.7e+00/ 14/ 53) | Complement and coagulation cascades (4.1e-05/ 1.0386/ 9/21) | ||
| 362 | 2.2/2.6 | 205 | 8 | ptr, ppa, mml, mmu, gga | ts | M phase (6.8e-18/4.2e+00/ 33/ 152) | microtubule cytoskeleton (1.1e-13/6.1e+00/ 33/ 227) | microtubule motor activity (2.3e-08/8.7e-01/ 12/ 30) | Cell cycle (3.8e-03/ 0.7214/ 6/46) | ||
| 363 | 2.2/2.6 | 124 | 6 | hsa, ptr, ppa, ggo | cb | regulation of RNA metabolic process (2.8e-05/1.1e+01/ 30/ 485) | nuclear body (1.4e-02/1.5e+00/ 7/ 66) | transcription regulator activity (1.3e-02/6.6e+00/ 17/ 297) | miR-495/1192 (0.018/ 6.0707/21/239) | ||
| 364 | 2.2/2.6 | 123 | 4 | mdo, oan | lv, ht | fumarate metabolic process (2.6e-02/4.4e-02/ 2/ 2) | mitochondrial part (2.0e-02/4.3e+00/ 12/ 191) | ||||
| 365 | 2.2/2.6 | 157 | 5 | hsa, ggo | kd | excretion (3.2e-07/7.1e-01/ 10/ 24) | apical part of cell (2.4e-09/2.1e+00/ 17/ 75) | active transmembrane transporter activity (5.0e-04/3.7e+00/ 15/ 130) | Aldosterone-regulated sodium reabsorption (5.3e-03/ 0.4922/ 5/16) | ||
| 366 | 2.2/2.6 | 144 | 4 | hsa, ptr, ppa, mml | lv | wound healing (6.2e-10/2.6e+00/ 20/ 88) | extracellular region (9.1e-08/1.5e+01/ 41/ 533) | endopeptidase inhibitor activity (7.1e-06/9.5e-01/ 10/ 34) | Complement and coagulation cascades (1.1e-10/ 0.8993/13/21) | ||
| 367 | 2.2/2.6 | 218 | 10 | ptr, ppa, mml, mmu, oan, gga | ts | M phase (5.3e-23/4.4e+00/ 39/ 152) | microtubule cytoskeleton (1.4e-17/6.5e+00/ 39/ 227) | microtubule motor activity (4.0e-08/9.3e-01/ 12/ 30) | Cell cycle (4.5e-03/ 0.7491/ 6/46) | ||
| 368 | 2.2/2.6 | 183 | 5 | ptr, ppa, ppy, mml | ht | heart development (2.0e-06/3.8e+00/ 19/ 117) | myofibril (8.9e-15/1.4e+00/ 19/ 45) | actin binding (1.5e-04/4.2e+00/ 17/ 124) | Hypertrophic cardiomyopathy (HCM) (5.3e-05/ 1.0253/ 9/34) | ||
| 369 | 2.2/2.6 | 177 | 6 | gga | kd, lv, ts | nucleic acid metabolic process (6.0e-03/3.2e+01/ 52/1075) | RNA polymerase II transcription factor activity, enhancer binding (2.8e-02/4.3e-01/ 4/ 14) | Allograft rejection (1.7e-02/ 0.1659/ 3/5) | |||
| 370 | 2.2/2.6 | 143 | 4 | gga | br, cb | DNA catabolic process (2.4e-02/3.8e-01/ 4/ 16) | postsynaptic membrane (3.1e-02/1.8e+00/ 7/ 76) | ligand-gated ion channel activity (2.6e-03/1.6e+00/ 9/ 72) | Neuroactive ligand-receptor interaction (2.0e-02/ 2.3993/ 9/102) | X (8.6e-03/ 3.647/14/145) | |
| 371 | 2.2/2.6 | 151 | 4 | ppa, ggo, ppy | lv | response to wounding (3.6e-09/6.5e+00/ 29/ 211) | extracellular region (3.6e-08/1.5e+01/ 42/ 533) | cytokine receptor activity (1.6e-04/8.1e-01/ 8/ 29) | Complement and coagulation cascades (1.4e-09/ 0.8486/12/21) | ||
| 372 | 2.2/2.6 | 147 | 4 | hsa, ptr, mml | lv | small molecule metabolic process (3.6e-06/1.8e+01/ 43/ 602) | extracellular region (4.3e-07/1.5e+01/ 40/ 533) | endopeptidase inhibitor activity (5.9e-05/9.5e-01/ 9/ 34) | Complement and coagulation cascades (1.9e-09/ 0.8739/12/21) | ||
| 373 | 2.2/2.6 | 159 | 4 | hsa, ggo | ht | muscle contraction (1.0e-04/2.0e+00/ 12/ 74) | myofibril (1.4e-14/1.2e+00/ 18/ 45) | structural constituent of muscle (1.5e-05/4.0e-01/ 7/ 14) | |||
| 374 | 2.2/2.6 | 189 | 3 | hsa, mml | ht | muscle system process (7.9e-10/2.7e+00/ 20/ 81) | contractile fiber (1.1e-17/1.5e+00/ 22/ 46) | structural molecule activity (2.4e-11/5.0e+00/ 29/ 147) | Dilated cardiomyopathy (6.1e-05/ 1.0458/ 9/34) | ||
| 375 | 2.2/2.6 | 210 | 10 | ptr, ppa, mml, mmu, mdo, gga | ts | M phase (9.6e-23/4.2e+00/ 38/ 152) | microtubule cytoskeleton (3.0e-17/6.3e+00/ 38/ 227) | microtubule motor activity (2.1e-08/8.6e-01/ 12/ 30) | Cell cycle (4.3e-04/ 0.7214/ 7/46) | ||
| 376 | 2.2/2.6 | 161 | 4 | mdo, oan | lv | organic acid metabolic process (6.1e-09/7.6e+00/ 31/ 228) | extracellular region (3.7e-05/1.7e+01/ 38/ 533) | vitamin binding (4.7e-06/1.7e+00/ 13/ 55) | Complement and coagulation cascades (1.7e-04/ 0.9119/ 8/21) | ||
| 377 | 2.2/2.6 | 209 | 10 | ptr, ppa, mml, mmu, mdo, oan | ts | M phase (2.2e-23/4.3e+00/ 39/ 152) | microtubule cytoskeleton (2.0e-17/6.2e+00/ 38/ 227) | microtubule motor activity (3.3e-06/8.8e-01/ 10/ 30) | Cell cycle (1.3e-03/ 0.5826/ 6/46) | ||
| 378 | 2.2/2.4 | 155 | 6 | ppy, mml, mdo | lv | response to wounding (8.2e-11/6.8e+00/ 32/ 211) | extracellular region (9.4e-10/1.6e+01/ 47/ 533) | vitamin binding (2.6e-05/1.7e+00/ 12/ 55) | Complement and coagulation cascades (6.1e-10/ 1.0386/13/21) | ||
| 379 | 2.2/2.4 | 165 | 4 | oan, gga | ht | muscle contraction (3.7e-05/2.2e+00/ 13/ 74) | myofibril (3.7e-08/1.3e+00/ 13/ 45) | titin binding (6.8e-03/1.2e-01/ 3/ 4) | Hypertrophic cardiomyopathy (HCM) (6.7e-03/ 1.1689/ 7/34) | ||
| 380 | 2.2/2.4 | 158 | 4 | mdo, oan | kd | excretion (2.2e-08/7.3e-01/ 11/ 24) | apical part of cell (5.3e-07/2.3e+00/ 15/ 75) | transporter activity (1.4e-06/1.4e+01/ 38/ 454) | Aldosterone-regulated sodium reabsorption (4.2e-03/ 0.4632/ 5/16) | ||
| 381 | 2.2/2.4 | 221 | 13 | ptr, ppa, mml, mmu, mdo, oan, gga | ts | M phase (5.3e-25/4.4e+00/ 41/ 152) | microtubule cytoskeleton (7.8e-20/6.5e+00/ 42/ 227) | microtubule motor activity (3.6e-08/9.2e-01/ 12/ 30) | Cell cycle (3.4e-04/ 0.6936/ 7/46) | ||
| 382 | 2.2/2.4 | 196 | 8 | ptr, ppa, mml, mmu, mdo | ts | M phase (5.9e-17/4.2e+00/ 32/ 152) | microtubule cytoskeleton (6.1e-13/6.0e+00/ 32/ 227) | microtubule motor activity (2.1e-08/8.6e-01/ 12/ 30) | |||
| 383 | 2.2/2.4 | 165 | 8 | hsa, ptr, ppa, ppy, mml | lv | response to wounding (1.2e-08/7.3e+00/ 30/ 211) | extracellular region (7.9e-09/1.7e+01/ 47/ 533) | endopeptidase inhibitor activity (1.9e-05/1.1e+00/ 10/ 34) | Complement and coagulation cascades (2.7e-11/ 1.0259/14/21) | ||
| 384 | 2.2/2.4 | 170 | 5 | mml, mmu | lv | organic acid metabolic process (3.6e-12/7.8e+00/ 36/ 228) | membrane attack complex (6.7e-05/1.3e-01/ 4/ 4) | vitamin binding (9.0e-08/1.7e+00/ 15/ 55) | Complement and coagulation cascades (2.0e-08/ 1.0893/12/21) | ||
| 385 | 2.2/2.4 | 184 | 8 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (5.0e-07/2.4e+00/ 16/ 74) | myofibril (1.0e-19/1.4e+00/ 23/ 45) | structural constituent of muscle (2.1e-06/4.7e-01/ 8/ 14) | Cardiac muscle contraction (7.0e-07/ 0.8444/10/25) | ||
| 386 | 2.2/2.4 | 161 | 8 | hsa, ptr, ppa, ppy, mml | lv | wound healing (2.4e-08/2.9e+00/ 19/ 88) | extracellular region (3.5e-08/1.7e+01/ 45/ 533) | vitamin binding (3.0e-06/1.7e+00/ 13/ 55) | Complement and coagulation cascades (1.4e-11/ 0.9626/14/21) | ||
| 387 | 2.2/2.4 | 114 | 4 | hsa | br | actin cytoskeleton organization (3.3e-02/2.0e+00/ 8/ 102) | eukaryotic translation initiation factor 4F complex (9.0e-03/4.1e-02/ 2/ 2) | lipid binding (2.3e-02/2.9e+00/ 10/ 153) | 10 (4.4e-02/ 5.651/16/277) | ||
| 388 | 2.2/2.4 | 161 | 4 | oan | kd, lv | urea cycle (4.0e-02/5.9e-02/ 2/ 2) | pre-snoRNP complex (3.8e-02/8.9e-02/ 2/ 3) | ||||
| 389 | 2.2/2.4 | 191 | 8 | hsa, ptr, ppa, ggo, mml, mmu | ts | M phase (2.4e-12/4.1e+00/ 27/ 152) | spindle (3.2e-07/1.9e+00/ 14/ 70) | microtubule motor activity (2.1e-04/8.5e-01/ 8/ 30) | Oocyte meiosis (1.4e-02/ 0.6116/ 5/39) | ||
| 390 | 2.2/2.4 | 188 | 7 | hsa, ptr, ppa, ggo, ppy, mml | ht | cardiac muscle tissue development (2.2e-06/1.1e+00/ 11/ 34) | myofibril (4.8e-16/1.4e+00/ 20/ 45) | structural constituent of muscle (3.6e-05/4.7e-01/ 7/ 14) | Cardiac muscle contraction (1.4e-07/ 0.7087/10/25) | ||
| 391 | 2.2/2.4 | 223 | 13 | oan | br, cb, ht, kd, lv, ts | nucleic acid metabolic process (2.8e-04/4.2e+01/ 70/1075) | nuclear part (1.9e-06/2.6e+01/ 55/ 637) | nucleic acid binding (5.9e-03/3.2e+01/ 53/ 802) | Spliceosome (2.9e-02/ 0.7563/ 5/22) | ||
| 392 | 2.2/2.4 | 148 | 9 | mmu | ht, kd, lv | ||||||
| 393 | 2.2/2.4 | 189 | 8 | gga | ht, kd, lv, ts | nucleic acid metabolic process (1.9e-04/3.5e+01/ 61/1075) | histone pre-mRNA 3'end processing complex (2.0e-02/6.6e-02/ 2/ 2) | histone pre-mRNA stem-loop binding (4.1e-02/6.9e-02/ 2/ 2) | Allograft rejection (2.0e-02/ 0.1809/ 3/5) | ||
| 394 | 2.2/2.2 | 152 | 11 | hsa, ptr, ppa, ggo, ppy, mml | lv | response to wounding (1.8e-10/6.6e+00/ 31/ 211) | extracellular region (5.6e-12/1.6e+01/ 50/ 533) | endopeptidase inhibitor activity (1.1e-05/1.0e+00/ 10/ 34) | Complement and coagulation cascades (1.1e-11/ 0.9373/14/21) | ||
| 395 | 2.2/2.2 | 172 | 6 | gga | ht, kd, lv | lymph node development (7.9e-03/1.2e-01/ 3/ 4) | late endosome (6.0e-03/1.3e+00/ 7/ 44) | Jak-STAT signaling pathway (1.4e-02/ 1.7581/ 8/53) | |||
| 396 | 2.2/2.2 | 167 | 11 | hsa, ptr, ppa, ppy, mml, mmu | lv | organic acid metabolic process (1.1e-13/7.8e+00/ 38/ 228) | extracellular region (3.8e-08/1.7e+01/ 46/ 533) | vitamin binding (5.3e-06/1.8e+00/ 13/ 55) | Complement and coagulation cascades (1.4e-09/ 1.1146/13/21) | ||
| 397 | 2.2/2.2 | 175 | 9 | mml, mmu, mdo, oan | lv | organic acid metabolic process (1.9e-18/8.3e+00/ 45/ 228) | platelet alpha granule lumen (9.2e-07/5.1e-01/ 8/ 15) | vitamin binding (2.5e-11/1.9e+00/ 19/ 55) | Complement and coagulation cascades (1.1e-11/ 1.1906/15/21) | ||
| 398 | 2.2/2.2 | 180 | 10 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle structure development (8.7e-07/4.5e+00/ 21/ 141) | myofibril (1.2e-18/1.4e+00/ 22/ 45) | actin binding (2.1e-05/4.0e+00/ 18/ 124) | Hypertrophic cardiomyopathy (HCM) (4.4e-06/ 1.0048/10/34) | ||
| 399 | 2.2/2.2 | 155 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | excretion (3.7e-07/7.2e-01/ 10/ 24) | apical plasma membrane (5.1e-12/1.7e+00/ 18/ 59) | peptidase activity, acting on L-amino acid peptides (3.1e-04/5.0e+00/ 18/ 171) | Aldosterone-regulated sodium reabsorption (4.9e-03/ 0.4825/ 5/16) | ||
| 400 | 2.2/2.2 | 176 | 6 | mdo, oan, gga | ht | energy derivation by oxidation of organic compounds (2.3e-08/1.9e+00/ 16/ 60) | myofibril (2.5e-12/1.4e+00/ 17/ 45) | NADH dehydrogenase activity (1.9e-04/4.0e-01/ 6/ 12) | Cardiac muscle contraction (3.1e-06/ 0.9952/10/25) | ||
| 401 | 2.2/2.2 | 207 | 10 | mdo | br, cb, ht, kd, lv | G1 phase of mitotic cell cycle (1.1e-02/1.4e-01/ 3/ 4) | intracellular membrane-bounded organelle (1.4e-03/9.5e+01/121/2681) | peroxisome targeting sequence binding (4.2e-02/6.9e-02/ 2/ 2) | MT (1.4e-02/ 0.227/ 4/ 6) | ||
| 402 | 2.2/2.2 | 174 | 10 | hsa, ptr, ppa, mml, mmu, mdo | lv | organic acid metabolic process (5.2e-16/8.3e+00/ 42/ 228) | extracellular region (6.8e-08/1.8e+01/ 46/ 533) | vitamin binding (2.7e-09/1.8e+00/ 17/ 55) | Complement and coagulation cascades (1.9e-10/ 1.2159/14/21) | ||
| 403 | 2.2/2.2 | 168 | 11 | hsa, ptr, ppa, ggo, ppy, mml, mdo | lv | organic acid metabolic process (1.7e-11/8.2e+00/ 36/ 228) | extracellular region (1.7e-09/1.8e+01/ 49/ 533) | vitamin binding (4.6e-05/1.8e+00/ 12/ 55) | Complement and coagulation cascades (7.8e-11/ 1.1273/14/21) | ||
| 404 | 2.2/2.2 | 108 | 7 | mmu, mdo, gga | cb | synaptic transmission, glutamatergic (1.2e-03/3.1e-01/ 5/ 16) | integral to membrane (2.5e-02/3.2e+01/ 46/1584) | ion transmembrane transporter activity (3.1e-03/5.7e+00/ 17/ 300) | Neuroactive ligand-receptor interaction (4.0e-02/ 1.7226/ 7/102) | ||
| 405 | 2.2/2.2 | 165 | 11 | hsa, ptr, ppa, ggo, mml, mdo | kd | excretion (1.9e-09/7.7e-01/ 12/ 24) | apical part of cell (1.3e-12/2.3e+00/ 21/ 75) | transmembrane transporter activity (8.8e-06/1.2e+01/ 33/ 368) | Aldosterone-regulated sodium reabsorption (6.3e-03/ 0.5115/ 5/16) | ||
| 406 | 2.2/2.2 | 167 | 8 | hsa, mml, mdo, oan | kd | excretion (1.9e-09/7.7e-01/ 12/ 24) | apical plasma membrane (1.5e-14/1.9e+00/ 21/ 59) | transmembrane transporter activity (1.2e-05/1.2e+01/ 33/ 368) | Aldosterone-regulated sodium reabsorption (7.2e-03/ 0.5308/ 5/16) | ||
| 407 | 2.2/2 | 167 | 16 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo | lv | organic acid metabolic process (4.4e-12/7.8e+00/ 36/ 228) | extracellular region (2.1e-08/1.7e+01/ 46/ 533) | vitamin binding (3.1e-05/1.8e+00/ 12/ 55) | Complement and coagulation cascades (4.5e-11/ 1.0766/14/21) | ||
| 408 | 2.2/2 | 116 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | regulation of transcription, DNA-dependent (3.8e-03/9.6e+00/ 23/ 469) | transcription regulator activity (4.4e-02/6.3e+00/ 15/ 297) | Long-term depression (1.3e-02/ 0.5971/ 5/30) | |||
| 409 | 2.2/2 | 78 | 8 | hsa, ptr, ggo | br | magnesium ion transport (2.7e-02/4.0e-02/ 2/ 3) | myelin sheath (1.6e-03/8.4e-02/ 3/ 6) | lipid binding (2.6e-02/1.9e+00/ 8/ 153) | |||
| 410 | 2.2/2 | 177 | 18 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | lv | organic acid metabolic process (5.9e-17/8.6e+00/ 44/ 228) | extracellular region (6.5e-09/1.8e+01/ 49/ 533) | oxidoreductase activity (8.0e-07/7.1e+00/ 27/ 205) | Complement and coagulation cascades (3.3e-10/ 1.2666/14/21) | ||
| 411 | 2.2/2 | 97 | 5 | hsa | kd, lv | sodium-independent organic anion transmembrane transporter activity (1.5e-02/3.4e-02/ 2/ 2) | |||||
| 412 | 2.2/2 | 189 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mmu | ht | muscle structure development (2.6e-06/4.8e+00/ 21/ 141) | myofibril (5.2e-18/1.5e+00/ 22/ 45) | structural constituent of muscle (3.8e-05/4.8e-01/ 7/ 14) | Cardiac muscle contraction (4.3e-07/ 0.7992/10/25) | ||
| 413 | 2.2/2 | 197 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo | ht | cardiac muscle tissue development (5.0e-07/1.2e+00/ 12/ 34) | myofibril (1.1e-17/1.5e+00/ 22/ 45) | structural constituent of muscle (5.2e-05/5.1e-01/ 7/ 14) | Cardiac muscle contraction (1.6e-07/ 0.9650/11/25) | ||
| 414 | 2.2/2 | 215 | 12 | gga | br, cb, ht, kd, lv, ts | nucleic acid metabolic process (8.3e-05/3.9e+01/ 67/1075) | nucleus (8.2e-03/5.7e+01/ 79/1528) | nucleic acid binding (2.8e-03/3.1e+01/ 53/ 802) | |||
| 415 | 2.2/2 | 112 | 7 | mmu, oan, gga | br | ion transport (2.9e-06/6.9e+00/ 25/ 332) | intrinsic to membrane (6.5e-08/3.4e+01/ 65/1617) | ion channel activity (2.3e-06/3.8e+00/ 19/ 176) | Neuroactive ligand-receptor interaction (2.0e-05/ 2.2762/13/102) | ||
| 416 | 2.2/1.8 | 208 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | ht | muscle contraction (8.7e-08/2.8e+00/ 18/ 74) | myofibril (1.1e-19/1.6e+00/ 24/ 45) | structural molecule activity (2.3e-06/5.6e+00/ 23/ 147) | Cardiac muscle contraction (8.5e-09/ 0.9650/12/25) | ||
| 417 | 2.2/1.8 | 67 | 16 | hsa, ptr, ppa, ggo, ppy, mml | br | sleep (3.1e-03/7.2e-02/ 3/ 6) | plasma membrane (3.4e-03/1.5e+01/ 29/1133) | voltage-gated cation channel activity (1.6e-04/7.8e-01/ 8/ 65) | |||
| 418 | 2.2/1.8 | 82 | 10 | mdo, oan, gga | cb, br | intrinsic to membrane (8.9e-03/2.3e+01/ 37/1617) | ligand-gated ion channel activity (2.3e-02/1.0e+00/ 6/ 72) | Neuroactive ligand-receptor interaction (4.3e-02/ 1.2919/ 6/102) | |||
| 419 | 2.2/1.8 | 149 | 6 | mmu | kd, lv | organic acid metabolic process (5.3e-03/5.9e+00/ 17/ 228) | subsynaptic reticulum (7.5e-03/6.7e+00/ 17/ 239) | ||||
| 420 | 2.2/1.8 | 136 | 8 | mmu | kd, lv, ts | peroxisome organization (2.9e-02/1.8e-01/ 3/ 8) | integral to peroxisomal membrane (6.6e-03/1.5e-01/ 3/ 6) | Peroxisome (1.8e-02/ 0.6514/ 5/30) | |||
| 421 | 2.2/1.8 | 102 | 6 | mdo, oan, gga | br | synaptic transmission (1.4e-04/2.9e+00/ 14/ 146) | ion channel complex (8.2e-06/2.1e+00/ 13/ 108) | ion channel activity (1.6e-05/3.5e+00/ 17/ 176) | Neuroactive ligand-receptor interaction (1.2e-04/ 2.2762/12/102) | X (2.8e-02/ 2.703/11/145) | |
| 422 | 2.2/1.8 | 118 | 11 | mml, mmu, mdo, oan, gga | br | ion transport (8.1e-07/7.4e+00/ 27/ 332) | plasma membrane (3.1e-09/2.6e+01/ 58/1133) | gated channel activity (5.2e-08/3.3e+00/ 20/ 146) | Neuroactive ligand-receptor interaction (7.4e-06/ 2.4608/14/102) | ||
| 423 | 2.2/1.6 | 70 | 20 | hsa, ptr, ppa, ggo, ppy, mml | br | nervous system development (5.5e-04/5.6e+00/ 18/ 467) | plasma membrane (5.8e-03/1.6e+01/ 29/1133) | voltage-gated cation channel activity (2.4e-04/8.4e-01/ 8/ 65) | Gastric acid secretion (2.3e-02/ 0.3981/ 4/30) | ||
| 424 | 2.2/1.6 | 117 | 23 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | ion transport (2.9e-06/6.9e+00/ 25/ 332) | ion channel complex (4.1e-09/2.5e+00/ 18/ 108) | gated channel activity (6.2e-09/3.2e+00/ 21/ 146) | Neuroactive ligand-receptor interaction (6.8e-05/ 2.1532/12/102) | ||
| 425 | 2.2/1.6 | 121 | 17 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | cb | multicellular organismal process (2.8e-05/3.2e+01/ 57/1507) | neuron projection (1.7e-03/3.6e+00/ 13/ 165) | gated channel activity (4.6e-04/3.2e+00/ 14/ 146) | Long-term depression (2.6e-02/ 0.7238/ 5/30) | ||
| 426 | 2.2/1.6 | 80 | 22 | hsa, ptr, ppa, ggo, ppy, mml, mmu | br | nervous system development (1.7e-03/6.7e+00/ 19/ 467) | plasma membrane (5.0e-07/1.8e+01/ 41/1133) | voltage-gated cation channel activity (7.3e-05/9.5e-01/ 9/ 65) | Neuroactive ligand-receptor interaction (6.1e-04/ 1.4765/ 9/102) | ||
| 427 | 2.2/1.6 | 73 | 10 | hsa, oan | br, cb | myelin sheath (3.9e-02/8.2e-02/ 2/ 6) | transmembrane receptor activity (7.5e-03/3.4e+00/ 12/ 271) | ||||
| 428 | 2.2/1.6 | 114 | 8 | oan, gga | kd, lv | cysteine metabolic process (1.1e-03/6.1e-02/ 3/ 3) | apical junction complex (4.3e-02/6.2e-01/ 4/ 30) | Allograft rejection (1.0e-02/ 0.1327/ 3/5) | |||
| 429 | 2.2/1.6 | 139 | 13 | hsa, mml | br, ht, kd, lv, ts | Golgi vesicle transport (1.5e-02/1.7e+00/ 8/ 64) | intracellular (7.4e-03/9.1e+01/107/3640) | ||||
| 430 | 2.2/1.6 | 142 | 10 | hsa, mml | br, ht, kd, lv, ts | DNA modification (1.2e-02/5.6e-01/ 5/ 20) | intracellular (3.0e-03/9.2e+01/109/3640) | ||||
| 431 | 2.2/1.6 | 146 | 8 | ptr, ppa, mmu | ht, kd | cellular respiration (4.7e-04/9.5e-01/ 8/ 36) | mitochondrion (9.7e-06/1.1e+01/ 30/ 427) | catalytic activity (1.2e-02/4.7e+01/ 67/1790) | Citrate cycle (TCA cycle) (1.0e-04/ 0.3715/ 6/14) | ||
| 432 | 2.2/1.4 | 113 | 29 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | synaptic transmission (1.3e-06/2.9e+00/ 17/ 146) | plasma membrane (9.4e-09/2.5e+01/ 56/1133) | voltage-gated cation channel activity (3.7e-08/1.3e+00/ 14/ 65) | Neuroactive ligand-receptor interaction (5.2e-05/ 2.0917/12/102) | ||
| 433 | 2.2/1.4 | 75 | 12 | mdo, oan, gga | br, cb | intrinsic to membrane (1.5e-03/2.2e+01/ 38/1617) | neuropeptide receptor activity (2.1e-02/1.6e-01/ 3/ 12) | ||||
| 434 | 2.2/1.4 | 185 | 15 | mmu | br, cb, ht, kd, lv | ||||||
| 435 | 2.2/1.4 | 125 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb | nervous system development (1.8e-04/1.1e+01/ 28/ 467) | neuron projection (2.5e-03/3.8e+00/ 13/ 165) | gated channel activity (1.9e-04/3.4e+00/ 15/ 146) | Long-term depression (2.0e-02/ 0.6695/ 5/30) | ||
| 436 | 2.2/1.4 | 54 | 18 | mmu, mdo, oan, gga | br, cb | synaptic transmission, glutamatergic (2.6e-02/1.6e-01/ 3/ 16) | membrane (4.3e-05/2.3e+01/ 40/2327) | ephrin receptor activity (2.7e-03/7.0e-02/ 3/ 7) | Axon guidance (5.3e-03/ 0.4922/ 5/51) | ||
| 437 | 2.2/1.2 | 228 | 13 | hsa, gga | kd, br, cb, ht, kd, lv, ts | nucleic acid metabolic process (1.9e-03/4.2e+01/ 66/1075) | nucleus (1.6e-02/6.0e+01/ 81/1528) | nucleic acid binding (5.9e-03/3.2e+01/ 53/ 802) | |||
| 438 | 2.2/1.2 | 210 | 17 | mmu | br, cb, ht, kd, lv, ts | apical cortex (2.2e-02/7.2e-02/ 2/ 2) | ligase activity (2.0e-02/5.6e+00/ 15/ 156) | ||||
| 439 | 2.2/1.2 | 69 | 24 | hsa, ptr, ppa, ggo, ppy, mml | kd, lv | organic acid metabolic process (4.7e-04/3.3e+00/ 14/ 228) | vesicle lumen (1.7e-02/2.0e-01/ 3/ 16) | cytokine receptor activity (2.4e-02/3.9e-01/ 4/ 29) | |||
| 440 | 2.2/1 | 63 | 47 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br, cb | synaptic transmission (7.2e-11/1.8e+00/ 18/ 146) | synapse (4.4e-14/2.0e+00/ 21/ 160) | transporter activity (1.7e-07/5.2e+00/ 23/ 454) | Amyotrophic lateral sclerosis (ALS) (4.8e-07/ 0.2533/ 7/20) | ||
| 441 | 2.2/1 | 61 | 48 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br, cb | synaptic transmission (3.9e-11/1.5e+00/ 17/ 146) | synapse (1.7e-11/1.8e+00/ 18/ 160) | ion transmembrane transporter activity (5.0e-10/3.0e+00/ 21/ 300) | Neuroactive ligand-receptor interaction (8.5e-06/ 0.9228/ 9/102) | ||
| 442 | 2.2/1 | 28 | 36 | hsa, ptr, ppa, ggo, ppy, mml, mmu | br, cb | synaptic transmission (2.4e-04/6.3e-01/ 7/ 146) | synapse (3.1e-03/8.1e-01/ 6/ 160) | transmembrane receptor activity (6.1e-04/1.1e+00/ 8/ 271) | Neuroactive ligand-receptor interaction (1.6e-03/ 0.6767/ 6/102) | ||
| 443 | 2.2/1 | 28 | 40 | hsa, ptr, ppa, ggo, ppy, mml, mmu, gga | br, cb | gamma-aminobutyric acid signaling pathway (6.6e-04/3.7e-02/ 3/ 9) | chloride channel complex (3.5e-04/1.4e-01/ 4/ 27) | GABA-A receptor activity (1.5e-05/4.0e-02/ 4/ 10) | Neuroactive ligand-receptor interaction (1.8e-04/ 0.4922/ 6/102) | ||
| 444 | 2.2/1 | 206 | 26 | hsa, ptr, ppa, ggo, mmu, mdo | br, kd, br, cb, ht, kd, lv, ts | macromolecule catabolic process (3.3e-02/6.5e+00/ 16/ 195) | ubiquitin ligase complex (4.0e-02/1.9e+00/ 7/ 56) | ubiquitin-protein ligase activity (7.5e-03/2.4e+00/ 10/ 71) | |||
| 445 | 2.2/1 | 69 | 49 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br, cb | synaptic transmission (1.1e-11/1.9e+00/ 19/ 146) | synapse (1.8e-14/2.1e+00/ 22/ 160) | transporter activity (9.9e-11/5.5e+00/ 28/ 454) | Neuroactive ligand-receptor interaction (2.2e-05/ 1.2919/10/102) | ||
| 446 | 2/3 | 308 | 5 | ptr, mml, mmu | ts | M phase (1.3e-15/6.8e+00/ 38/ 152) | microtubule cytoskeleton (4.0e-12/1.0e+01/ 40/ 227) | microtubule motor activity (1.7e-05/1.4e+00/ 11/ 30) | |||
| 447 | 2/3 | 296 | 5 | oan, gga | ts | M phase (4.2e-15/7.1e+00/ 38/ 152) | non-membrane-bounded organelle (6.8e-10/3.9e+01/ 82/ 855) | nucleic acid binding (1.2e-05/3.7e+01/ 69/ 802) | Homologous recombination (1.7e-03/ 0.3914/ 5/11) | ||
| 448 | 2/3 | 224 | 4 | oan | br, cb | mRNA metabolic process (3.5e-03/4.5e+00/ 15/ 118) | micro-ribonucleoprotein complex (2.6e-02/8.0e-02/ 2/ 2) | RNA binding (1.3e-02/8.4e+00/ 20/ 212) | |||
| 449 | 2/3 | 292 | 4 | ptr, ppa, mml | ts | M phase (3.0e-10/7.2e+00/ 32/ 152) | microtubule cytoskeleton (5.9e-07/1.0e+01/ 32/ 227) | microtubule motor activity (1.2e-04/1.4e+00/ 10/ 30) | |||
| 450 | 2/3 | 268 | 4 | oan | kd, lv | zinc ion transport (3.9e-02/4.8e-01/ 4/ 10) | transition metal ion transmembrane transporter activity (2.4e-02/4.4e-01/ 4/ 9) | ||||
| 451 | 2/3 | 263 | 3 | mmu | lv | organic acid metabolic process (4.8e-09/1.2e+01/ 39/ 228) | endoplasmic reticulum membrane (1.9e-04/9.9e+00/ 26/ 198) | cofactor binding (1.3e-07/3.9e+00/ 21/ 83) | Complement and coagulation cascades (2.3e-03/ 1.3806/ 8/21) | ||
| 452 | 2/3 | 281 | 3 | oan | ts | M phase (7.0e-08/6.9e+00/ 28/ 152) | nucleus (5.1e-08/6.8e+01/112/1528) | nucleic acid binding (7.0e-05/3.7e+01/ 66/ 802) | |||
| 453 | 2/3 | 248 | 3 | hsa | ht | muscle contraction (3.9e-06/3.2e+00/ 17/ 74) | myofibril (1.6e-13/1.9e+00/ 20/ 45) | structural molecule activity (3.0e-06/6.6e+00/ 25/ 147) | Hypertrophic cardiomyopathy (HCM) (2.9e-02/ 1.5790/ 7/34) | ||
| 454 | 2/2.8 | 245 | 4 | mdo | br, cb | GPI anchor biosynthetic process (1.1e-03/5.7e-01/ 6/ 13) | GPI-anchor transamidase complex (2.4e-03/1.3e-01/ 3/ 3) | GPI-anchor transamidase activity (5.2e-03/1.3e-01/ 3/ 3) | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (3.7e-03/ 0.4710/ 5/11) | MT (2.2e-02/ 0.266/ 4/ 6) | |
| 455 | 2/2.8 | 314 | 4 | mmu, gga | ts | M phase (1.4e-10/7.0e+00/ 32/ 152) | chromosome (6.6e-08/6.8e+00/ 27/ 150) | microtubule motor activity (6.7e-04/1.4e+00/ 9/ 30) | Cell cycle (1.8e-02/ 1.4150/ 7/46) | ||
| 456 | 2/2.8 | 234 | 3 | hsa | br | cytoskeleton organization (3.9e-02/8.0e+00/ 18/ 193) | eukaryotic translation initiation factor 4F complex (2.9e-02/8.5e-02/ 2/ 2) | translation initiation factor activity (5.8e-03/7.9e-01/ 6/ 19) | |||
| 457 | 2/2.8 | 245 | 3 | hsa | kd | excretion (1.1e-06/1.1e+00/ 11/ 24) | apical plasma membrane (4.3e-08/2.6e+00/ 17/ 59) | peptidase activity, acting on L-amino acid peptides (5.8e-04/7.5e+00/ 22/ 171) | Aldosterone-regulated sodium reabsorption (2.1e-02/ 0.7045/ 5/16) | ||
| 458 | 2/2.8 | 273 | 6 | oan | ht, kd, lv | RNA processing (5.7e-03/8.3e+00/ 21/ 176) | intracellular (6.1e-04/1.8e+02/202/3640) | RNA binding (4.5e-02/1.0e+01/ 21/ 212) | |||
| 459 | 2/2.6 | 300 | 8 | ptr, ppa, mml, mmu, mdo | ts | M phase (1.7e-17/6.7e+00/ 40/ 152) | microtubule cytoskeleton (1.4e-16/9.9e+00/ 46/ 227) | microtubule motor activity (1.4e-06/1.3e+00/ 12/ 30) | Cell cycle (9.8e-03/ 1.2485/ 7/46) | ||
| 460 | 2/2.6 | 262 | 6 | hsa, ptr, ppa, ggo | ht | cardiac chamber development (3.1e-05/1.2e+00/ 10/ 26) | myofibril (2.0e-15/2.1e+00/ 22/ 45) | structural constituent of muscle (1.7e-05/6.5e-01/ 8/ 14) | Cardiac muscle contraction (2.2e-05/ 1.2515/10/25) | ||
| 461 | 2/2.6 | 251 | 3 | ppa, ppy | lv | response to wounding (3.2e-10/1.1e+01/ 39/ 211) | extracellular region (2.5e-07/2.5e+01/ 56/ 533) | cytokine receptor activity (1.5e-06/1.4e+00/ 12/ 29) | Complement and coagulation cascades (4.6e-10/ 1.3046/14/21) | ||
| 462 | 2/2.6 | 272 | 3 | mmu | ht | cellular respiration (1.8e-07/1.7e+00/ 14/ 36) | myofibril (4.9e-15/2.2e+00/ 22/ 45) | structural constituent of muscle (2.3e-05/6.9e-01/ 8/ 14) | Cardiac muscle contraction (1.7e-04/ 1.2214/ 9/25) | ||
| 463 | 2/2.6 | 245 | 5 | ptr, ppa, ggo, ppy | lv | response to wounding (4.3e-07/1.1e+01/ 34/ 211) | extracellular region (8.1e-09/2.5e+01/ 59/ 533) | cytokine receptor activity (1.4e-06/1.4e+00/ 12/ 29) | Complement and coagulation cascades (1.4e-09/ 1.4312/14/21) | ||
| 464 | 2/2.6 | 238 | 4 | gga | br, cb | DNA catabolic process (2.1e-02/6.7e-01/ 5/ 16) | postsynaptic membrane (1.6e-02/3.1e+00/ 10/ 76) | ligand-gated ion channel activity (5.9e-04/2.9e+00/ 13/ 72) | Neuroactive ligand-receptor interaction (2.8e-02/ 3.6297/11/102) | X (2.5e-03/ 6.095/20/145) | |
| 465 | 2/2.6 | 313 | 8 | ptr, ppa, mml, mmu, gga | ts | M phase (2.0e-18/6.7e+00/ 41/ 152) | microtubule cytoskeleton (6.7e-15/1.0e+01/ 44/ 227) | microtubule motor activity (2.0e-07/1.4e+00/ 13/ 30) | Cell cycle (1.1e-04/ 1.4427/10/46) | ||
| 466 | 2/2.6 | 228 | 4 | mdo | kd, lv | organelle membrane (1.0e-02/2.9e+01/ 46/ 674) | phosphoenolpyruvate carboxykinase activity (4.9e-02/7.8e-02/ 2/ 2) | ||||
| 467 | 2/2.6 | 264 | 5 | mmu, mdo | lv | organic acid metabolic process (5.1e-17/1.2e+01/ 52/ 228) | endoplasmic reticulum part (3.2e-07/1.1e+01/ 34/ 227) | vitamin binding (5.0e-07/2.8e+00/ 17/ 55) | Complement and coagulation cascades (1.4e-05/ 1.5959/11/21) | ||
| 468 | 2/2.6 | 257 | 4 | hsa, ggo | ht | muscle contraction (8.0e-06/3.4e+00/ 17/ 74) | contractile fiber (3.7e-14/2.1e+00/ 21/ 46) | structural molecule activity (1.3e-06/6.8e+00/ 26/ 147) | Cardiac muscle contraction (1.5e-03/ 1.2515/ 8/25) | ||
| 469 | 2/2.6 | 307 | 10 | ptr, ppa, mml, mmu, mdo, oan | ts | M phase (2.2e-25/6.6e+00/ 49/ 152) | microtubule cytoskeleton (4.9e-18/9.7e+00/ 48/ 227) | microtubule motor activity (1.4e-06/1.3e+00/ 12/ 30) | Oocyte meiosis (1.7e-02/ 0.9879/ 6/39) | ||
| 470 | 2/2.6 | 235 | 4 | gga | kd, lv | regulation of multi-organism process (1.7e-02/6.4e-01/ 5/ 15) | late endosome (8.3e-03/1.8e+00/ 8/ 44) | Allograft rejection (3.5e-02/ 0.2322/ 3/5) | |||
| 471 | 2/2.6 | 300 | 10 | ptr, ppa, mml, mmu, oan, gga | ts | M phase (1.9e-20/6.5e+00/ 43/ 152) | microtubule cytoskeleton (9.5e-18/9.5e+00/ 47/ 227) | microtubule motor activity (1.3e-07/1.3e+00/ 13/ 30) | Cell cycle (2.3e-03/ 1.3040/ 8/46) | ||
| 472 | 2/2.6 | 236 | 4 | oan, gga | lv | organic acid catabolic process (1.9e-04/2.2e+00/ 12/ 48) | extracellular region (2.6e-04/2.4e+01/ 46/ 533) | peptidase regulator activity (6.2e-03/1.9e+00/ 9/ 43) | Complement and coagulation cascades (2.4e-05/ 1.3046/10/21) | ||
| 473 | 2/2.6 | 322 | 10 | oan | br, cb, ht, kd, lv | RNA processing (1.6e-04/9.7e+00/ 27/ 176) | nucleus (2.6e-05/8.6e+01/125/1528) | RNA methyltransferase activity (1.0e-02/6.1e-01/ 5/ 11) | |||
| 474 | 2/2.4 | 284 | 4 | mdo, oan | ht | energy derivation by oxidation of organic compounds (5.7e-12/3.0e+00/ 23/ 60) | mitochondrion (4.6e-15/2.1e+01/ 66/ 427) | oxidoreductase activity (7.4e-04/1.1e+01/ 27/ 205) | Citrate cycle (TCA cycle) (4.8e-05/ 0.8275/ 8/14) | ||
| 475 | 2/2.4 | 246 | 6 | mdo, oan, gga | kd | excretion (4.1e-09/1.1e+00/ 13/ 24) | apical plasma membrane (8.3e-09/2.7e+00/ 18/ 59) | transporter activity (1.5e-04/2.1e+01/ 44/ 454) | Lysosome (1.8e-02/ 2.3378/ 9/51) | ||
| 476 | 2/2.4 | 268 | 7 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle structure development (1.4e-06/7.0e+00/ 26/ 141) | myofibril (1.9e-17/2.1e+00/ 24/ 45) | structural constituent of muscle (1.6e-06/6.9e-01/ 9/ 14) | Cardiac muscle contraction (1.3e-05/ 1.1761/10/25) | ||
| 477 | 2/2.4 | 217 | 7 | hsa, ptr, ppa, ggo | kd | excretion (3.0e-08/1.0e+00/ 12/ 24) | apical part of cell (1.0e-09/3.0e+00/ 20/ 75) | peptidase activity, acting on L-amino acid peptides (6.3e-05/6.9e+00/ 23/ 171) | Vibrio cholerae infection (1.1e-02/ 0.5971/ 5/15) | ||
| 478 | 2/2.4 | 244 | 3 | ppy, mml | lv | response to wounding (1.0e-10/1.0e+01/ 39/ 211) | extracellular region (9.8e-09/2.5e+01/ 60/ 533) | vitamin binding (3.1e-05/2.5e+00/ 14/ 55) | Complement and coagulation cascades (4.7e-11/ 1.3806/15/21) | ||
| 479 | 2/2.4 | 262 | 8 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle structure development (3.2e-06/6.8e+00/ 25/ 141) | myofibril (1.0e-18/2.1e+00/ 25/ 45) | structural molecule activity (1.3e-07/6.9e+00/ 28/ 147) | Cardiac muscle contraction (1.1e-06/ 1.1761/11/25) | ||
| 480 | 2/2.4 | 302 | 8 | hsa, ptr, ppa, ggo, mml, mmu | ts | M phase (6.3e-17/7.0e+00/ 40/ 152) | microtubule cytoskeleton (1.1e-11/1.0e+01/ 40/ 227) | microtubule motor activity (1.2e-04/1.4e+00/ 10/ 30) | Cell cycle (5.3e-03/ 1.4982/ 8/46) | ||
| 481 | 2/2.4 | 234 | 6 | hsa, ptr, ppa, mml | lv | organic acid metabolic process (1.1e-08/1.1e+01/ 37/ 228) | extracellular region (7.4e-07/2.4e+01/ 53/ 533) | vitamin binding (3.1e-06/2.4e+00/ 15/ 55) | Complement and coagulation cascades (4.5e-11/ 1.3679/15/21) | ||
| 482 | 2/2.4 | 252 | 4 | mdo, gga | lv | small molecule metabolic process (2.3e-06/3.0e+01/ 62/ 602) | extracellular region (1.6e-03/2.6e+01/ 46/ 533) | endopeptidase inhibitor activity (1.0e-02/1.7e+00/ 8/ 34) | Complement and coagulation cascades (3.1e-04/ 1.3679/ 9/21) | ||
| 483 | 2/2.4 | 248 | 3 | mmu | kd | sodium ion transport (1.3e-02/2.1e+00/ 9/ 47) | brush border (2.8e-05/8.1e-01/ 8/ 18) | active transmembrane transporter activity (3.1e-03/5.6e+00/ 17/ 130) | Glycosphingolipid biosynthesis - lacto and neolacto series (8.4e-03/ 0.3251/ 4/7) | ||
| 484 | 2/2.4 | 203 | 6 | hsa, ptr, ppa, ggo | cb | regulation of RNA metabolic process (2.2e-03/1.8e+01/ 36/ 485) | nuclear body (3.9e-02/2.4e+00/ 8/ 66) | potassium channel activity (1.7e-02/2.3e+00/ 9/ 61) | |||
| 485 | 2/2.4 | 269 | 5 | mml, mmu | lv | organic acid metabolic process (9.4e-18/1.2e+01/ 53/ 228) | endoplasmic reticulum part (8.5e-08/1.2e+01/ 36/ 227) | vitamin binding (2.4e-09/2.8e+00/ 20/ 55) | Complement and coagulation cascades (4.2e-10/ 1.6339/15/21) | ||
| 486 | 2/2.4 | 235 | 10 | hsa, ptr, ppa, ggo, ppy, mml | lv | response to wounding (4.9e-08/1.0e+01/ 35/ 211) | extracellular region (8.9e-10/2.4e+01/ 60/ 533) | cytokine receptor activity (7.2e-05/1.3e+00/ 10/ 29) | Complement and coagulation cascades (3.7e-11/ 1.3426/15/21) | ||
| 487 | 2/2.4 | 270 | 6 | gga | br, cb, ht | DNA catabolic process (2.7e-02/7.2e-01/ 5/ 16) | nucleus (3.4e-02/6.9e+01/ 89/1528) | X (3.8e-05/ 6.911/26/145) | |||
| 488 | 2/2.4 | 187 | 4 | ggo | kd, lv | vesicle lumen (3.0e-03/5.2e-01/ 5/ 16) | cytokine binding (4.1e-03/1.4e+00/ 8/ 43) | Hematopoietic cell lineage (3.0e-02/ 0.7793/ 5/19) | |||
| 489 | 2/2.4 | 214 | 9 | hsa, ptr, ppa, ggo | kd | excretion (4.1e-07/9.9e-01/ 11/ 24) | apical part of cell (6.2e-09/2.9e+00/ 19/ 75) | peptidase activity, acting on L-amino acid peptides (5.8e-05/6.9e+00/ 23/ 171) | Vibrio cholerae infection (1.2e-02/ 0.6062/ 5/15) | ||
| 490 | 2/2.2 | 254 | 11 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle structure development (1.4e-06/6.5e+00/ 25/ 141) | myofibril (6.8e-17/2.0e+00/ 23/ 45) | structural molecule activity (6.0e-08/6.7e+00/ 28/ 147) | Cardiac muscle contraction (6.6e-06/ 1.0856/10/25) | ||
| 491 | 2/2.2 | 311 | 13 | oan | br, cb, ht, kd, lv, ts | RNA processing (4.1e-05/9.6e+00/ 28/ 176) | nucleus (3.6e-06/8.6e+01/128/1528) | nucleic acid binding (9.0e-04/4.4e+01/ 71/ 802) | Spliceosome (1.3e-02/ 0.9554/ 6/22) | ||
| 492 | 2/2.2 | 193 | 9 | hsa, ptr, ppa, ggo, ppy | cb | regulation of RNA metabolic process (1.8e-03/1.6e+01/ 34/ 485) | nuclear body (2.8e-02/2.3e+00/ 8/ 66) | ||||
| 493 | 2/2.2 | 246 | 8 | hsa, ptr, ggo, mmu | kd | excretion (1.3e-06/1.1e+00/ 11/ 24) | apical part of cell (5.2e-15/3.5e+00/ 27/ 75) | active transmembrane transporter activity (5.8e-07/6.1e+00/ 25/ 130) | Aldosterone-regulated sodium reabsorption (5.3e-03/ 0.8106/ 6/16) | ||
| 494 | 2/2.2 | 217 | 11 | hsa, ptr, ppa, ggo, mml | kd | excretion (5.0e-07/1.0e+00/ 11/ 24) | apical part of cell (1.1e-09/3.0e+00/ 20/ 75) | peptidase activity, acting on L-amino acid peptides (2.2e-04/7.0e+00/ 22/ 171) | Vibrio cholerae infection (1.5e-02/ 0.6423/ 5/15) | ||
| 495 | 2/2.2 | 232 | 6 | mmu | kd, lv | organic acid metabolic process (4.1e-05/9.5e+00/ 28/ 228) | subsynaptic reticulum (1.0e-02/1.0e+01/ 22/ 239) | cofactor binding (7.0e-04/3.4e+00/ 14/ 83) | Peroxisome (1.5e-02/ 1.3752/ 7/30) | ||
| 496 | 2/2.2 | 238 | 5 | hsa, mdo | kd | excretion (9.6e-07/1.1e+00/ 11/ 24) | apical part of cell (3.2e-12/3.4e+00/ 24/ 75) | transmembrane transporter activity (2.4e-05/1.7e+01/ 40/ 368) | Aldosterone-regulated sodium reabsorption (2.3e-03/ 0.6755/ 6/16) | ||
| 497 | 2/2.2 | 300 | 10 | gga | br, cb, ht, kd, lv | nucleic acid metabolic process (1.1e-04/5.5e+01/ 88/1075) | nucleus (4.7e-03/8.0e+01/107/1528) | DNA binding (1.3e-02/2.8e+01/ 47/ 529) | T cell receptor signaling pathway (4.4e-02/ 2.2346/ 8/39) | ||
| 498 | 2/2.2 | 241 | 8 | hsa, mml, mdo, oan, gga | kd | excretion (4.6e-09/1.1e+00/ 13/ 24) | apical part of cell (1.1e-10/3.3e+00/ 22/ 75) | transmembrane transporter activity (2.1e-05/1.6e+01/ 40/ 368) | Proximal tubule bicarbonate reclamation (9.0e-04/ 0.3619/ 5/8) | ||
| 499 | 2/2.2 | 266 | 6 | mdo | br, cb, ts | ATP synthesis coupled electron transport (6.4e-03/7.9e-01/ 6/ 17) | respiratory chain (2.9e-03/8.3e-01/ 6/ 18) | NADH dehydrogenase activity (7.8e-03/5.6e-01/ 5/ 12) | Parkinson's disease (1.8e-06/ 1.2214/11/27) | MT (2.3e-03/ 0.286/ 5/ 6) | |
| 500 | 2/2.2 | 259 | 4 | mdo, gga | ht | muscle contraction (1.1e-05/3.5e+00/ 17/ 74) | myofibril (1.1e-09/2.1e+00/ 17/ 45) | NADH dehydrogenase activity (8.2e-03/5.6e-01/ 5/ 12) | Cardiac muscle contraction (3.6e-05/ 1.3269/10/25) | ||
| 501 | 2/2.2 | 263 | 6 | mml, mdo, oan | lv | organic acid metabolic process (1.5e-12/1.2e+01/ 46/ 228) | extracellular space (2.8e-07/1.2e+01/ 35/ 226) | vitamin binding (1.3e-07/2.9e+00/ 18/ 55) | Complement and coagulation cascades (1.3e-08/ 1.7099/14/21) | ||
| 502 | 2/2.2 | 279 | 4 | mml, mmu | ht | cellular respiration (2.9e-08/1.8e+00/ 15/ 36) | myofibril (2.6e-17/2.2e+00/ 24/ 45) | structural constituent of muscle (2.8e-05/7.1e-01/ 8/ 14) | Cardiac muscle contraction (2.6e-07/ 1.3118/12/25) | ||
| 503 | 2/2.2 | 255 | 6 | gga | ht, kd, lv | negative regulation of muscle cell differentiation (9.2e-03/3.1e-01/ 4/ 7) | late endosome (4.1e-02/2.0e+00/ 7/ 44) | DNA binding (2.9e-02/2.4e+01/ 40/ 529) | Allograft rejection (4.1e-02/ 0.2503/ 3/5) | ||
| 504 | 2/2.2 | 277 | 8 | gga | ht, kd, lv, ts | nucleic acid metabolic process (5.4e-04/5.2e+01/ 81/1075) | nucleus (1.1e-02/7.3e+01/ 97/1528) | nucleic acid binding (7.4e-03/4.0e+01/ 62/ 802) | Allograft rejection (4.3e-02/ 0.2563/ 3/5) | ||
| 505 | 2/2.2 | 301 | 10 | mdo | br, cb, ht, kd, lv | attachment of GPI anchor to protein (9.5e-03/1.5e-01/ 3/ 3) | intracellular membrane-bounded organelle (1.8e-04/1.4e+02/175/2681) | GPI-anchor transamidase activity (7.7e-03/1.5e-01/ 3/ 3) | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (6.7e-03/ 0.5507/ 5/11) | MT (3.9e-02/ 0.327/ 4/ 6) | |
| 506 | 2/2 | 137 | 8 | hsa, ptr, ggo | br | two-component signal transduction system (phosphorelay) (2.9e-02/4.7e-02/ 2/ 2) | myelin sheath (6.9e-03/1.5e-01/ 3/ 6) | lipid binding (2.3e-02/3.4e+00/ 11/ 153) | |||
| 507 | 2/2 | 191 | 4 | oan, gga | br | G-protein coupled receptor protein signaling pathway (2.8e-05/6.1e+00/ 22/ 175) | plasma membrane (1.1e-05/4.0e+01/ 70/1133) | neurotransmitter receptor activity (1.6e-05/8.2e-01/ 9/ 23) | Neuroactive ligand-receptor interaction (3.8e-06/ 3.9373/18/102) | X (5.6e-03/ 4.973/17/145) | |
| 508 | 2/2 | 276 | 16 | hsa, ptr, ppa, ppy, mml, mmu, mdo, oan, gga | lv | organic acid metabolic process (6.8e-19/1.3e+01/ 57/ 228) | endoplasmic reticulum part (1.1e-12/1.2e+01/ 45/ 227) | cofactor binding (1.8e-07/4.4e+00/ 22/ 83) | Complement and coagulation cascades (2.7e-09/ 1.8872/15/21) | ||
| 509 | 2/2 | 256 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo | lv | organic acid metabolic process (9.4e-18/1.2e+01/ 53/ 228) | endoplasmic reticulum part (3.1e-08/1.1e+01/ 36/ 227) | vitamin binding (2.7e-06/2.7e+00/ 16/ 55) | Complement and coagulation cascades (1.1e-08/ 1.6846/14/21) | ||
| 510 | 2/2 | 229 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mdo | kd | excretion (3.9e-08/1.0e+00/ 12/ 24) | apical part of cell (6.4e-13/3.2e+00/ 24/ 75) | active transmembrane transporter activity (2.5e-05/5.5e+00/ 21/ 130) | Vibrio cholerae infection (1.6e-02/ 0.6604/ 5/15) | ||
| 511 | 2/2 | 189 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | multicellular organismal process (3.1e-03/4.9e+01/ 73/1507) | synapse (3.8e-02/5.4e+00/ 13/ 160) | gated channel activity (7.6e-03/5.0e+00/ 15/ 146) | |||
| 512 | 2/2 | 157 | 6 | hsa, ptr, ppa, ppy | br | RNA catabolic process (2.5e-02/6.8e-01/ 5/ 23) | voltage-gated potassium channel complex (3.1e-02/1.3e+00/ 6/ 46) | G-protein coupled receptor activity (1.7e-02/3.3e+00/ 11/ 120) | Phosphatidylinositol signaling system (3.7e-02/ 0.8106/ 5/32) | ||
| 513 | 2/2 | 240 | 13 | hsa, ptr, ppa, ggo, ppy, mml, mdo | lv | organic acid metabolic process (5.0e-11/1.1e+01/ 42/ 228) | extracellular region (6.0e-08/2.5e+01/ 57/ 533) | cytokine receptor activity (1.2e-05/1.4e+00/ 11/ 29) | Complement and coagulation cascades (1.1e-10/ 1.4692/15/21) | ||
| 514 | 2/2 | 250 | 4 | mdo, oan | kd | excretion (1.6e-06/1.2e+00/ 11/ 24) | apical part of cell (1.7e-08/3.5e+00/ 20/ 75) | transporter activity (8.9e-06/2.2e+01/ 49/ 454) | Aldosterone-regulated sodium reabsorption (4.7e-03/ 0.7913/ 6/16) | ||
| 515 | 2/2 | 270 | 15 | hsa, ptr, ppa, ggo, ppy, mml, mmu | ht | muscle contraction (4.5e-06/3.7e+00/ 18/ 74) | myofibril (2.3e-17/2.1e+00/ 24/ 45) | structural molecule activity (6.7e-09/7.3e+00/ 31/ 147) | Cardiac muscle contraction (2.1e-06/ 1.2515/11/25) | ||
| 516 | 2/2 | 162 | 6 | hsa, ptr, ppa, ppy | br | voltage-gated potassium channel complex (3.4e-02/1.4e+00/ 6/ 46) | inositol or phosphatidylinositol kinase activity (2.8e-02/4.3e-01/ 4/ 15) | ||||
| 517 | 2/1.8 | 218 | 9 | mmu | ht, kd, lv | transcription from RNA polymerase III promoter (8.5e-03/3.0e-01/ 4/ 8) | cytoplasmic part (1.1e-02/7.1e+01/ 93/1844) | ||||
| 518 | 2/1.8 | 257 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | lv | organic acid metabolic process (4.8e-18/1.2e+01/ 54/ 228) | endoplasmic reticulum part (2.1e-09/1.1e+01/ 38/ 227) | cofactor binding (3.7e-07/4.2e+00/ 21/ 83) | Complement and coagulation cascades (2.0e-08/ 1.7732/14/21) | ||
| 519 | 2/1.8 | 302 | 12 | mdo | br, cb, ht, kd, lv, ts | ribonucleoprotein complex biogenesis (2.5e-02/2.9e+00/ 10/ 54) | intracellular membrane-bounded organelle (9.9e-05/1.4e+02/181/2681) | Parkinson's disease (2.4e-03/ 1.3516/ 8/27) | MT (3.0e-03/ 0.328/ 5/ 6) | ||
| 520 | 2/1.8 | 150 | 9 | hsa, ptr, ppa, ggo, ppy, mml | br | nervous system development (5.1e-04/1.3e+01/ 30/ 467) | voltage-gated potassium channel complex (1.9e-04/1.3e+00/ 9/ 46) | voltage-gated cation channel activity (1.4e-04/1.7e+00/ 11/ 65) | |||
| 521 | 2/1.8 | 187 | 8 | oan, gga | br, cb | neurotransmitter receptor activity (9.2e-04/7.9e-01/ 7/ 23) | X (2.3e-03/ 4.973/18/145) | ||||
| 522 | 2/1.8 | 171 | 13 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (2.9e-07/4.6e+00/ 22/ 146) | voltage-gated potassium channel complex (1.4e-07/1.5e+00/ 13/ 46) | voltage-gated cation channel activity (5.7e-08/2.0e+00/ 16/ 65) | Neuroactive ligand-receptor interaction (1.0e-02/ 3.1375/11/102) | ||
| 523 | 2/1.8 | 215 | 10 | mmu, mdo | ts, ht, kd, lv | RNA processing (3.5e-02/6.5e+00/ 16/ 176) | intracellular (2.1e-03/1.3e+02/153/3640) | transition metal ion binding (2.1e-02/2.3e+01/ 39/ 619) | Parkinson's disease (1.3e-02/ 0.9445/ 6/27) | MT (1.4e-02/ 0.230/ 4/ 6) | |
| 524 | 2/1.8 | 152 | 9 | hsa, ptr, ggo | br | two-component signal transduction system (phosphorelay) (3.4e-02/5.3e-02/ 2/ 2) | myelin sheath (8.9e-03/1.7e-01/ 3/ 6) | Axon guidance (3.2e-02/ 1.1689/ 6/51) | |||
| 525 | 2/1.8 | 159 | 14 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (4.0e-04/4.1e+00/ 16/ 146) | voltage-gated potassium channel complex (3.9e-05/1.4e+00/ 10/ 46) | cation channel activity (4.3e-06/3.5e+00/ 18/ 125) | Calcium signaling pathway (2.4e-02/ 1.9686/ 8/68) | ||
| 526 | 2/1.6 | 174 | 20 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (2.0e-07/4.5e+00/ 22/ 146) | plasma membrane (9.3e-07/3.7e+01/ 69/1133) | cation channel activity (1.1e-05/3.8e+00/ 18/ 125) | Neuroactive ligand-receptor interaction (4.4e-03/ 3.3221/12/102) | ||
| 527 | 2/1.6 | 207 | 13 | hsa, ptr, ppa, ggo, ppy, mml, mdo | cb | nervous system development (2.2e-04/1.6e+01/ 37/ 467) | ion channel complex (1.3e-02/4.0e+00/ 12/ 108) | gated channel activity (2.3e-03/5.5e+00/ 17/ 146) | |||
| 528 | 2/1.6 | 236 | 19 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | ion transport (2.1e-12/1.5e+01/ 50/ 332) | synapse part (3.4e-17/5.6e+00/ 36/ 123) | gated channel activity (3.2e-13/6.4e+00/ 35/ 146) | Neuroactive ligand-receptor interaction (4.4e-09/ 4.9216/24/102) | 8 (1.4e-02/ 9.671/24/234) | |
| 529 | 2/1.6 | 169 | 11 | mmu, mdo, oan, gga | br, cb | G-protein coupled receptor protein signaling pathway (7.1e-06/5.6e+00/ 22/ 175) | plasma membrane (4.7e-09/3.6e+01/ 73/1133) | neurotransmitter binding (8.8e-06/9.9e-01/ 10/ 30) | Neuroactive ligand-receptor interaction (1.4e-04/ 4.0603/16/102) | X (3.7e-02/ 4.386/14/145) | |
| 530 | 2/1.6 | 237 | 11 | mmu | ht, kd, lv, ts | proteasome complex (1.0e-02/7.1e-01/ 5/ 17) | Proteasome (3.0e-02/ 0.4578/ 4/11) | ||||
| 531 | 2/1.6 | 164 | 10 | mmu, mdo, oan, gga | br, cb | G-protein coupled receptor protein signaling pathway (1.9e-04/5.3e+00/ 19/ 175) | plasma membrane (2.6e-08/3.4e+01/ 69/1133) | ion channel activity (2.0e-05/5.4e+00/ 21/ 176) | Neuroactive ligand-receptor interaction (3.5e-04/ 2.9530/13/102) | X (9.3e-03/ 4.208/15/145) | |
| 532 | 2/1.6 | 143 | 10 | mmu, gga | br, cb | ion transport (9.6e-04/8.5e+00/ 23/ 332) | ion channel complex (8.7e-04/2.9e+00/ 12/ 108) | ion transmembrane transporter activity (6.6e-05/7.6e+00/ 24/ 300) | |||
| 533 | 2/1.4 | 183 | 24 | hsa, ptr, ppa, ggo, ppy, mml, mmu | br | synaptic transmission (1.0e-07/4.8e+00/ 23/ 146) | plasma membrane (6.1e-08/3.9e+01/ 75/1133) | ion channel activity (2.1e-07/5.7e+00/ 25/ 176) | Neuroactive ligand-receptor interaction (4.7e-06/ 3.5682/17/102) | ||
| 534 | 2/1.4 | 160 | 10 | hsa, ggo | ht, kd, lv | translation (2.7e-02/3.4e+00/ 11/ 114) | mitochondrion (4.4e-03/1.2e+01/ 26/ 427) | Parkinson's disease (8.9e-04/ 0.8142/ 7/27) | |||
| 535 | 2/1.4 | 210 | 27 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | synaptic transmission (8.1e-15/5.6e+00/ 34/ 146) | plasma membrane (4.3e-16/4.6e+01/103/1133) | ion channel activity (3.2e-13/6.8e+00/ 36/ 176) | Neuroactive ligand-receptor interaction (2.2e-11/ 4.1834/25/102) | ||
| 536 | 2/1.4 | 222 | 20 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb | nervous system development (1.0e-07/1.9e+01/ 48/ 467) | synapse (8.5e-05/6.5e+00/ 21/ 160) | gated channel activity (4.8e-07/6.0e+00/ 25/ 146) | Neuroactive ligand-receptor interaction (1.2e-02/ 3.7527/12/102) | ||
| 537 | 2/1.2 | 190 | 22 | hsa, ptr, ppa, mmu, mdo | br, ht, kd, lv, ts | organic acid metabolic process (4.3e-02/7.4e+00/ 17/ 228) | peroxisome (2.3e-03/1.1e+00/ 7/ 33) | catalytic activity (1.0e-02/6.1e+01/ 83/1790) | Peroxisome (2.1e-02/ 1.0495/ 6/30) | ||
| 538 | 2/1.2 | 223 | 23 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb, br | transmission of nerve impulse (2.7e-08/6.6e+00/ 28/ 163) | synapse (1.2e-11/6.7e+00/ 32/ 160) | gated channel activity (2.5e-08/5.9e+00/ 27/ 146) | Neuroactive ligand-receptor interaction (6.6e-04/ 4.1218/15/102) | ||
| 539 | 2/1.2 | 143 | 20 | hsa, mmu, mdo, oan, gga | lv, br, cb | transmission of nerve impulse (3.2e-05/4.2e+00/ 18/ 163) | membrane (1.9e-09/6.1e+01/ 98/2327) | ion transmembrane transporter activity (9.8e-05/7.8e+00/ 24/ 300) | Neuroactive ligand-receptor interaction (8.7e-03/ 2.5838/10/102) | ||
| 540 | 2/1 | 288 | 37 | hsa, ptr, ppa, ggo, mmu, mdo | br, kd, ts, br, cb, ht, kd, lv | estrogen receptor signaling pathway (1.9e-02/3.8e-01/ 4/ 8) | intracellular membrane-bounded organelle (1.1e-03/1.3e+02/163/2681) | catalytic activity (2.4e-02/8.7e+01/111/1790) | |||
| 541 | 1.8/3 | 424 | 6 | oan | ht, kd, lv | cellular metabolic process (4.8e-03/1.8e+02/212/2383) | intracellular (1.2e-06/2.8e+02/319/3640) | ||||
| 542 | 1.8/3 | 366 | 3 | mmu | kd | transmembrane transport (3.5e-03/1.8e+01/ 36/ 278) | brush border membrane (2.7e-04/8.6e-01/ 7/ 13) | active transmembrane transporter activity (3.9e-04/8.5e+00/ 24/ 130) | Lysosome (1.9e-02/ 3.4451/11/51) | ||
| 543 | 1.8/3 | 469 | 4 | mml, mmu | ts | cell cycle phase (6.3e-15/1.5e+01/ 54/ 202) | microtubule cytoskeleton (2.3e-13/1.6e+01/ 54/ 227) | microtubule motor activity (6.0e-04/2.2e+00/ 11/ 30) | Oocyte meiosis (3.3e-03/ 2.2581/10/39) | ||
| 544 | 1.8/3 | 430 | 4 | ptr, ppa, mml | ts | M phase (2.1e-12/1.0e+01/ 42/ 152) | microtubule cytoskeleton (8.7e-10/1.5e+01/ 46/ 227) | microtubule motor activity (4.3e-04/2.1e+00/ 11/ 30) | Cell cycle (4.1e-02/ 2.1918/ 8/46) | ||
| 545 | 1.8/3 | 370 | 3 | hsa | kd | excretion (4.5e-05/1.7e+00/ 11/ 24) | apical plasma membrane (4.5e-07/4.0e+00/ 19/ 59) | exopeptidase activity (4.2e-04/2.5e+00/ 12/ 37) | |||
| 546 | 1.8/3 | 393 | 4 | mdo, oan | lv | organic acid metabolic process (7.8e-09/1.7e+01/ 49/ 228) | endoplasmic reticulum part (2.5e-07/1.7e+01/ 44/ 227) | catalytic activity (1.7e-04/1.3e+02/175/1790) | Complement and coagulation cascades (1.7e-08/ 2.1659/15/21) | ||
| 547 | 1.8/3 | 415 | 3 | mmu | ht | cellular respiration (4.2e-08/2.6e+00/ 17/ 36) | myofibril (1.1e-12/3.2e+00/ 23/ 45) | structural constituent of muscle (2.8e-04/1.0e+00/ 8/ 14) | Cardiac muscle contraction (1.0e-04/ 1.9150/11/25) | ||
| 548 | 1.8/3 | 360 | 4 | oan | br, cb | Toll-like receptor signaling pathway (3.2e-03/ 1.8275/ 9/30) | |||||
| 549 | 1.8/3 | 422 | 4 | ptr, ppa, gga | ts | M phase (7.1e-16/1.0e+01/ 46/ 152) | microtubule cytoskeleton (4.2e-14/1.5e+01/ 52/ 227) | microtubule motor activity (8.7e-06/2.0e+00/ 13/ 30) | Cell cycle (8.9e-05/ 2.1641/12/46) | ||
| 550 | 1.8/3 | 363 | 4 | mdo | br, cb | GPI anchor biosynthetic process (6.4e-04/8.2e-01/ 7/ 13) | GPI-anchor transamidase complex (6.2e-03/1.9e-01/ 3/ 3) | GPI-anchor transamidase activity (1.3e-02/1.9e-01/ 3/ 3) | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (1.2e-03/ 0.6369/ 6/11) | ||
| 551 | 1.8/3 | 378 | 4 | gga | kd, lv | lymph node development (4.8e-02/2.7e-01/ 3/ 4) | late endosome (2.8e-03/2.9e+00/ 11/ 44) | T cell receptor signaling pathway (4.3e-02/ 2.7756/ 9/39) | |||
| 552 | 1.8/2.8 | 434 | 3 | oan | ts | M phase (6.7e-13/1.1e+01/ 44/ 152) | nucleus (7.6e-09/1.1e+02/167/1528) | nucleic acid binding (6.7e-04/5.8e+01/ 90/ 802) | Cell cycle (3.0e-02/ 2.5802/ 9/46) | ||
| 553 | 1.8/2.8 | 455 | 6 | ptr, ppa, mml, mmu | ts | M phase (1.3e-14/1.1e+01/ 46/ 152) | microtubule cytoskeleton (5.9e-13/1.6e+01/ 53/ 227) | microtubule motor activity (1.8e-05/2.2e+00/ 13/ 30) | |||
| 554 | 1.8/2.8 | 389 | 3 | ppa, ggo | lv | response to wounding (3.0e-09/1.6e+01/ 47/ 211) | vesicle lumen (1.5e-06/1.1e+00/ 10/ 16) | cytokine receptor activity (1.4e-06/2.1e+00/ 14/ 29) | Complement and coagulation cascades (3.6e-09/ 1.9252/15/21) | ||
| 555 | 1.8/2.8 | 384 | 3 | hsa, mml | ht | cardiac muscle tissue development (1.2e-07/2.4e+00/ 16/ 34) | contractile fiber (6.3e-18/3.2e+00/ 28/ 46) | actin binding (2.6e-07/8.8e+00/ 31/ 124) | Dilated cardiomyopathy (3.0e-05/ 2.3993/13/34) | ||
| 556 | 1.8/2.8 | 342 | 3 | ptr, ppa | cb | gene expression (1.4e-03/6.6e+01/ 97/1086) | spliceosomal complex (4.2e-02/2.0e+00/ 7/ 32) | ||||
| 557 | 1.8/2.8 | 432 | 5 | mdo, oan | ts | M phase (1.2e-20/1.0e+01/ 53/ 152) | chromosome (3.2e-12/1.0e+01/ 40/ 150) | nucleic acid binding (1.3e-04/5.5e+01/ 89/ 802) | Cell cycle (2.4e-03/ 2.6080/11/46) | ||
| 558 | 1.8/2.6 | 396 | 6 | gga | ht, kd, lv | nucleic acid metabolic process (1.4e-02/7.6e+01/103/1075) | nucleus (6.9e-03/1.1e+02/135/1528) | DNA binding (8.8e-03/3.7e+01/ 59/ 529) | |||
| 559 | 1.8/2.6 | 372 | 4 | gga | br, cb | mitochondrial transport (4.2e-02/1.2e+00/ 6/ 19) | chloride channel complex (2.1e-02/1.7e+00/ 7/ 27) | ligand-gated ion channel activity (1.2e-03/4.7e+00/ 16/ 72) | X (5.6e-03/ 9.537/25/145) | ||
| 560 | 1.8/2.6 | 326 | 3 | hsa, ggo | cb | regulation of transcription (1.7e-04/4.4e+01/ 74/ 731) | nucleus (3.0e-03/9.1e+01/121/1528) | transcription regulator activity (4.7e-05/1.8e+01/ 42/ 297) | miR-129/129-5p (0.031/ 9.3175/26/143) | ||
| 561 | 1.8/2.6 | 402 | 4 | ptr, ppa, ppy | ht | muscle contraction (5.5e-04/5.4e+00/ 18/ 74) | myofibril (9.3e-13/3.2e+00/ 23/ 45) | structural constituent of muscle (2.4e-04/1.0e+00/ 8/ 14) | Cardiac muscle contraction (3.0e-05/ 1.6737/11/25) | ||
| 562 | 1.8/2.6 | 367 | 4 | ppa, ggo, ppy | lv | defense response (2.7e-11/1.3e+01/ 45/ 175) | extracellular region (2.0e-07/3.6e+01/ 73/ 533) | cytokine receptor activity (9.5e-08/2.0e+00/ 15/ 29) | Complement and coagulation cascades (4.5e-09/ 1.9632/15/21) | ||
| 563 | 1.8/2.6 | 330 | 4 | oan, gga | br | synaptic transmission (2.3e-04/8.8e+00/ 25/ 146) | integral to plasma membrane (2.6e-05/2.4e+01/ 50/ 413) | neurotransmitter binding (2.3e-05/1.8e+00/ 12/ 30) | Neuroactive ligand-receptor interaction (4.0e-06/ 5.8444/22/102) | X (1.9e-03/ 8.543/25/145) | |
| 564 | 1.8/2.6 | 403 | 4 | oan | kd, lv | cellular amino acid derivative metabolic process (1.4e-02/4.3e+00/ 13/ 58) | intracellular membrane-bounded organelle (2.5e-03/1.9e+02/229/2681) | ferrous iron binding (4.9e-02/2.9e-01/ 3/ 4) | |||
| 565 | 1.8/2.6 | 298 | 5 | mmu | br, cb | transmission of nerve impulse (6.0e-03/8.4e+00/ 21/ 163) | membrane (8.7e-03/1.3e+02/153/2327) | ion channel activity (7.4e-03/9.3e+00/ 22/ 176) | |||
| 566 | 1.8/2.6 | 460 | 8 | ptr, ppa, mml, mmu, gga | ts | M phase (8.3e-18/1.1e+01/ 50/ 152) | microtubule cytoskeleton (1.6e-17/1.6e+01/ 60/ 227) | microtubule motor activity (1.7e-05/2.2e+00/ 13/ 30) | Cell cycle (4.3e-03/ 2.3305/10/46) | ||
| 567 | 1.8/2.6 | 323 | 4 | hsa, ptr, ppa | cb | regulation of cellular process (3.2e-04/1.2e+02/153/2023) | nucleoplasm part (1.7e-02/1.2e+01/ 24/ 205) | transcription regulator activity (2.2e-03/1.8e+01/ 36/ 297) | |||
| 568 | 1.8/2.6 | 380 | 6 | ptr, ppa, ggo, ppy, mml | ht | cardiac chamber development (1.5e-05/1.8e+00/ 12/ 26) | myofibril (2.6e-14/3.0e+00/ 24/ 45) | structural molecule activity (4.7e-05/1.0e+01/ 29/ 147) | Cardiac muscle contraction (1.9e-04/ 1.6285/10/25) | ||
| 569 | 1.8/2.6 | 444 | 8 | ptr, ppa, mml, mmu, mdo | ts | M phase (2.5e-17/1.1e+01/ 49/ 152) | microtubule cytoskeleton (3.3e-14/1.6e+01/ 54/ 227) | microtubule motor activity (8.3e-05/2.1e+00/ 12/ 30) | Cell cycle (1.3e-02/ 2.2195/ 9/46) | ||
| 570 | 1.8/2.6 | 377 | 4 | hsa, ggo | ht | muscle contraction (1.8e-07/5.1e+00/ 23/ 74) | contractile fiber (4.5e-15/3.1e+00/ 25/ 46) | structural molecule activity (4.1e-07/1.0e+01/ 33/ 147) | Dilated cardiomyopathy (5.9e-05/ 2.5633/13/34) | ||
| 571 | 1.8/2.6 | 380 | 5 | ptr, ppa, ggo, ppy | ht | cardiac chamber development (9.9e-05/1.8e+00/ 11/ 26) | myofibril (1.5e-15/3.0e+00/ 25/ 45) | structural constituent of muscle (1.7e-04/9.6e-01/ 8/ 14) | Cardiac muscle contraction (1.2e-05/ 1.5078/11/25) | ||
| 572 | 1.8/2.6 | 466 | 10 | oan | br, cb, ht, kd, lv | cellular macromolecule metabolic process (2.5e-05/1.5e+02/193/1795) | intracellular (6.0e-06/3.0e+02/342/3640) | RNA binding (3.4e-04/1.7e+01/ 38/ 212) | |||
| 573 | 1.8/2.6 | 361 | 3 | oan, gga | kd | excretion (2.3e-05/1.6e+00/ 11/ 24) | apical part of cell (1.4e-04/4.8e+00/ 17/ 75) | secondary active transmembrane transporter activity (5.6e-03/5.5e+00/ 16/ 84) | Aldosterone-regulated sodium reabsorption (1.3e-02/ 0.9843/ 6/16) | ||
| 574 | 1.8/2.6 | 370 | 4 | ptr, ppa, ppy | lv | defense response (6.6e-08/1.3e+01/ 39/ 175) | extracellular space (1.8e-07/1.6e+01/ 42/ 226) | cytokine receptor activity (1.2e-07/2.0e+00/ 15/ 29) | Complement and coagulation cascades (6.9e-09/ 2.0265/15/21) | ||
| 575 | 1.8/2.4 | 397 | 3 | mmu | lv | organic acid metabolic process (1.0e-11/1.7e+01/ 54/ 228) | endoplasmic reticulum part (1.4e-06/1.7e+01/ 42/ 227) | cofactor binding (2.4e-07/5.9e+00/ 25/ 83) | Complement and coagulation cascades (9.2e-05/ 1.9759/11/21) | ||
| 576 | 1.8/2.4 | 448 | 10 | ptr, ppa, mml, mmu, mdo, oan | ts | M phase (1.3e-23/1.1e+01/ 57/ 152) | microtubule cytoskeleton (9.4e-18/1.6e+01/ 60/ 227) | nucleic acid binding (1.2e-05/5.6e+01/ 95/ 802) | Cell cycle (5.2e-03/ 2.3860/10/46) | ||
| 577 | 1.8/2.4 | 386 | 4 | mdo, oan | kd | excretion (7.0e-05/1.8e+00/ 11/ 24) | apical part of cell (1.8e-07/5.5e+00/ 23/ 75) | transporter activity (2.2e-03/3.3e+01/ 57/ 454) | Aldosterone-regulated sodium reabsorption (4.6e-03/ 1.1773/ 7/16) | ||
| 578 | 1.8/2.4 | 409 | 3 | mml, oan | lv | organic acid metabolic process (4.8e-08/1.8e+01/ 48/ 228) | endoplasmic reticulum (7.6e-05/2.8e+01/ 53/ 356) | vitamin binding (2.5e-05/4.3e+00/ 18/ 55) | Complement and coagulation cascades (1.2e-09/ 2.1912/16/21) | ||
| 579 | 1.8/2.4 | 382 | 5 | hsa, ptr, mml | lv | organic acid metabolic process (3.1e-17/1.7e+01/ 62/ 228) | extracellular space (2.3e-04/1.7e+01/ 36/ 226) | vitamin binding (2.4e-07/3.8e+00/ 20/ 55) | Complement and coagulation cascades (7.9e-09/ 2.0519/15/21) | ||
| 580 | 1.8/2.4 | 424 | 11 | ptr, ppa, mml, mmu, oan, gga | ts | M phase (3.0e-21/9.7e+00/ 52/ 152) | microtubule cytoskeleton (5.1e-17/1.4e+01/ 56/ 227) | microtubule motor activity (6.1e-06/2.0e+00/ 13/ 30) | Homologous recombination (4.1e-03/ 0.4843/ 5/11) | ||
| 581 | 1.8/2.4 | 389 | 7 | hsa, ptr, ppa, ppy, mml | lv | organic acid metabolic process (1.7e-13/1.7e+01/ 57/ 228) | extracellular space (8.2e-06/1.7e+01/ 40/ 226) | cytokine receptor activity (1.2e-05/2.1e+00/ 13/ 29) | Complement and coagulation cascades (3.0e-08/ 2.2672/15/21) | ||
| 582 | 1.8/2.4 | 444 | 13 | oan | br, cb, ht, kd, lv, ts | nucleic acid metabolic process (2.3e-05/8.3e+01/125/1075) | nucleus (1.6e-08/1.2e+02/178/1528) | nucleic acid binding (2.5e-04/6.2e+01/ 96/ 802) | |||
| 583 | 1.8/2.4 | 328 | 5 | hsa, ptr, ppa, ggo | cb | regulation of cellular process (1.9e-04/1.2e+02/153/2023) | spectrin-associated cytoskeleton (4.8e-02/1.2e-01/ 2/ 2) | transcription regulator activity (7.7e-03/1.8e+01/ 34/ 297) | |||
| 584 | 1.8/2.4 | 435 | 10 | ptr, ppa, mml, mmu, mdo, gga | ts | M phase (6.2e-22/1.0e+01/ 54/ 152) | microtubule cytoskeleton (2.4e-19/1.5e+01/ 61/ 227) | microtubule motor activity (7.9e-06/2.0e+00/ 13/ 30) | Cell cycle (3.1e-03/ 2.2195/10/46) | ||
| 585 | 1.8/2.4 | 386 | 4 | oan, gga | lv | organic acid metabolic process (2.2e-07/1.7e+01/ 45/ 228) | endoplasmic reticulum part (3.5e-05/1.6e+01/ 38/ 227) | cofactor binding (1.9e-03/6.0e+00/ 18/ 83) | Complement and coagulation cascades (9.2e-08/ 2.0012/14/21) | ||
| 586 | 1.8/2.4 | 393 | 4 | mml, mdo | lv | organic acid metabolic process (1.3e-13/1.8e+01/ 58/ 228) | extracellular space (4.1e-05/1.7e+01/ 39/ 226) | vitamin binding (6.7e-07/4.1e+00/ 20/ 55) | Complement and coagulation cascades (4.9e-06/ 2.2799/13/21) | ||
| 587 | 1.8/2.4 | 374 | 6 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle structure development (3.5e-06/9.5e+00/ 30/ 141) | contractile fiber (2.0e-17/3.1e+00/ 27/ 46) | structural molecule activity (2.7e-07/9.8e+00/ 33/ 147) | Cardiac muscle contraction (2.2e-05/ 1.6134/11/25) | ||
| 588 | 1.8/2.4 | 365 | 8 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (8.4e-08/4.9e+00/ 23/ 74) | contractile fiber (1.5e-16/3.0e+00/ 26/ 46) | structural molecule activity (5.0e-08/9.7e+00/ 34/ 147) | Cardiac muscle contraction (1.9e-05/ 1.5832/11/25) | ||
| 589 | 1.8/2.4 | 381 | 6 | mdo | ht, kd, lv | metabolic process (1.5e-02/1.8e+02/204/2657) | mitochondrion (2.4e-03/2.9e+01/ 50/ 427) | catalytic activity (2.0e-03/1.2e+02/154/1790) | Parkinson's disease (1.0e-02/ 1.7262/ 8/27) | ||
| 590 | 1.8/2.4 | 336 | 5 | hsa, ggo | kd | excretion (2.0e-06/1.5e+00/ 12/ 24) | apical part of cell (8.3e-09/4.6e+00/ 23/ 75) | active transmembrane transporter activity (2.0e-04/8.2e+00/ 24/ 130) | Vibrio cholerae infection (4.7e-02/ 0.9138/ 5/15) | ||
| 591 | 1.8/2.2 | 376 | 11 | hsa, ptr, ppa, ggo, ppy, mml | lv | organic acid metabolic process (3.1e-12/1.7e+01/ 55/ 228) | extracellular region (3.9e-06/3.8e+01/ 71/ 533) | cytokine receptor activity (1.7e-07/2.1e+00/ 15/ 29) | Complement and coagulation cascades (2.0e-08/ 2.2039/15/21) | ||
| 592 | 1.8/2.2 | 374 | 11 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (3.6e-06/5.0e+00/ 21/ 74) | myofibril (2.2e-15/3.0e+00/ 25/ 45) | structural molecule activity (8.3e-09/9.9e+00/ 36/ 147) | Cardiac muscle contraction (3.0e-05/ 1.6737/11/25) | ||
| 593 | 1.8/2.2 | 333 | 4 | hsa | br | axonogenesis (2.9e-02/5.2e+00/ 14/ 89) | main axon (2.3e-02/5.5e-01/ 4/ 9) | translation initiation factor activity (2.6e-02/1.1e+00/ 6/ 19) | |||
| 594 | 1.8/2.2 | 319 | 10 | hsa, ptr, ppa, ggo, mml | kd | excretion (1.2e-06/1.4e+00/ 12/ 24) | apical part of cell (3.3e-10/4.3e+00/ 24/ 75) | active transmembrane transporter activity (2.2e-04/7.6e+00/ 23/ 130) | Vibrio cholerae infection (6.6e-03/ 0.8595/ 6/15) | ||
| 595 | 1.8/2.2 | 392 | 7 | hsa, mml, mdo, gga | lv | organic acid metabolic process (3.7e-13/1.8e+01/ 57/ 228) | endoplasmic reticulum part (8.0e-09/1.7e+01/ 47/ 227) | oxidoreductase activity (2.0e-06/1.5e+01/ 41/ 205) | Complement and coagulation cascades (7.9e-08/ 2.4318/15/21) | ||
| 596 | 1.8/2.2 | 441 | 11 | hsa, ptr, ppa, ggo, mml, mmu, mdo | ts | M phase (4.3e-17/1.0e+01/ 48/ 152) | microtubule cytoskeleton (7.9e-15/1.6e+01/ 55/ 227) | microtubule motor activity (1.2e-05/2.1e+00/ 13/ 30) | Cell cycle (3.1e-03/ 2.2195/10/46) | ||
| 597 | 1.8/2.2 | 410 | 6 | mdo, oan, gga | lv | organic acid metabolic process (2.8e-11/1.8e+01/ 55/ 228) | endoplasmic reticulum part (1.5e-06/1.8e+01/ 43/ 227) | vitamin binding (2.1e-05/4.2e+00/ 18/ 55) | Complement and coagulation cascades (3.0e-06/ 2.1659/13/21) | ||
| 598 | 1.8/2.2 | 437 | 10 | gga | br, cb, ht, kd, lv | nucleic acid metabolic process (3.0e-03/8.1e+01/113/1075) | nucleus (1.1e-03/1.1e+02/149/1528) | DNA binding (3.2e-03/4.0e+01/ 65/ 529) | T cell receptor signaling pathway (4.1e-02/ 2.7521/ 9/39) | ||
| 599 | 1.8/2.2 | 398 | 5 | mmu, mdo | lv | organic acid metabolic process (1.3e-16/1.8e+01/ 63/ 228) | endoplasmic reticulum part (5.1e-11/1.7e+01/ 51/ 227) | cofactor binding (3.0e-08/6.2e+00/ 27/ 83) | Complement and coagulation cascades (6.4e-07/ 2.3432/14/21) | ||
| 600 | 1.8/2.2 | 336 | 6 | ggo | br, cb, ht | macromolecule catabolic process (4.1e-02/1.1e+01/ 23/ 195) | endoplasmic reticulum membrane (4.6e-02/1.2e+01/ 22/ 198) | ||||
| 601 | 1.8/2.2 | 400 | 6 | mml, mdo, oan | lv | organic acid metabolic process (3.7e-15/1.8e+01/ 61/ 228) | endoplasmic reticulum part (1.0e-08/1.8e+01/ 48/ 227) | vitamin binding (1.2e-06/4.3e+00/ 20/ 55) | Complement and coagulation cascades (7.9e-08/ 2.4318/15/21) | ||
| 602 | 1.8/2.2 | 360 | 6 | mmu | kd, lv | organic acid metabolic process (7.5e-07/1.4e+01/ 40/ 228) | subsynaptic reticulum (1.6e-04/1.6e+01/ 35/ 239) | cofactor binding (1.1e-05/5.3e+00/ 21/ 83) | Metabolic pathways (8.7e-04/24.9101/45/353) | ||
| 603 | 1.8/2.2 | 393 | 9 | hsa, ptr, ppa, mml, mmu, mdo | lv | organic acid metabolic process (1.6e-18/1.8e+01/ 66/ 228) | endoplasmic reticulum part (3.1e-11/1.7e+01/ 52/ 227) | cofactor binding (2.8e-08/6.2e+00/ 27/ 83) | Metabolic pathways (6.2e-09/39.6007/78/353) | ||
| 604 | 1.8/2.2 | 381 | 9 | hsa, ptr, ppa, ggo, ppy, mml | lv | organic acid metabolic process (6.5e-15/1.7e+01/ 59/ 228) | vesicle lumen (2.6e-05/1.2e+00/ 9/ 16) | vitamin binding (2.7e-05/3.8e+00/ 17/ 55) | Complement and coagulation cascades (7.5e-09/ 2.0392/15/21) | ||
| 605 | 1.8/2.2 | 410 | 5 | mmu, gga | lv | organic acid metabolic process (1.4e-18/1.8e+01/ 67/ 228) | endoplasmic reticulum part (4.6e-08/1.8e+01/ 47/ 227) | cofactor binding (6.5e-08/6.5e+00/ 27/ 83) | Complement and coagulation cascades (6.8e-06/ 2.3432/13/21) | ||
| 606 | 1.8/2.2 | 388 | 9 | mmu, mdo, oan, gga | lv | organic acid metabolic process (9.3e-18/1.7e+01/ 64/ 228) | endoplasmic reticulum part (7.8e-10/1.7e+01/ 49/ 227) | cofactor binding (5.4e-09/6.2e+00/ 28/ 83) | Complement and coagulation cascades (1.4e-08/ 2.1405/15/21) | ||
| 607 | 1.8/2 | 391 | 6 | mdo, oan | lv, kd | cellular amine metabolic process (7.7e-06/8.3e+00/ 27/ 114) | endoplasmic reticulum part (1.8e-03/1.6e+01/ 33/ 227) | vitamin binding (2.1e-02/4.0e+00/ 12/ 55) | Cysteine and methionine metabolism (6.5e-03/ 0.9156/ 6/11) | ||
| 608 | 1.8/2 | 395 | 15 | hsa, ptr, ppa, ppy, mml, mmu, mdo, oan | lv | organic acid metabolic process (3.0e-19/1.8e+01/ 68/ 228) | endoplasmic reticulum part (3.5e-15/1.7e+01/ 59/ 227) | oxidoreductase activity (6.6e-11/1.5e+01/ 50/ 205) | Complement and coagulation cascades (8.3e-08/ 2.4445/15/21) | ||
| 609 | 1.8/2 | 352 | 9 | hsa, ptr, ppa, ggo, ppy, mml | cb | biological regulation (1.6e-03/1.4e+02/174/2267) | synapse (9.9e-04/1.0e+01/ 25/ 160) | gated channel activity (5.9e-04/9.4e+00/ 25/ 146) | |||
| 610 | 1.8/2 | 327 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | excretion (1.4e-06/1.5e+00/ 12/ 24) | apical part of cell (6.6e-10/4.5e+00/ 24/ 75) | active transmembrane transporter activity (3.5e-04/7.9e+00/ 23/ 130) | Vibrio cholerae infection (9.1e-03/ 0.9228/ 6/15) | ||
| 611 | 1.8/2 | 336 | 7 | mmu, mdo, oan | kd | excretion (1.7e-06/1.5e+00/ 12/ 24) | apical part of cell (2.2e-10/4.6e+00/ 25/ 75) | transporter activity (4.7e-10/2.8e+01/ 70/ 454) | Aldosterone-regulated sodium reabsorption (3.0e-03/ 1.0808/ 7/16) | ||
| 612 | 1.8/2 | 403 | 6 | mdo | br, cb, ts | mitochondrial electron transport, NADH to ubiquinone (5.7e-03/8.3e-01/ 6/ 12) | intracellular part (2.6e-05/2.4e+02/277/3542) | catalytic activity (5.9e-04/1.2e+02/163/1790) | Parkinson's disease (4.8e-06/ 1.7099/12/27) | MT (6.9e-03/ 0.432/ 5/ 6) | |
| 613 | 1.8/2 | 317 | 5 | hsa, ptr, ppa, ppy | br | RNA catabolic process (2.9e-03/1.4e+00/ 8/ 23) | small-subunit processome (1.5e-02/2.4e-01/ 3/ 4) | G-protein coupled amine receptor activity (3.6e-02/5.1e-01/ 4/ 9) | |||
| 614 | 1.8/2 | 361 | 9 | mmu | ht, kd, lv | organic acid metabolic process (1.2e-03/1.4e+01/ 32/ 228) | mitochondrion (5.9e-04/2.8e+01/ 50/ 427) | catalytic activity (1.8e-02/1.1e+02/142/1790) | Peroxisome (2.6e-02/ 2.0446/ 8/30) | ||
| 615 | 1.8/2 | 375 | 14 | hsa, ptr, ppa, ggo, ppy, mml, mmu | lv | organic acid metabolic process (4.3e-17/1.7e+01/ 62/ 228) | endoplasmic reticulum part (2.0e-06/1.6e+01/ 41/ 227) | vitamin binding (3.2e-05/3.9e+00/ 17/ 55) | Complement and coagulation cascades (2.0e-08/ 2.2039/15/21) | ||
| 616 | 1.8/2 | 383 | 14 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo | lv | organic acid metabolic process (8.9e-19/1.8e+01/ 66/ 228) | endoplasmic reticulum part (4.6e-11/1.7e+01/ 51/ 227) | oxidoreductase activity (3.3e-07/1.5e+01/ 42/ 205) | Complement and coagulation cascades (4.8e-08/ 2.3432/15/21) | ||
| 617 | 1.8/2 | 336 | 11 | hsa, mml, mdo, oan, gga | kd | organic acid metabolic process (8.6e-08/1.5e+01/ 42/ 228) | apical part of cell (6.4e-13/4.7e+00/ 28/ 75) | active transmembrane transporter activity (8.9e-06/8.2e+00/ 27/ 130) | Proximal tubule bicarbonate reclamation (3.4e-04/ 0.5597/ 6/8) | ||
| 618 | 1.8/2 | 341 | 6 | mdo, oan, gga | cb | synaptic transmission, glutamatergic (2.1e-03/9.7e-01/ 7/ 16) | synapse (4.7e-02/9.7e+00/ 19/ 160) | Phosphatidylinositol signaling system (3.3e-02/ 1.6405/ 7/32) | X (2.3e-02/ 8.849/22/145) | ||
| 619 | 1.8/2 | 433 | 10 | mdo | br, cb, ht, kd, lv | amyloid precursor protein metabolic process (1.3e-02/6.6e-01/ 5/ 9) | intracellular membrane-bounded organelle (1.8e-04/2.0e+02/245/2681) | GPI-anchor transamidase activity (1.9e-02/2.2e-01/ 3/ 3) | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (2.1e-02/ 0.7497/ 5/11) | ||
| 620 | 1.8/1.8 | 337 | 9 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (1.1e-05/8.9e+00/ 28/ 146) | plasma membrane (2.0e-05/7.0e+01/108/1133) | voltage-gated cation channel activity (2.1e-06/3.9e+00/ 19/ 65) | Neuroactive ligand-receptor interaction (4.3e-03/ 6.0905/17/102) | ||
| 621 | 1.8/1.8 | 383 | 19 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | lv | organic acid metabolic process (8.2e-20/1.8e+01/ 68/ 228) | endoplasmic reticulum part (3.5e-15/1.7e+01/ 58/ 227) | oxidoreductase activity (3.0e-08/1.5e+01/ 44/ 205) | Complement and coagulation cascades (8.3e-08/ 2.4445/15/21) | ||
| 622 | 1.8/1.8 | 441 | 12 | mdo | br, cb, ht, kd, lv, ts | RNA processing (4.8e-03/1.4e+01/ 29/ 176) | intracellular membrane-bounded organelle (1.2e-04/2.1e+02/253/2681) | helicase activity (1.5e-02/4.4e+00/ 13/ 57) | Parkinson's disease (2.0e-02/ 1.9542/ 8/27) | MT (9.3e-03/ 0.476/ 5/ 6) | |
| 623 | 1.8/1.8 | 359 | 5 | ptr, mml, mdo | cb | nervous system development (6.9e-03/3.0e+01/ 51/ 467) | neuron projection (8.2e-03/1.1e+01/ 23/ 165) | potassium channel activity (2.1e-02/4.0e+00/ 12/ 61) | |||
| 624 | 1.8/1.8 | 310 | 9 | hsa, ptr, ppa, ggo, ppy | br | nervous system development (1.8e-03/2.5e+01/ 47/ 467) | dendrite (4.7e-03/4.7e+00/ 14/ 82) | voltage-gated cation channel activity (3.0e-03/3.6e+00/ 13/ 65) | Phosphatidylinositol signaling system (4.7e-02/ 1.7756/ 7/32) | ||
| 625 | 1.8/1.8 | 322 | 8 | mmu, mdo, oan, gga | br | G-protein coupled receptor protein signaling pathway (4.0e-09/1.0e+01/ 37/ 175) | plasma membrane (9.4e-14/6.7e+01/128/1133) | gated channel activity (3.0e-06/8.8e+00/ 29/ 146) | Neuroactive ligand-receptor interaction (2.5e-07/ 6.4596/25/102) | ||
| 626 | 1.8/1.8 | 382 | 8 | mdo, oan, gga | kd, lv | cellular amino acid metabolic process (1.4e-04/6.4e+00/ 21/ 90) | apical part of cell (2.9e-05/5.2e+00/ 19/ 75) | secondary active transmembrane transporter activity (1.0e-02/5.9e+00/ 16/ 84) | Lysosome (4.0e-02/ 3.8758/11/51) | ||
| 627 | 1.8/1.8 | 336 | 6 | hsa, mml, mmu | br | synaptic transmission (2.3e-11/8.8e+00/ 37/ 146) | plasma membrane (1.5e-10/7.1e+01/126/1133) | ion channel activity (1.1e-10/1.1e+01/ 41/ 176) | Neuroactive ligand-receptor interaction (2.9e-05/ 6.5826/22/102) | ||
| 628 | 1.8/1.6 | 350 | 13 | hsa, ptr, ppa, ggo, ppy, mml, mdo | cb | nervous system development (3.8e-05/2.9e+01/ 57/ 467) | synapse (9.1e-04/1.0e+01/ 25/ 160) | gated channel activity (6.9e-05/9.2e+00/ 27/ 146) | |||
| 629 | 1.8/1.6 | 346 | 18 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (5.0e-11/9.0e+00/ 37/ 146) | synapse (2.3e-11/1.0e+01/ 39/ 160) | ion channel activity (2.1e-08/1.1e+01/ 37/ 176) | Neuroactive ligand-receptor interaction (6.8e-05/ 6.3981/21/102) | ||
| 630 | 1.8/1.6 | 375 | 8 | mdo, oan | ht, kd, lv | organic acid metabolic process (5.2e-04/1.6e+01/ 35/ 228) | mitochondrion (2.0e-06/2.9e+01/ 60/ 427) | catalytic activity (8.3e-06/1.2e+02/166/1790) | Metabolic pathways (6.3e-03/27.0392/45/353) | ||
| 631 | 1.8/1.6 | 370 | 13 | hsa, ppy, mml, mmu, mdo, oan, gga | br | synaptic transmission (2.2e-18/1.0e+01/ 49/ 146) | synapse part (1.8e-23/8.6e+00/ 51/ 123) | gated channel activity (1.1e-13/1.0e+01/ 44/ 146) | Neuroactive ligand-receptor interaction (1.2e-11/ 7.3824/33/102) | ||
| 632 | 1.8/1.4 | 367 | 27 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | br | synaptic transmission (6.7e-22/9.8e+00/ 53/ 146) | synapse (3.0e-25/1.1e+01/ 60/ 160) | ion channel activity (4.2e-16/1.2e+01/ 52/ 176) | Neuroactive ligand-receptor interaction (2.6e-09/ 7.5669/30/102) | ||
| 633 | 1.8/1.4 | 362 | 18 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan | cb | synaptic transmission (8.2e-07/9.4e+00/ 31/ 146) | synapse (1.1e-07/1.1e+01/ 34/ 160) | gated channel activity (1.4e-06/9.5e+00/ 31/ 146) | Long-term potentiation (2.3e-02/ 1.5229/ 7/25) | ||
| 634 | 1.8/1.4 | 313 | 12 | mdo, oan, gga | br, cb | gamma-aminobutyric acid signaling pathway (5.0e-03/5.1e-01/ 5/ 9) | intrinsic to membrane (9.1e-05/8.9e+01/125/1617) | neurotransmitter receptor activity (2.1e-03/1.3e+00/ 8/ 23) | Neuroactive ligand-receptor interaction (2.0e-03/ 5.1062/16/102) | X (4.5e-05/ 8.262/28/145) | |
| 635 | 1.8/1.4 | 326 | 15 | mmu, mdo, oan, gga | br, cb | ion transport (7.9e-09/2.0e+01/ 53/ 332) | membrane (4.1e-14/1.4e+02/209/2327) | gated channel activity (2.1e-08/8.8e+00/ 33/ 146) | Neuroactive ligand-receptor interaction (4.5e-07/ 6.1520/24/102) | ||
| 636 | 1.8/1.4 | 365 | 23 | hsa, ptr, ppa, ggo, ppy, mml, mmu | br | synaptic transmission (1.6e-18/9.5e+00/ 48/ 146) | synapse (1.3e-18/1.1e+01/ 51/ 160) | ion channel activity (5.3e-15/1.1e+01/ 49/ 176) | Neuroactive ligand-receptor interaction (2.5e-06/ 7.2593/25/102) | ||
| 637 | 1.8/1.2 | 370 | 21 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | cb, br | synaptic transmission (2.6e-09/9.8e+00/ 36/ 146) | synapse (2.7e-10/1.1e+01/ 39/ 160) | gated channel activity (2.6e-07/9.8e+00/ 33/ 146) | MAPK signaling pathway (2.2e-02/ 6.5229/16/103) | ||
| 638 | 1.8/1 | 333 | 36 | hsa, ptr, ppa, ggo, ppy, mml, mmu, mdo, oan, gga | kd, lv | organic acid metabolic process (1.2e-08/1.5e+01/ 44/ 228) | apical part of cell (5.0e-08/4.6e+00/ 22/ 75) | cofactor binding (3.5e-06/5.4e+00/ 22/ 83) | Metabolic pathways (1.3e-05/27.8908/54/353) | ||
| 639 | 1.8/1 | 449 | 25 | hsa, ptr, ppa, ggo, mmu | br, kd, br, cb, ht, kd, lv, ts | cellular macromolecule catabolic process (1.3e-03/1.2e+01/ 29/ 167) | intracellular organelle part (2.4e-04/1.3e+02/169/1671) | RNA binding (2.6e-02/1.6e+01/ 30/ 212) |
